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Laminopathies are a heterogeneous group of diseases associated with mutations in A-type lamins, 
which together with B-type lamins, form the nuclear lamina: a proteinaceous network underlying 
the nuclear membrane. A-type lamins are encoded by the LMNA gene, and more than 300 
mutations have been described, associated with more than 16 phenotypes. The majority of 
mutations affect striated muscle to cause Emery-Dreifuss muscular dystrophy (EDMD) or 
cardiomyopathy, while others result in lipodystrophy, neuropathy or premature ageing syndromes. 
However, clear genotype-phenotype correlations are not established, the pathogenic mechanisms 
are little understood and therapies are lacking.  
This thesis first explores genotype-phenotype for LMNA mutations and makes correlations by 
characterising both physical-chemical properties of the amino-acid change, and position in the 3D 
structure of lamin A. LMNA mutations associated with muscular dystrophies, premature ageing 
disorders and lipodystrophies clustered in the Ig-fold domain of lamin A and resulted in a similar 
change in charge, suggesting that modification of specific protein-protein interactions contribute to 
different phenotypes.   
Next, I investigated the effects of four pathogenic EDMD mutations on nuclear morphology, 
nuclear protein distribution and myogenic cell function. I found that some mutations led to severe 
nuclear deformations and mislocalisation of lamin B, while others caused accumulation of lamin A-
positive nuclear foci. Myogenic differentiation was mildly affected by some mutant lamin A species. 
Finally, I describe a series of proof-of-principle experiments investigating a potential therapeutic 
intervention for laminopathies. A lamin A variant with a deletion corresponding to regions encoded 
by exon 5, removing 42 amino acids in the central rod domain, localised correctly. It could also 
rescue both abnormal nuclear morphology, and correct lamin B1 and emerin localisation in lmna-
null embryonic fibroblasts.  
This work advances the current understanding of genotype-phenotype correlations in laminopathies 
and provides proof-of-principle that oligonucleotide-mediated exon skipping is a potential therapy 
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Chapter 1  
Introduction 
 
Mutations in the nuclear lamina protein LMNA cause a series of diseases, collectively called 
laminopathies, affecting various tissues. In particular, EDMD affects skeletal muscle. This thesis 
explores lamin mutations that underlie laminopathies and examines mutation location in chapter 3 
and attempts to make genotype-phenotype correlations. Chapters 4 and 5 investigate the effects of 
four pathogenic EDMD mutations on myogenic cell nuclear structure and function. Finally chapter 
6 describes a series of proof-of-principle experiments investigating potential therapeutic 
interventions for certain laminopathies. As such I will begin with introducing skeletal muscle, then 
describe nuclear structure and the role of the nuclear envelope as well as lamins and their binding 
partners, before covering disease phenotypes of laminpathies and the current understanding of the 
pathogenic mechanism of mutant lamin A. 
 
1.1 Skeletal muscle in health and disease 
1.1.1 Muscle structure and function 
Skeletal muscle represents just over 30% of body weight for women and around 38% for men 
making it the most abundant tissue of the body (Janssen et al., 2000). The function of skeletal 
muscle is to provide coordinated body movements through attachment to the skeleton via tendons. 
To ensure proper function it is heavily vascularised and intensively innervated. Skeletal muscle is 
organised in a hierarchical structure, depicted in figure 1.1. Each muscle is formed by thousands of 
myofibres, the functional units, organised in fibre bundles called fascicles. Myofibres themselves are 
packed with myofibrils, which contain bundles of actin and myosin, forming the contractile 
apparatus of skeletal muscle (reviewed in (Grefte et al., 2007)). 
Myofibrils contain actin and myosin filaments organised into sarcomeres, the contractile units of 
skeletal muscle. The sarcomere arrangement also gives myofibres a striated appearance under the 
microscope. Neighbouring sarcomeres share a Z-disc which provides a scaffold for the attachment 
of thin filaments formed by filamentous actin and the tropomyosin-troponin complex. Thick 
filaments which are formed by myosin subunits are anchored at the M-band. The area spanned by 
the thick filament is known as the A-band. The area on both sides to the Z-disc which is not 
occupied by thick filaments is knows as the I-band. Myosin heads attach to the thin filaments and 
provide contraction driven by ATP, the sliding filament theory (Huxley and Niedergerke, 1954; 
Huxley and Hanson, 1954). For a muscle to contract, fibres depolarise as a consequence of nerve 
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activation and release Ca2+ ions into the cytoplasm. Relaxation of muscle is passive and requires a 
counteracting muscle to contract (reviewed in (Sparrow and Schock, 2009)). 
The myosin heavy chain (MyHC) subtype present in the myofibrils of a myofibre determine its 
fibre type. In man, three fibre types are present: slow twitch type I and fast twitch type IIa and type 
IIx fibres. Fibres of different types differ from each other in terms of their resistance to fatigue and 
the power produced. Type I fibres are fatigue resistant and provide little force. Type IIa and IIx 
provide higher force but are less resistant to fatigue. The fibre type composition and distribution 
varies between muscles depending on their use in the organism, for example postural support 
versus lifting (reviewed in Schiaffino and Reggiani (2011)). Other mammals (apart from man) also 




Figure 1.1 The structure of skeletal muscle. Skeletal muscle is formed by bundles of myofibres and ends with 
tendons on either side which are attached to the skeleton. Myofibres are multinucleated cells formed by the fusion of 
myoblasts. Their cell wall (sarcolemma) is covered by a basal lamina. Located beneath the basal lamina are muscle 
stem cells (satellite cells) which provide new myoblasts for homeostasis and repair. Muscle fibres are packed with 
myofibrils which contain sarcomeres. A sarcomere is a contractile unit and consists of thick and thin filaments. The 
sarcomere arrangement of alternating A and I-bands give skeletal muscle fibres their striated appearance. The 
dystrophin-associated protein complex (DAPC) (also dystrophin-glycoprotein complex, DGC) directly links the actin 
cytoskeleton to the extracellular matrix (ECM) and provides structural stability to the contracting myofibre. Its main 
components are dystrophin (green), the dystroglycan-complex (blue) and the sarcoglycan-complex (red). 
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Skeletal muscle, which is striated and under voluntary control, represents only one of three types of 
muscle cells in mammals. The others are involuntary including cardiac muscle and smooth muscle 
cells. 
Cardiac muscle resembles skeletal muscle in that the actin and myosin filaments are also arranged in 
sarcomeres giving them a striated appearance. In contrast to skeletal muscle fibres however, 
cardiomyocytes do not form large syncytia and are not innervated individually. Cardiomyocytes are 
rod shaped and form a branched network of cells which are connected with each other through the 
intercalated disk providing (1) mechanical attachment through the fascia adherens (anchoring actin 
filaments to the intercalated disc) and desmosomes as well as (2) electrical coupling through gap 
junctions allowing the action potential to pass across adjacent cells (Perriard et al., 2003).  
Smooth muscle cells are arranged in sheets or layers of cells and found in multiple tissues in the 
body including blood vessels, stomach, intestines, airways etc. Smooth muscle cells lack the striated 
pattern and are innervated by the autonomous nervous system. However, contraction can also be 
indiced by hormones (Webb, 2003). 
1.1.2 Muscle development and regeneration 
1.1.2.1 Early embryonic development of skeletal muscle 
During gastrulation in early embryonic development a mesodermal layer is formed between the 
endoderm and ectoderm. The mesoderm forms connective tissue, cartilage, bones, blood, blood 
vessels and muscle. Nearly all skeletal muscles (with the exception of certain head muscles which 
are of cephalic mesenchymal origin) are derived from the paraxial mesoderm which forms cell 
clusters (somites) on either side of the neural tube and notochord. Later in development, the dorsal 
part of the somite forms the dermomyotome which is characterised by the expression of two 
members of the paired/homeodomain transcription factors, Pax3 and Pax7 (Relaix et al., 2004). 
Within the dermomyotome two distinct muscle lineages exist, the epaxial lineage forming the deep 
back muscles and the hypaxial lineage giving rise to intercostal, abdominal and limb muscles. After 
formation of the dermomyotome, some muscle progenitor cells migrate from the dorsolateral lip 
into the limb buds while maintaining Pax3 expression, to seed sites including the limbs and 
diaphragm with muscle progenitors. Other cells delaminate from the dermomyotome and 
downregulate Pax3 expression, then up-regulate expression of myogenic regulatory factors (MRFs) 
such as Myf5 and MyoD giving rise to the myotome where they form embryonic fibres (primary 
myogenesis). Later in embryogenesis, the remaining Pax3/Pax7 positive cells migrate from the 
dermomyotome into the myotome and contribute to muscle development (secondary myogenesis) 
where fetal fibres are formed (reviewed in (Bryson-Richardson and Currie, 2008; Grefte et al., 2007; 
Muntoni et al., 2002)). 
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1.1.2.2 Muscle satellite cells 
The myofibre is a syncytium formed by fusion of mononucleated myoblasts. Importantly, they also 
giving rise to satellite cells, the muscle resident stem cell, which are responsible for postnatal muscle 
growth (Moss and Leblond, 1971). In mature muscle they become mitotically quiescent (Schultz et 
al., 1978) and are located beneath the basal lamina and resting on the plasmalemma of the myofibre. 
These are the muscle resident stem cells, crucial in muscle homeostasis and repair (reviewed in 
Zammit (2008)). 
The mechanism of muscle regeneration has been of interest to anatomists and physiologists since 
the mid-19th century (reviewed in Scharner and Zammit (2011)). It was observed that muscle has a 
remarkable capacity to regenerate which occurs in three phases: inflammation, tissue formation and 
tissue remodelling. The source of muscle regeneration was long unknown until Mauro and Katz 
identified cells at the edge of skeletal muscle fibres which they termed satellite cells (Katz, 1961; 
Mauro, 1961). Satellite cells are by definition quiescent myogenic cells and show the adult stem cell 
characteristics of proliferation, differentiation and self-renewal. Muscle satellite cells from adult 
muscle are well characterized with respect to markers and strongly express Pax7 (Seale et al., 2000), 
M-cadherin (Irintchev et al., 1994), Myf5 and the surface marker CD34 (Beauchamp et al., 2000). 
1.1.2.3 Adult muscle regeneration and repair 
When muscle is injured by either trauma or disease, myofibres become necrotic and release 
cytoplasmic proteins such as muscle creatin kinase (MCK) into the blood stream. This is followed 
by an inflammatory response and the infiltration of muscle tissue with neutrophils and 
macrophages (Charge and Rudnicki, 2004). Concomitantly, the trauma induces the activation of 
quiescent satellite cells which migrate underneath the basal lamina to the site of injury or across to 
neighbouring myofibres if the basal lamina is breached (Collins et al., 2005).  
Myogenic progression and differentiation during adult myogenesis closely resembles embryonic 
development and also involves Pax7 and MRFs (summarised in Fig. 1.2) (Zammit et al., 2006a). 
What cues trigger satellite cell activation upon injury remain to be fully determined and may vary 
depending on the type of injury. One pathway implicated in satellite cell activation is through the 
hepatocyte growth factor (HGF). HGF is present in the basal lamina of muscle fibers and satellite 
cells express the HGF receptor c-Met (Tatsumi and Allen, 2004). Exogenous HGF has been shown 
to induce satellite cell activation in vivo while blocking HGF by antibodies prevents satellite cell 
activation (Tatsumi et al., 1998). 
After activation, quiescent satellite cells overcome the G0-G1 block, enter the cell cycle and start to 
proliferate (at this stage they become myoblasts). Proliferating myoblasts are characterised by the 
rapid up-regulation of MyoD and Myf5 (Cooper et al., 1999; Cornelison and Wold, 1997). During 
the proliferative phase some cells down-regulate MyoD, exit the cell cycle and return to quiescence, 
expressing Pax7. These cells undergo self-renewal and will be available for further regeneration. 
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The remaining cells commit to the myogenic program by down-regulating Pax7 and inducing the 
expression of myogenin and MRF4 (Zammit et al., 2004). The terminal differentiation program 
then continues with the expression of the cell cycle arrest protein p21 and permanent exit from cell 
cycle at G0 (Guo et al., 1995). Individual myoblasts continue to fuse and form myotubes or nascent 
myofibers and start to express muscle specific proteins such as MyHC. These myofibres continue 
to grow by the addition of myoblasts and start to assemble myofibrils and sarcomeres before they 
get innervated and fully integrated into the regenerated muscle. Early stages of regeneration are 
histologically characterised by inflammatory infiltration and necrotic fibres containing cellular 
debris. Later stages are characterised by a large variation in fibre size and the presence of myofibres 
with centrally located nuclei (Charge and Rudnicki, 2004). Unaffected fibres may show 
compensatory hypertrophy. In man, the entire regeneration process is completed in approx. three 




Figure 1.2 The myogenic program of satellite cells. Quiescent satellite cells lie dormant beneath the basal lamina 
of skeletal muscle fibres and express CD34, Pax7 and Myf5. Activated satellite cells start to proliferate and express 
MyoD together with Pax7. At this point some cells down-regulate MyoD and exit the cell cycle (self-renewal) while 
others exit the cell cycle and start to express myogenin (commitment). Cells continue to fuse to form nascent 
multinucleated myotubes and continue to grow to form mature myofibres (modified from Zammit et al. (2004) and 
Zammit et al. (2006a)). 
 
Besides satellite cells, cells of non-muscle origin have also been implicated in skeletal muscle 
regeneration. These include interstitial cells (Tamaki et al., 2002), endothelial-associated cells (De 
Angelis et al., 1999) side population cells (Asakura et al., 2002) as well as bone marrow derived 
myogenic progenitors (LaBarge and Blau, 2002). However, genetic ablation of satellite cells in adult 
mice has been shown to completely block regenerative myogenesis, demonstrating their absolute 
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requirement to regenerate muscle damaged by injury (Lepper et al., 2011), and so presumably also 
disease. 
1.1.3 Muscular dystrophies 
Many diseases affect skeletal muscle. Of particular interest are the muscular dystrophies which 
include a large range of disorders all characterised by muscle weakness and wasting though they 
vary in severity, type of muscle groups affected and heart involvement (Emery, 2002). Since 
muscular dystrophies result in muscle fibre damage and sometimes degeneration, hallmarks of on-
going regeneration such as centrally nucleated myofibres, are often seen. Muscular dystrophies can 
be subdivided in a number of ways, including muscle groups affected, type of gene mutated etc. In 
general, muscular dystrophies can be classified into two distinct groups: (1) Diseases with 
pathologies directly caused by proteins predominantly expressed in muscle (2) diseases caused by 
widely expressed nuclear proteins (Morgan and Zammit, 2010). 
1.1.3.1 Muscular dystrophies directly related genes predominantly expressed in muscle 
The most common muscular dystrophy is Duchenne muscular dystrophy (DMD), which is caused 
by mutations in the DMD gene encoding dystrophin, located on the X-chromosome (Hoffman et 
al., 1987). DMD boys suffer from early onset muscle weakness resulting in delayed walking and calf 
hypertrophy. Patients are usually wheelchair bound by the mid-teens and usually die from cardiac 
failure or respiratory arrest in their mid- to late twenties (Hoffman et al., 1987; Muntoni et al., 
2003). In DMD patients, dystrophin expression is usually lost due to nonsense mutation or large 
deletions resulting in a frameshift. In frame deletions in DMD that result in a shorter but partially 
functional dystrophin protein are associated with Becker muscular dystrophy (BMD) (Chaturvedi et 
al., 2001; Muntoni et al., 2003). BMD patients usually have a milder disease, with later onset of 
symptoms and can remain ambulant for life (McNally and Pytel, 2007). Treatment for DMD is 
currently not available, however, gene therapy including splice modulation by antisense 
oligonucleotides to restore dystrophin expression are currently being tested in clinical trials (Cirak et 
al., 2011; Goemans et al., 2011). 
The different phenotype between DMD and BMD shows the importance of dystrophin to the 
muscle. Dystrophin is a large protein and a main part of the dystrophin-associated glycoprotein 
complex (DGC) (Fig. 1.1). The cysteine-rich C-terminus of dystrophin directly binds to β-
dystroglycan, a transmembrane protein located at the sarcolemma, which is connected to the 
extracellular matrix via α-dystroglycan (Ibraghimov-Beskrovnaya et al., 1992). The central part of 
dystrophin contains 24 spectrin repeats interrupted by four hinge points (Koenig and Kunkel, 1990) 
and at its N-terminus is a calponin-like actin binding domain, which binds to F-actin of the 
cytoskeleton (Rybakova et al., 2000). Hence, dystrophin forms a strong link between the 
cytoskeleton and the extracellular matrix. A disruption of this link induces pathological myofibre 
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damage, which leads to successive rounds of regeneration (Straub et al., 1997). Over time muscle 
tissue gets replaced by adipose and connective tissue leading to the failure of the muscle. 
Other examples of genes primarily expressed in muscle and involved in muscular dystrophy are 
sarcoglycans and dysferlin, both associated with limb-girdle muscular dystrophy (LGMD), which 
resembles Duchene-type dystrophy (McNally and Pytel, 2007). Sarcoglycans are transmembrane 
proteins located at the sarcolemma and form a unit with the DGC (Ozawa et al., 2005) (Fig. 1.1). 
Mutations in sarcoglycans also disrupt the DGC, leading to myofibre damage and muscular 
dystrophy. 
In contrast, dysferlin, also a membrane bound protein, is not associated with the DGC and plays a 
different pathogenic role when disrupted. Dysferlin is highly expressed in skeletal and cardiac 
muscle and has been shown to play a role in vesicle trafficking and membrane repair. Loss of 
dysferlin results in defective membrane repair and progressive myofibre loss, and leads to a 
dystrophic phenotype (Bansal et al., 2003).  
1.1.3.2 Muscular dystrophies caused by nuclear proteins 
In addition to mutations in genes primarily expressed in muscle tissues, muscular dystrophies are 
also caused by mutations in ubiquitously expressed nuclear proteins. Examples are oculopharyngeal 
muscular dystrophy (OPMD), associated with nuclear aggregates of poly A binding protein 1 
(PABPN1) (Fan et al., 2001) and Emery-Dreifuss muscular dystrophy (EDMD) which is associated 
with mutations in proteins of the inner and outer nuclear membranes (emerin (Bione et al., 1994) 
and nesprins (Zhang et al., 2007)) or nuclear lamins (Bonne et al., 1999). 
EDMD was first described by Alan Emery and Fritz Dreifuss in 1966 as an “unusual type of 
benign X-linked muscular dystrophy” that is distinct from DMD and BMD (Emery and Dreifuss, 
1966). EDMD is characterized by the clinical triad of (1) early joint contractures of elbows, Achilles 
tendons and posterior neck, (2) childhood onset of slowly progressive muscle wasting with an early 
humero-peroneal distribution later affecting the limb-girdle musculature and (3) adult onset cardiac 
disease, which is characterised by cardiomyopathy, atrio-ventricular conduction defect and 
arrhythmias (Emery, 2000).  
Skeletal muscle biopsies from EDMD patients show mild dystrophic changes including split, 
necrotic and regenerating fibres with central nuclei. Muscle fibres are variable in size (hypertrophic 
and atrophic) and an increase in endomysial connective tissue is frequently observed (Mittelbronn 
et al., 2006; Sewry et al., 2001). Unlike DMD, EDMD is not associated with repeated rounds of 
muscle degeneration and regeneration. Currently there is no treatment available for EDMD. 
However, if diagnosed early, patients receive a pacemaker or implantable cardioverter-defibrillator 
(ICD) to prevent sudden cardiac death, which is the primary cause of death in EDMD patients. 
There are three forms of EDMD, the X-linked form (X-EDMD) is caused by mutations in EMD 
(Bione et al., 1994) and FHL1 (Gueneau et al., 2009), the autosomal dominant (AD) and autosomal 
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recessive forms are both caused by mutations in LMNA (Bonne et al., 1999; Raffaele Di Barletta et 
al., 2000). The FHL1 gene encodes a LIM domain protein containing two zinc fingers in tandem 
which has been implicated in sarcomere assembly (Gueneau et al., 2009; McGrath et al., 2006). 
EMD encodes emerin, a transmembrane protein located at the inner nuclear membrane and 
LMNA encodes A-type lamins forming the nuclear lamina underlying the inner nuclear membrane. 
Mutations in EMD usually result in a loss of emerin expression while the majority of LMNA 
mutations that cause EDMD are missense mutations. The functions of emerin and lamin, as well 
their role in disease pathology are reviewed in detail in the sections below.  
The overall prevalence for EDMD is approx. 1:50,000 (Juliet Ellis, personal communication) 
however for X-EDMD it is estimated to be 1:100,000 (Bonne et al., 1993). Also, of all diagnosed 
EDMD patients, 56%-64% do express emerin and have no mutation identified in EMD, FHL1 or 
LMNA suggesting that yet unidentified genes play a role in EDMD pathology (Gueneau et al., 
2009; Meinke et al., 2011). 
Mutations in LMNA have also been associated with other muscular dystrophies such as lamin-
associated congenital muscular dystrophy (L-CMD) (Quijano-Roy et al., 2008), limb-girdle muscular 
dystrophy (LGMD1B) (Muchir et al., 2000) and cardiomyopathy with conduction defects (DCM-
CD) (Fatkin et al., 1999) as well as other disorders. The diseases caused by mutations in lamins 
(collectively called laminopathies) are reviewed in section 1.4. 
1.1.3.3 Potential contribution of a dysfunctional satellite cell pool to muscular dystrophy 
Satellite cells have been suggested to contribute to both muscle protein specific muscular 
dystrophies as well as muscular dystrophies associated with ubiquitously expressed genes (Gnocchi 
et al., 2008; Morgan and Zammit, 2010). Satellite cells can either contribute indirectly to the 
pathology by exhaustion of satellite cells or directly by a defective pool which is unable to progress 
through one or more steps in the myogenic pathway. 
The former has been shown to be the case in the pathology of DMD. Excessive myofibre damage 
caused by the lack of dystrophin protein induces myofibre degeneration and satellite cell mediated 
repair (Straub et al., 1997). Since satellite cell derived myofibres also lack dystrophin, the muscle will 
continue to accumulate myofibre damage and be replaced in subsequent rounds of regeneration. 
These chronic rounds of degeneration and repair lead to a decline in the replicative capacity of 
myoblasts (Webster and Blau, 1990). This constant demand for a large number of satellite cells may 
ultimately lead to their exhaustion, resulting in a progression of the dystrophic phenotype. Indeed 
the dystrophic phenotype is worse in mice where telomerase is inactivated, presumably due to 
limited satellite cell proliferation (Sacco et al., 2010). 
In contrast, pathogenic mutations in nuclear proteins might affects satellite cells directly. Mutations 
may delay satellite cell activation from quiescence; they may affect myoblast proliferation and 
expansion; block their ability to differentiate and form new myofibres; or hinder their fusion to 
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existing fibres (Morgan and Zammit, 2010). On one hand, defective satellite cells may affect muscle 
in pre- or postnatal development, where satellite cells continue to supply myoblasts, which could 
explain congenital muscular dystrophy. On the other hand, defective satellite cells could also affect 
muscle homeostasis and repair in adult muscle which could explain the pathology of late onset 
muscular dystrophies (Morgan and Zammit, 2010). One example where defective satellite cells may 
play a role is in the pathology of EDMD, by targeting cell cycle dependent events since EDMD 
proteins are known to have an indirect role in these (Gnocchi et al., 2008; Morgan and Zammit, 
2010). Lamins and emerin as well as their interacting proteins demonstrate a large array of functions 
in the nucleus including chromatin organisation, cell cycle regulation and gene transcription. The 





1.2 The nuclear envelope 
1.2.1 Structure and function of the nuclear envelope 
In eukaryotes, the genetic material is confined in the largest organelle of the cell, the nucleus. Each 
nucleus is delimited by a structure called nuclear envelope consisting of two phospholipid bilayers 
(the inner and outer nuclear membrane) as well as the nuclear lamina, a proteinaceous meshwork 
underlying the inner nuclear membrane (Hetzer, 2010; Pederson, 2011). The outer nuclear 
membrane is continuous with membranes forming the endoplasmic reticulum. Although the inner 
and outer nuclear membranes are continuous, they maintain a specific protein composition (see 
below). The inner nuclear membrane is closely associated and structurally supported by the 
underlying nuclear lamina which is formed by a sheet of intermediate filament proteins (Dechat et 
al., 2010). Spotted throughout the nuclear envelope are nuclear pore complexes (NPCs) penetrating 
the nuclear membranes and the nuclear lamina. NPCs allow bidirectional trafficking of high 
molecular weight molecules such as nucleic acids and proteins between the nucleus and the 
cytoplasm (Wente and Rout, 2010). The main function of the nuclear envelope is to protect the 
genetic information and to provide a compartment to concentrate enzymes and substrates for 
biochemical processes at work in the nucleus such as DNA replication, transcription, RNA 
processing and ribosome synthesis.  
1.2.2 Nuclear envelope proteins 
To date, a large number of proteins have been described to be associated with the nuclear envelope. 
These include transmembrane proteins located at the inner or outer nuclear membrane as well as 
nuclear lamins and lamin associated proteins (Wilson and Foisner, 2010). Figure 1.3 gives an 
overview of the nuclear envelope and its components and their interaction with regulatory proteins 
and signalling cascades. A short description of the major nuclear envelope proteins is given below. 
1.2.2.1 Emerin 
Emerin is a serine-rich transmembrane protein located at the inner nuclear membrane and is widely 
expressed in humans as shown by mRNA and protein studies (Bione et al., 1994; Nagano et al., 
1996). The N-terminus of emerin contains a LEM domain (common to LAP2, emerin and MAN1) 
which binds barrier-to-autointegration factor (BAF), a small DNA crosslinking molecule (Lee et al., 
2001). Emerin has been shown to interact with a multitude of binding partners including structural 
proteins such as lamins (Clements et al., 2000), actin (Fairley et al., 1999) and nesprins (Zhang et al., 
2005) as well as transcriptional repressors such as germ-cell-less (GCL) (Holaska et al., 2003) and 
BCL2-associated transcription factor (Btf) (Haraguchi et al., 2004). The localisation of emerin to the 





Figure 1.3 Structure and function of the nuclear envelope. Schematic representation of the nuclear envelope, 
and the interaction of nuclear envelope transmembrane proteins with the nuclear lamina and chromatin. See main 
text for a detailed explanation. ? represents unknown/undescribed nuclear envelope transmembrane proteins. 
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Mutations in EMD are associated with X-linked Emery-Dreifuss muscular dystrophy mainly due to 
nonsense mutations resulting in a loss of emerin expression (Bione et al., 1994; Nagano et al., 1996; 
Yates and Wehnert, 1999). However, missense mutations and in-frame deletions in EMD have also 
been associated with X-EDMD (Brown et al., 2011). Emerin null mice do not display an obvious 
skeletal muscle phenotype or joint abnormalities (Melcon et al., 2006; Ozawa et al., 2006). However, 
mice greater 40 weeks of age demonstrate a prolongation of atrioventricular conduction time 
(Ozawa et al., 2006). In a genome wide expression analysis hearts from emerin null mice showed 
increased Erk1/2 mitogen-activated protein kinase (MAPK) signalling and activation of downstram 
targets (Muchir et al., 2007a). 
1.2.2.2 Lamin B receptor 
The lamin B receptor (LBR) is targeted to the inner nuclear membrane via 8 transmembrane 
domains (Worman et al., 1990). The LBR directly binds lamin B and has been shown to interact 
with double stranded DNA (Ye and Worman, 1994), the heterochromatin-associated protein-1 
(HP1) (Ye and Worman, 1996), chromatin associated protein HA95, lamin associated protein-2β 
(LAP2β) and emerin (Martins et al., 2000). HP1 directly interacts with methylated H3K9 via its 
chromo domain bridging the nuclear lamina with heterochromatin (Ye et al., 1997). LBR also has a 
conserved Tudor domain which binds H4K20me2 and a sterol reductase domain, the function of 
which is unclear. Taken together, LBR might play a role in post-mitotic nuclear reformation as well 
as compartmentalisation of heterochromatin in the interphase nucleus (reviewed in Olins et al. 
(2010)). 
1.2.2.3 Lamin associated proteins 
The lamin associated polypeptide (LAP) family is encoded by two genes. LAP1 proteins (LAP1A, 
LAP1B and LAP1C) as well as two out of six LAP2 proteins (LAP2β-ε) contain a C-terminal 
transmembrane domain and are localised to the inner nuclear membrane. LAP2α and LAP2ζ lack 
the transmembrane domain and are found in the nucleoplasm (Berger et al., 1996; Foisner and 
Gerace, 1993). All LAP isoforms share an N-terminal LEM-domain which binds BAF (Furukawa, 
1999; Shumaker et al., 2001) (see section 1.2.2.1). LAP1A and LAP1B have been shown to bind to 
A and B-type lamins, whereas LAP2C only binds lamin B (Foisner and Gerace, 1993). 
Lap2α directly interacts with nucleoplasmic lamin A (Dechat et al., 2000) and together, they have 
been shown to form a complex with the retinoblastoma protein (pRb) (Markiewicz et al., 2002). 
Overexpression of Lap2α in vitro results in cell cycle repression of E2F-dependent transcription in 
an pRb dependent manner (Dorner et al., 2006) while loss of Lap2α has different effects on the cell 
cycle depending on the organism for yet unknown reasons. In human fibroblasts, loss of Lap2a 
induces cell cyle arrest (Pekovic et al., 2007) while in mice, loss of Lap2α (Naetar et al., 2008) or 
lamin A/C (Nitta et al., 2006; Van Berlo et al., 2005) is associated with cell cycle progression. 
Interestingly, knocking out Lap2α in mice has been shown to induce a cardiac phenotype and result 
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in delayed satellite differentiation, although delayed muscle regeneration was not observed (Gotic et 
al., 2010a; Gotic et al., 2010b). 
1.2.2.4 SUN-domain proteins 
SUN (Sad1, UNC-84 homology) domain proteins SUN1 and SUN2 are located to the INM and 
have a central helical coil domain that mediates dimerization (Tzur et al., 2006). The N-terminal 
domain is exposed to the nucleoplasm and has been shown to interact directly with A-type lamins 
(Haque et al., 2006) as well as emerin and short nesprin-2 isoforms (Haque et al., 2010). The C-
terminal SUN-domain protrudes into the perinuclear space and interacts with the KASH (Klarsicht, 
ANC1, Syne homology) domain found in nesprins, forming the LINC complex (linker of 
nucleoskeleton and cytoskeleton) (Crisp et al., 2006; Padmakumar et al., 2005). Disruption of the 
LINC complex has been shown to induce defects in nuclear morphology (Khatau et al., 2009) and 
affect the localisation of skeletal muscle nuclei as well as strain transmission between the cytoplasm 
and nucleus (Lombardi et al., 2011; Zhang et al., 2010).   
1.2.2.5 Nesprins 
Nesprins (Nuclear envelope spectrin repeat proteins) comprise of a large protein family of spectrin 
repeat proteins encoded by four genes (SYNE1-4) (Mellad et al., 2011). Nesprins are characterised 
by a central rod region, variable in length, and a C-terminal KASH transmembrane domain which 
facilitates nuclear membrane localisation and interacts with the SUN-domain in the perinuclear 
space forming the LINC complex (Crisp et al., 2006; Padmakumar et al., 2005). Two giant isoforms 
(nesprin-1 and 2) have N-terminal calponin homology (CH) domains which bind to F-actin. 
Nesprin 3 has an N-terminal plectin-binding motif which interacts with cytoplasmic intermediate 
filament proteins and nesprin-4 directly interacts with microtubules (Roux et al., 2009; Wilhelmsen 
et al., 2005; Zhen et al., 2002). Nesprins are localised both to the ONM and INM depending on 
their size and interaction partners (Razafsky and Hodzic, 2009). Human patients with missense 
mutations in nesprin-1 and 2 (Zhang et al., 2007) as well as mice with a deletion of the KASH 
domain in nesprin-1 (Puckelwartz et al., 2009), show a skeletal muscle phenotype resembling 
EDMD. However, it has not been excluded that the missense mutations are in fact polymorphisms 
in these patients and thus not EDMD-causing. 
1.2.2.6 MAN1 
MAN1 (also known as LEMD3) is an integral protein of the INM. Located at the N-terminus is a 
LEM domain, located on the C-terminus is a winged helix domain which binds DNA, and an RR-
motif which is a binding site for regulatory Smads (R-Smads) (Bengtsson, 2007). MAN1 is 
anchored to the INM via two transmembrane domains meaning that both the N-and C-terminal 
end of the protein are inside the nucleoplasm. Being able to bind R-Smads but not inhibitory 
Smads, MAN1 acts as an inhibitor of BMP and TGF-β signalling. Overexpression of MAN1 has 
been shown to block transcription of BMP and TGF-β targets upon cytokine stimulation. At the 
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same time, loss of MAN1 at the INM results in increased TGF-β signalling (Lin et al., 2005). Loss-
of-function mutations in MAN1 result in osteopoikilosis, Buschke-Ollendorff syndrome and 
melorheostosis, phenotypes characterised by increased bone density and associated with increased 
TGF-β signalling (Hellemans et al., 2004). 
1.2.2.7 Other/novel nuclear envelope transmembrane proteins (NETs) 
Other nuclear envelope transmembrane proteins include a large number of uncharacterised nuclear 
envelope transmembrane proteins (NETs). In 2003 Schirmer E.C. and colleagues performed a large 
scale proteomics analysis on the nuclear envelope which resulted in the identification of 67 novel 
proteins (Schirmer et al., 2003). Some of the novel NETs are ubiquitously expressed and have been 
shown to regulate the cell cycle (Korfali et al., 2011) while others have a tissue specific chromatin 
organisation expression pattern and are involved in the regulation of differentiation (Schirmer EC, 
personal communication).  
1.2.2.8 Nuclear lamins 
Nuclear lamins are the major component of the nuclear envelope and form the nuclear lamina, a 
proteinaceous network underlying the inner nuclear membrane. Lamins are members of the 
intermediate filament protein family and divided into A-type lamins (lamins A and C) and B-type 
lamins (lamin B1 and lamin B2). Mutations in lamins have been shown to cause a variety of diseases 
with a large range of phenotypes collectively called laminopathies (reviewed in the following 




1.3 Type V intermediate filaments: nuclear lamins 
1.3.1 The intermediate filament protein family 
Intermediate filament (IF) proteins by definition assemble into filaments 9-10nm in diameter and 
are a major component of the cytoskeleton and nucleoskeleton (Herrmann and Aebi, 2004). 
Intermediate filaments were named because of their intermediate size forming a cytoarchitectural 
bridge between microfilaments (MFs, 7nm in diameter) and microtubules (MTs, 20-25nm in 
diameter) (Ishikawa et al., 1968). MFs and MTs are rather sensitive to shear stress compared to IFs 
which show more viscoelastic properties under the same conditions (Janmey et al., 1998).  
IF proteins are grouped into five sequence homology classes (SHCs). These are acidic keratins 
(SHC I), basic keratins (SHC II), desmin-/vimentin type proteins (SHC III), neurofilament proteins 
(SHC IV) and later discovered insoluble members of the nuclear lamina, the lamins (SHC V) 
(Herrmann and Aebi, 2004). To date, 73 intermediate filament proteins have been described in 
human where keratins (54/73 form the largest group) (Szeverenyi et al., 2008). 
All IF proteins share a common tripartite domain organisation formed by the central rod domain 
flanked by a short N-terminal head domain and a larger C-terminal tail domain (Fuchs and Weber, 
1994). The central rod domain is highly conserved between intermediate filaments and is 
characterised by a heptad substructure which allows the formation α-helical coiled-coils leading to 
dimerisation of two IF proteins ((Herrmann and Aebi, 2004), Appendix 1).  
1.3.2 Discovery and evolutional origin of lamins 
The nuclear lamina (then known as ‘fibrous lamina’ from studies in the Amoeba (Pappas, 1956)) was 
first described in vertebrate cells in an ultrastructural analysis of nuclei from various animals 
including leech, cat and guinea pig (Fawcett, 1966). Later, Larry Gerace and colleagues raised 
antibodies against 3 polypeptide chains (P70, P67 and P60, later termed lamins A, B and C) present 
in the nuclear lamina, which they isolated together with nuclear pore complexes from rat liver 
nuclei (Gerace et al., 1978). The antibodies were used in immunofluorescence staining and marked 
the nuclear lamina in K22 rat liver cells. Importantly, Gerace et al. also noted a disintegration of the 
lamina in mitotic cells stained with antibodies raised against P70 (lamin A) and concluded correctly 
that a major portion of the lamina is in fact a polymer which undergoes reversible disassembly 
during mitosis (Gerace et al., 1978). In a follow up paper they analysed lamin A, C and B 
individually and found that mitotic lamins A and C occur in a soluble state, while mitotic lamin B is 
membrane associated. Further, the analysis of the isoelectric point of mitotic lamins led them to the 
conclusion that reversible enzymatic phosphorylation of lamins may be involved in modulating the 
polymerisation state of the lamina during mitosis (Gerace and Blobel, 1980). This landmark paper 
sparked the field of lamin research which is growing larger ever since. 
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The main difference between cytoplasmic IFs and nuclear lamins in vertebrates is that the central 
rod domain of lamins is 42 amino acids (six heptads) longer. Lamins also have a nuclear localisation 
signal (NLS) and a C-terminal CaaX cassette which serves as a target for a series of posttranslational 
modifications both lacking in cytoplasmic IFs. Lamins are found in all metazoans however simple 
metazoans only express nuclear IFs suggesting that cytoplasmic IFs originated from an ur-lamin 
(Erber et al., 1999). Further, the rod domains of invertebrate IFs is the 42 amino acids longer than 
that if vertebrate IFs and therefore closer to nuclear lamins supporting this theory (Weber et al., 
1988; Weber et al., 1989). 
Invertebrates have only one lamin gene with exceptions such as D. melanogaster which expresses two 
nuclear lamins, lamin A and B. Vertebrates have four lamin genes (encoding lamin B1, B2, LIII and 
lamin A), acquired after two rounds of genome duplications that possibly occurred in the ancestral 
vertebrates. Amphibians, fish and birds still possess all four lamin genes; mammals however have 
lost the LIII gene (reviewed in (Peter and Stick, 2012)).   
1.3.3 Lamin genes and proteins  
Lamins are divided into two groups based on their sequence homology, structural features and 
dynamic properties: (1) A-type lamins (Lamin A, A-Δ10 and C) expressed by the LMNA gene 
through alternative splicing (Fig. 1.2) and (2) B-type lamins (lamin B1 and B2) expressed by 
LMNB1 and LMNB2 respectively. Both lamin types are described in detail below. 
1.3.3.1 A-type lamins 
A-type lamins are expressed in all vertebrates by the LMNA gene located on human chromosome 
1q (Lin and Worman, 1993; Wydner et al., 1996). The LMNA gene contains 12 exons and is 
alternatively spliced to give rise to 3 proteins: lamin A, lamin A-Δ10 and lamin C (Fig. 1.4). Lamin 
A is produced by alternative splicing of exon 10. It is 664 amino acids in length and the longest 
isoform of A-type lamins. The lamin C protein ends at exon 10 which makes it identical to lamin A 
up to codon 566. The last six amino acids (567-572) are unique to lamin C (Lin and Worman, 
1993). Lamin A-Δ10 lacks exon 10, shortening the tail domain by 30 amino acids (Fig. 1.4) 
(Machiels et al., 1996). 
The major isoforms, lamin A and C, are expressed in the majority of differentiated cells but are 
lacking in embryonic stem cells (ESCs) (Constantinescu et al., 2006). In most tissues, lamin A and C 
are expressed at equal levels. In the brain however, lamin C is the predominant form of A-type 
lamin, likely due to the expression of miR-9, a brain-specific microRNA which has been shown to 
specifically down-regulate lamin A (Jung et al., 2011). The minor isoform lamin A-Δ10 has been 
detected in tumour cell lines as well as several normal cell types but is not well characterised 
(Machiels et al., 1996). In mouse, the LMNA gene has been shown to give rise to a fourth splice 
30 
 
variant termed lamin C2. Lamin C2 has an alternative start site in LMNA intron 1 and its 
expression is restricted to the germline (Furukawa et al., 1994). 
In man, loss of A-type lamins is postnatally lethal (van Engelen et al., 2005). In mice however, 
absence of lamin A and C does not produce an embryonic phenotype but the mice suffer growth 
retardation, muscle dystrophy and die prematurely (Sullivan et al., 1999). 
 
 
Figure 1.4 The LMNA gene and lamin proteins. The LMNA gene is alternatively spliced and gives rise to lamin A, 
lamin AΔ10 and lamin C. The C-terminal end of lamin C (residues 567-572, highlighted in purple) is specific to lamin 
C. 
 
1.3.3.2 B-type lamins 
B-type lamins (lamin B1 or lamin B2) are encoded by LMNB1 and LMNB2 respectively and all 
metazoans express at least one B-type lamin (Hoger et al., 1990; Vorburger et al., 1989). In mice, 
LMNB2 has been shown to give rise to an alternative splice product, lamin B3, which is restricted 
to the germline (Furukawa and Hotta, 1993). In mammals, at least one B-type lamin is expressed in 
all somatic cell types including undifferentiated cells in early stages of embryonic development (Liu 
et al., 2011; Stewart and Burke, 1987). 
B-type lamins have been associated with the assembly of the mitotic spindle matrix as well as DNA 
replication, genome organisation and apoptosis and are therefore thought to be essential for 
proliferation and cell survival (Guelen et al., 2008; Harborth et al., 2001; Liu et al., 2000; Tsai et al., 
2006). Mice with homozygous mutations disrupting the lamin B1 protein develop lung and bone 
defects during embryogenesis and die at birth, even though lamin B2 is expressed normally 
(Vergnes et al., 2004). Fibroblasts from lamin B1 mutant mice display severely dysmorphic nuclei, 
impaired differentiation and premature senescence (Vergnes et al., 2004). 
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Recently, several groups have challenged the essential role of B-type lamins in basic cell function 
and produced a series of publications which reshaped the current view. Using a conditional 
knockout system, Yang et al. showed that keratinocytes which lack both lamin B1 and lamin B2 
have no defects in cell proliferation and have normal skin or hair development (Yang et al., 2011). 
The same group showed that forebrain-specific removal of lamin B1 and B2 results in severe 
atrophy of the cortex, demonstrating an essential role in brain development (Coffinier et al., 2011). 
Using a total lamin B knockout mouse, Kim et al. found that B-type lamins are essential for 
organogenesis and brain development confirming results obtained in the conditional knockout. 
Interestingly, ES cells from the total knockout which lack all A and B-type lamins showed no 
abnormalities in emerin localisation or nuclear shape (Kim et al., 2011). 
In man, loss-of-function mutations in lamin B are not described. However, a gene duplication of 
LMNB1 is associated with autosomal dominant leukodystrophy, a neurological disorder 
characterised by myelin loss in the central nervous system (Padiath et al., 2006). 
1.3.3.3 Posttranslational processing of prelamin A  
All lamins (except lamin C) are expressed as a pre-form and end in a C-terminal CAAX cassette 
which undergoes a highly structured sequence of posttranslational modifications before mature 
lamins are incorporated into the nuclear lamina (Fig. 1.5). The CAAX cassette consists of a 
cysteine, two aliphatic amino acids and any COOH-terminal amino acid (Davies et al., 2009). 
The first step in this maturation process is a posttranslational prenylation step, where a 15-carbon 
farnesyl or a 20-carbon geranylgeranyl lipid is added to the thiol group of the cysteine, depending 
on the last (X) residue. When the last residue is a leucine or phenylalanine, the cysteine is 
geranylgeranylated by geranylgeranyltransferase type I (GGTase-I), otherwise (as it is the case for 
lamins) it is farnesylated by farnesyltransferase (FTase) (Zhang and Casey, 1996). 
Next, the last three amino acids (AAX) are cleaved off by either RCE1 (Ras converting enzyme-1) 
or ZMPSTE2424 (Zink-metalloproteinase STE24), both metalloproteinases located on the 
membrane of the endoplasmic reticulum (Schmidt et al., 1998). The farnesylated cysteine residue is 
then carboxymethylated by ICMT (isoprenyl-cysteine-carboxyl-methyl-transferase), another ER 
bound enzyme (Dai et al., 1998). Lamins A and B share these first three modifications steps.  
Mature B-type lamins remain permanently farnesylated and are believed to be membrane associated 
through their hydrophobic farnesyl group (Farnsworth et al., 1989). Prelamin A undergoes a second 
endoproteolytic cleavage step carried out by Zmpste24, the only enzyme known so far to perform 
this cleavage (Bergo et al., 2002; Pendas et al., 2002). This final cut removes the last 15 amino acids 
including the farnesyl-cysteine and solubilizes the mature form of lamin A before it gets targeted to 






Figure 1.5 Posttranslational processing of prelamin A. In a sequence of prelamin A prenylation, the first 
endoproteolytic cleavage, methylation and the second endoproteolytic cleavage, the last 18 amino acids of the C-
terminal tail of prelamin A are removed which forms mature lamin A. Lamin B lacks the second proteolytic cleavage 
site and stays permanently farnesylated. 
 
Faulty posttranslational processing of prelamin A is associated with a number of pathologies. A 50 
amino acid deletion in the tail domain of lamin A, caused by a point mutation (c.1824C>T; 
p.G608G) which activates a cryptic splice site in exon 11, has been shown to cause Hutchinson-
Gilford progeria syndrome (HGPS), a premature ageing syndrome (De Sandre-Giovannoli et al., 
2003; Eriksson et al., 2003). The protein product with the deletion (termed progerin) lacks the 
second endoproteolytic cleavage site and remains permanently farnesylated. Similarly, mutations in 
ZMPSTE24 also lead to permanently farnesylated prelamin A, resulting in restrictive dermopathy 
(RD) and other progeroid phenotypes (Agarwal et al., 2003; Navarro et al., 2004; Shackleton et al., 
2005). Further, missense mutations of residues in the Zmpste24 recognition site (RSYLLG) have 
been shown to partially inhibit cleavage by ZMPSTE24 (Barrowman et al., 2012) and are associated 
with a large array of phenotypes including muscular dystrophy and premature ageing (Csoka et al., 
2004; Genschel et al., 2001; Rankin et al., 2008). For a detailed description of the pathology and 
pathogenic mechanism of progerin, see section 1.4. 
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1.3.4 Structure and assembly of A-type lamins 
Lamins, like all intermediate filament proteins, are characterised by a tripartite structural 
organisation which consists of a short globular head domain, a central rod domain and a long 
globular tail domain. The basic features of lamin A are schematically represented in figure 1.6.  
1.3.4.1 The central rod domain 
The central rod domain of lamin A is formed of 2 α-helical coils, coil 1 and coil 2, separated by a 
flexible hinge region (L12). Coil 1 and coil 2 are subdivided by linkers L1 and L2 respectively which 
are relatively rigid and seem to adopt an α-helical conformation (North et al., 1994; Smith et al., 
2002) (Fig. 1.6A). Coils 1 and 2 are characterised by a heptad repeat pattern typical for α-helices 
which engage in coiled-coil interaction (Conway and Parry, 1990; Herrmann and Aebi, 2004; Mason 
and Arndt, 2004). 
In a typical α-helical, approximately 70-75% of the a and d positions in the heptad repeat pattern (a-
b-c-d-e-f-g)n are hydrophobic residues (Conway and Parry, 1990). These are on average 3.5 residues 
apart and will form a stripe of hydrophobic residues on the surface of the α-helix, which facilitates 
hydrophobic interaction of two or more α-helices (Fig. 1.6B) (Parry et al., 2008). Importantly, helix-
stabilising hydrogen bonds in the vicinity of hydrophobic residues are slightly shorter than those 
further away resulting in the helices coiling around each other in a left-handed manner (Cohen and 
Parry, 1990). The α-helical coiled-coil formation of part of the lamin A central rod domains was 
confirmed by crystal structure (Strelkov et al., 2004). A typical example of a heptad repeat sequence 
(taken from the lamin A central rod domain) is illustrated in figure 1.6C. 
Approximately 30 amino acids of the C- and N-terminal ends of coil 1 and coil 2 of lamin A 
respectively, are highly conserved among IFs. These intermediate filament consensus motifs 
(IFCMs) are thought to play a crucial role in filament assembly (Kapinos et al., 2010). Structural 
data show that rod fragments of lamin A containing IFCMs form relatively labile coiled coils which 
might promote “unzipping” of lamin A dimers and allow α-helices to engage in interaction with a 
neighbouring dimer (Kapinos et al., 2011). This hypothesis is supported by the observation that 
vimentin with a mutated IFCM demonstrated an increased thermodynamic stability but fails to 
form long filaments in vitro and in situ (Meier et al., 2009). 
1.3.4.2 The Ig-like fold domain 
The tail region of all lamin proteins contains a conserved Immunoglobulin-like fold (Ig-like fold) 
domain. In lamin A, it stretches from residue 428-547 and comprises two β-sheets which fold to 
form a β-sandwich. The 3D structure of the Ig-fold domain has been solved independently by 









Figure 1.6 Structures of the central rod domain and Ig-fold domain of lamin A. (A) Schematic of the lamin A 
protein. (B) Structure of α-helical coiled coil formed by part of central rod domain of lamin A. Residues on heptad 
repeat positions a and d are highlighted in red and form a seam at the interface of the two α-helices (taken from 
(Kapinos et al., 2011)). (C) Two consecutive heptad repeats (residues 338-351) from the human lamin A central rod 
domain are shown. Sequences of α-helical coiled-coils display a periodicity of seven amino acids (heptad repeats) 
with nonpolar amino acids occupying heptad positions a and d. Occasionally charged amino acids are located on 
position a or d such as lysine 341. In this case, lysine 341 forms a salt bridge with a glutamate residue of the 
neighbouring α-helix, reinforcing the coiled coil (Kapinos et al., 2011). (D) NMR structure of the Ig-like fold domain of 
lamin A (Krimm et al., 2002). Two β-sheets comprised of nine strands forming a β-sandwich are shown in cartoon 
representation. The surface of the molecule is indicated in faint grey. (E) Two dimensional representation of the lamin 
A Ig-like fold. Amino acid residues located on strands c and f (orange) as well as b and e (lavender) form a 






Ig-folds (as the name suggests) were first described in immunoglobulins and have seven to nine 
antiparallel β-strands forming two distinct β-pleated sheets which fold into a β-sandwich (Bork et 
al., 1994). Ig-folds and Ig-like folds both have the same structural arrangement though the number 
of strands and their arrangement does vary between different proteins. Common to all Ig-like 
domains is a 2-plus-2 stranded hydrophobic structural core formed by strands e and b of one β-
sheet and strands f and c of the other (Bork et al., 1994). Residues in this common core are aligned 
against each other which makes it is less flexible as compared to surrounding strands. Disruptions 
to core residues are thought to disrupt the stability of the domain, interfering with its function 
(Krimm et al., 2002).  
In lamins, the Ig-fold has been shown to bind to a large number of interacting proteins (see section 
1.3.5). It has also been shown that the Ig-like fold also plays a role in lamin assembly.  Introduction 
of a lamin B3 Ig-fold motif into Xenopus oocytes has been shown to be sufficient to inhibit lamin 
polymerisation (Shumaker et al., 2005).     
1.3.4.3 Lamin filament assembly and disassembly 
Intermediate filaments assemble in 3 different assembly groups: 1 2 and 3 (reviewed in Herrmann 
and Aebi (2004)). The assembly of nuclear lamin (assembly group 3) is illustrated in figure 1.7. 
Initially, two lamin monomers form a parallel dimer by a coiled-coil α-helix of the central rod 
domains. These lamin dimers form polar head to tail polymers, which associate with other head-to-
tail polymers in an antiparallel fashion to build 10nm IF fibres (Ben-Harush et al., 2009). In 
contrast, cytoplasmic IF dimers (assembly group 1 and 2) associate laterally to build antiparallel 
tetramers and unit length filaments (10nm in diameter), which elongate to form IF fibres 
(Herrmann et al., 2009; Stuurman et al., 1998). 
A and B-type lamins form separate filament networks as seen by whole mount electron microscopy 
in Xenopus oocytes (Goldberg et al., 2008) and high resolution confocal microscopy of human cells 
(Shimi et al., 2008). However there is strong evidence that these two networks interact with each 
other such as the mislocalisation of lamin B in cells lacking A-type lamins as well as cell expressing 
mutant lamin A (Muchir et al., 2004; Ostlund et al., 2001; Sullivan et al., 1999; Taimen et al., 2009). 
Lamin A and C have been shown to form heterodimers in vitro, however, whether they also 
heterodimerise in vivo and form a filament network is in question (Herrmann H., personal 
communication). Pull down assays of the soluble A-type lamin fraction has shown that lamin A and 
C completely segregate, suggesting that, at least in the soluble fraction, lamin A and C do not form 





Figure 1.7 Mechanism of lamin filament assembly. Two lamin monomers dimerise and associate into polymers in 
a head-to-tail arrangement. Multiple of these primary filaments continue to associate laterally with other head-to-tail 
polymers to form 10nm intermediate filament fibres. 
 
During mitosis the lamin filament network is disassembled in a process called nuclear envelope 
breakdown (NEBD). In this process cyclin dependent kinase-1 (Cdk1), protein kinase C (PKC) and 
other mitotic kinases phosphorylate lamins, Nups, LAP2 and LBR, leading to depolymerisation and 
solubilisation of lamins (Guttinger et al., 2009; Margalit et al., 2005). In late anaphase and telophase, 
the nuclear envelope attaches to and spreads around the condensed chromatin in the daughter cells, 
possibly with the help of the DNA-binding activity of some INM proteins (Ulbert et al., 2006). 
Concomitantly, NPCs get integrated into the newly forming NE. Once the nuclear membrane is 
formed around the chromosomes, B-type lamins get dephosphorylated by protein phosphatase 1 
(PP1) and start to assemble at the nuclear lamina (Steen and Collas, 2001). A-type lamins are 
imported through the newly formed NPCs and assemble to reform an intact nuclear lamina (Broers 
et al., 1999). 
1.3.5 Lamin binding proteins and their implication in disease 
Lamins interact with a large variety of nuclear proteins and are therefore involved in numerous 
cellular processes and mutations in lamins result in a range of phenotypes termed laminopathies 
(Wilson and Foisner, 2010; Zastrow et al., 2004). The pathogenic mechanism for the majority of 
LMNA mutations is still unknown. However, proposed disease mechanisms for laminopathies are 
closely linked to the function of lamins and lamin interacting proteins (Broers et al., 2006; Worman 
and Bonne, 2007). 
The functions of lamins and their interacting proteins can be classified into 3 major groups: (1) 
maintaining the integrity of nuclear structure and mechanics, (2) regulation of DNA replication and 
cell cycle and (3) modulation of gene expression and cell signalling pathways. The major lamin 
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interacting proteins described so far as well as the region in lamin A they bind to are depicted in 
figure 1.8. For details in their implication in disease refer to section 1.4.2. 
 
 
Figure 1.8 Lamin A interacting proteins. The schematic shows the lamin A protein and lamin A interaction 
partners, modified and updated from Zastrow et al. (2004).  
 
Lamin binding proteins include structural proteins: SUN1/2 (Haque et al., 2006; Haque et al., 
2010), nesprin-1α (Mislow et al., 2002), nesprin-2 (Zhang et al., 2005), emerin (Lee et al., 2001; 
Sakaki et al., 2001), actin (Sasseville and Langelier, 1998; Simon et al., 2010) and Nup88 (Lussi et al., 
2011); proteins involved in cell cycle regulation: pRb (Ozaki et al., 1994), Lap2α (Dechat et al., 
2000), cyclin D3 (Mariappan et al., 2007) and PCNA (Shumaker et al., 2008); and proteins involved 
in gene transcription and cell signalling: c-Fos, Erk1/2 (Gonzalez et al., 2008), MOK2 (Dreuillet et 
al., 2002), PKCα (Martelli et al., 2002), SREBP1 (Lloyd et al., 2002) and MAN1 (Mansharamani and 





1.4.1 Types of laminopathies 
Laminopathies are a heterogeneous group of diseases associated with defects in A-type lamins and 
can be separated into primary and secondary laminopathies. 
Primary laminopathies result from mutations in the LMNA gene and encompass at least 16 
different diseases that can be categorised into 4 major phenotypic groups: (1) diseases affecting 
striated muscle, either skeletal muscle with/without cardiac involvement or cardiac muscle only, (2) 
lipodystrophy disorders affecting white adipose tissue and/or the skeleton, (3) peripheral 
neuropathy associated with demyelination of motor neurons, (4) premature aging syndromes. Some 
LMNA mutations have been associated with isolated phenotypes or heterogeneous disorders 
comprising overlapping pathologies in different tissues (summarised in table 1.1) (Worman 2012). 
Table 1.1 Categories of Laminopathies 
Skeletal muscle phenotype 
(with/without cardiac involvement) 
MIM# Ref. where first described 
AD-Emery Dreifuss Muscular Dystrophy (AD-EDMD) 
AR-Emery Dreifuss Muscular Dystrophy (AR-EDMD) 
Limb-girdle muscular dystrophy type 1B (LGMD1B) 






(Bonne et al., 1999) 
(Raffaele Di Barletta et al., 2000)
(Muchir et al., 2000) 
(Quijano-Roy et al., 2008) 
Cardiac only phenotype MIM#  
Dilated Cardiomyopathy with conduction defects 
(DCM-CD) 
115200 (Fatkin et al., 1999) 
Premature ageing phenotypes MIM#  
Hutchinson-Gilford Progeria Syndrome (HGPS) 
Atypical Werner Syndrome (WS) 
Mandibuacral dyspasia with type A lipodystrophy 
(MADA) 






(Eriksson et al., 2003) 
(Chen et al., 2003) 
(Novelli et al., 2002) 
 
(Navarro et al., 2004) 
Lipodystrophy syndromes MIM#  
Dunningan-type Familial Partial Lipodystrophy (FPLD2) 
Köbberling-type Familial Partial Lipodystrophy (FPLD1)
151660 
608600 
(Shackleton et al., 2000) 
(Savage et al., 2004) 
Neuropathies MIM#  
Charcot Marie Tooth Disease type 2B1 (CMT-2B1) 
 





(De Sandre-Giovannoli et al., 
2002) 
(Rudnik-Schoneborn et al., 
2007) 





(Renou et al., 2008) 
(Decaudain et al., 2007) 
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Secondary laminopathies are caused by mutations in Zmpste24, leading to defects in 
posttranslational modification of A-type lamins and include restrictive dermopathy (Navarro et al., 
2004) and Mandibuloacral dysplasia (Agarwal et al., 2003). 
1.4.1.1 Striated muscle laminopathies 
Mutations affecting striated muscle can be divided into those resulting in skeletal muscle 
laminopathies with or without cardiac involvement, and those affecting cardiac tissue only. 
The first mutations identified in the LMNA gene were those causing autosomal dominant Emery-
Dreifuss muscular dystrophy (AD-EDMD) characterised by the clinical triad consisting of joint 
contractures, slowly progressive muscle weakness with a humero-peroneal distribution and cardiac 
involvement (Bonne et al., 1999), see section 1.1.3.2 for details. 
Soon after, mutations causing an autosomal recessive (AR) form of EDMD and limb-girdle 
muscular dystrophy type 1B (LGMD1B) were identified (Muchir et al., 2000; Raffaele Di Barletta et 
al., 2000). LGMD1B is an autosomal dominantly inherited and slowly progressive muscle dystrophy 
involving muscles in hip and shoulders (limb-girdle musculature) and age related cardiac conduction 
defects and cardiomyopathy. The main difference to EDMD is the involved muscle groups and the 
absence of contractures (van der Kooi et al., 1997). 
In 2008, lamin mutations were shown to be associated with a severe early-onset congenital form of 
muscular dystrophy (L-CMD) (Quijano-Roy et al., 2008). L-CMD patients showed upper proximal 
and lower distal muscular weakness, rigid spine, contractures and cardiac arrhythmias, which 
resembles the phenotype seen in EDMD patients.  
Another striated muscle pathology involving mutations in lamin A/C is dilated cardiomyopathy 
with conduction system disorder (DCM-CD) (Fatkin et al., 1999). Hearts of DCM-CD patients 
present with ventricular dilation, reduced systolic function and conduction defects including sinus 
bradycardia, atrioventricular conduction block, or atrial arrhythmias. Skeletal muscle involvement 
and joint contractures are not observed in DCM-CD patients (Fatkin et al., 1999). 
Mutations resulting in striated muscle laminopathies include missense mutations, nonsense 
mutations, insertions, deletions and splice site mutations distributed throughout the protein 
(www.umd.be/LMNA). A clear genotype-phenotype correlation has not been observed so far 
within this group of laminopathies and is further explored in chapter 3. 
1.4.1.2 Premature ageing syndromes 
A number of LMNA mutations result in premature ageing syndromes, a group of diseases 
characterised by the early onset of features resembling normal ageing. 
Hutchinson-Gilford progeria syndrome (HGPS), likely to be the best known premature ageing 
syndrome, is a rare genetic disorder that occurs in one out of 4-8 million births. The clinical aspects 
were first described by Hutchinson (1886) by  and Gilford (1897). The earliest signs of HGPS 
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appear by the age of 3 and are a severe growth retardation and loss of scalp hair, followed by the 
appearance of characteristic facial dysmorphic traits including a visible vein across the nasal bridge.   
Patients also develop lipodystrophy especially in facial areas, osteolysis and a thin and atrophic skin. 
The cardiovascular system is severely affected and patients suffer from cardiomyopathy and 
atherosclerosis, the muscle mass decreases and joints stiffen. By the age of 9, strokes are very 
frequent, causing seizures, headache, vertigo, and limb weakness. HGPS patients have an average 
life expectancy of 13.5 years with myocardial infarction as the leading cause of death (Hennekam, 
2006; Merideth et al., 2008). 
In the majority of patients, these phenotypes are caused by a de novo single base mutation in codon 
608 at exon 11 of the LMNA gene (c.1824C>T/p.G608G) which leads to the activation of a 
cryptic splicing donor site in the LMNA gene resulting in an in-frame deletion of 150 nucleotides 
(De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). The incorrectly spliced m-RNA gives rise 
to lamin A with an internal deletion of 50 amino acids called progerin. This protein lacks the 
second endoproteolytic cleavage site recognized by Zmpste24 and therefore remains permanently 
farnesylated. Accumulation of progerin or full length farnesylated lamin A at the nuclear envelope 
results in severely dysmorphic nuclei, mislocalisation of nuclear envelope proteins, accumulation of 
DNA damage by defective DNA repair and premature senescence (Goldman et al., 2004; Liu et al., 
2005; Scaffidi and Misteli, 2005). Many (but not all; see Verstraeten et al. (2006)) mutations in 
LMNA which result in HGPS and progeroid phenotypes, have the accumulation of farnesylated 
lamin A in common, either caused by missense mutations or similar splicing defects as described 
above (Navarro et al., 2004). 
Progeroid phenotypes, similar to HGPS but with atypical features, include atypical Werner’s 
syndrome (WS), Mandibacra dysplasia (MADA) and restrictive dermopathy (RD). The clinical 
features of WS are similar to HGPS however the life expectancy is higher in patients with WS 
(Chen et al., 2003). Patients with RD, a severe progeroid disease with similarities to HGPS, 
however, die soon after birth (Navarro et al., 2004). Patients with MADA are characterised by 
growth retardation, craniofacial abnormalities, osteolysis as well as a generalised lipodystrophy, 
however they survive until adulthood (Novelli et al., 2002). Recessive null mutations in Zmpste24 
have also been shown to cause RD (Navarro et al., 2004) while mutations reducing, but not 
abolishing Zmpste24 activity are associated with the less severe MAD type B phenotype (Agarwal 
et al., 2003) and other progeroid phenotypes (Shackleton et al., 2005). 
1.4.1.3 Lipodystrophy disorders 
The most prevalent lipodystrophy disorder caused by mutations in LMNA is the Dunningan-type 
Familial Partial Lipodystrophy (FPLD2) (Shackleton et al., 2000). The disease is primarily 
characterised by abnormal subcutaneous adipose tissue distribution, shifting from limbs to the face 
and neck, beginning in late childhood or early adult life. Other features of FPLD include metabolic 
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abnormalities including insulin-resistance, liver steatosis which may lead to cirrhosis, and premature 
atherosclerosis (Bidault et al., 2011). 
The majority of affected individuals harbour mutations on residue R482 located in the Ig-fold 
domain, which results in the loss of a positive charge on the surface of the domain. However, 
FPLD2 mutations are also found in other parts of the protein including the central rod domain and 
tail domain (www.umd.be/LMNA).  
In addition to the Dunningan-type, LMNA mutations also cause Köbberling-type familial partial 
lipodystrophy (FPLD1) as found in a family compound heterozygous for LMNA mutations 
p.S583L and p.T528M (Savage et al., 2004). FPLD1 has a very similar phenotypic manifestation to 
FPLD2 however subcutaneous truncal fat is preserved in these patients. 
1.4.1.4 Laminopathies affecting the peripheral nervous system 
A small number of LMNA mutations affect axonal myelination of peripheral neurons which results 
in autosomal recessive Charcot-Marie-Tooth disease type 2 (ARCMT2) (De Sandre-Giovannoli et 
al., 2002). The majority of patients are homozygous for p.R298C and suffer from lower proximal 
and upper limb muscle weakness likely to be a secondary effect to the neuropathy. The onset of 
disease is variable and ranges from 6 to 27 years (Bernard et al., 2006). Demyelinating neuropathies 
are assumed to originate from defective Schwann cells resulting in improper myelination or 
demyelination which leads to axonal loss. Histologically, nerve bundles in CMT2 patients show an 
abundance of unmyelinated fibres as well as a reduced fibre density (De Sandre-Giovannoli et al., 
2002). Interestingly, lmna-null mice have a peripheral neuropathy resembling the phenotype seen in 
CMT2 patients (De Sandre-Giovannoli et al., 2002). How mutations in lamins may affect Schwann 
cells is not known. However, with a mouse model currently in progress we might soon have insight 
into the pathogenic role of LMNA mutations in CMT2.  
1.4.2 How do mutations in lamins cause disease? 
Ever since LMNA mutations have been associated with pathologies research has been conducted 
to elucidate the pathogenic mechanism behind different laminopathies. From this research three 
non-mutually exclusive hypotheses emerged: the ‘mechanical stress’ hypothesis, the ‘gene 
expression’ hypothesis and the ‘cell proliferation’ hypothesis (Broers et al., 2006; Worman, 2012; 
Worman and Bonne, 2007).  
1.4.2.1 The ‘mechanical stress’ hypothesis 
Given the nature of intermediate filaments, it is not surprising that lamins play a major role in 
maintaining the nuclear architecture and protecting the nuclear membrane from tearing especially in 
cells subjected to mechanical stress such as skeletal and cardiac muscle. Nuclei in lmna-null MEFs 
show severe deformations as well as defective mechanotransduction and reduced viability under 
mechanical stress (Lammerding et al., 2004). Lamin A/C and emerin have been shown to directly 
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interact with each other (Lee et al., 2001; Sakaki et al., 2001) and mutations in both proteins result 
in EDMD. Ultrastructural analysis of skeletal muscle from patients with autosomal dominant 
EDMD and X-linked EDMD reveals widespread breakage of nuclear envelopes and leakage of 
chromatin into the cytoplasm (Fidzianska and Hausmanowa-Petrusewicz, 2003; Fidzianska et al., 
1998; Park et al., 2009), providing a potential pathogenic mechanism for LMNA mutations. 
A disruption of the interaction of lamins with members of the LINC complex might contribute to 
the pathology of mutations. The LINC complex (composed of SUN-domain proteins and nesprins) 
forms a direct link between the nuclear lamina and all three cytoskeletal protein networks, 
cytoplasmic IFs, F-actin and tubulin (section 1.2.2). Disruption of the LINC complex has been 
shown to induce defects in nuclear morphology (Khatau et al., 2009) and affect the localisation of 
skeletal muscle nuclei as well as strain transmission between the cell and nucleus (Lombardi et al., 
2011; Zhang et al., 2010), while mutations in giant nesprins 1 and 2 result in a pathology resembling 
that of EDMD (Zhang et al., 2007). 
SUN-domain proteins have also been suggested to play a role in the pathology of EDMD and 
HGPS (Haque et al., 2010). Both EDMD and HGPS mutations were shown to disrupt the 
interaction between lamin A and SUN1/2, however, HGPS mutations resulted in an increased 
expression of SUN1 at the nuclear envelope (Haque et al., 2010). Accumulation of SUN1 at the 
nuclear envelope was also found in lmna-null cells (Chen et al., 2012) and prelamin A-mediated 
accumulation of SUN1 in myonuclei has been shown to play a role in nuclear positioning (Mattioli 
et al., 2011) suggesting that SUN1 is implicated in the pathogenic mechanism of laminopathies. 
Indeed, removal of SUN1 can rescue cellular phenotypes commonly found in HGPS cells including 
nuclear deformations, lamin B localisation and premature senescence. Further, knocking down 
SUN1 improves body weight and life span of lmna-null mice as well as mice expressing farnesylated 
lamin A (Chen et al., 2012). Together, this suggests that SUN1 accumulation is a common 
pathogenic event in HGPS disorders and provides a potential target for future therapies. However, 
whether SUN1 plays a similar pathogenic role in other laminopathies remains to be determined. 
1.4.2.2 The ‘gene expression’ hypothesis 
Lamins are able to directly and indirectly bind chromatin, transcription factors and members of cell 
signalling cascades. Mutations in lamins might therefore affect cell/tissue function by directly 
modulating gene expression and regulation. 
High resolution mapping of the interaction of the entire genome of human fibroblasts with the 
nuclear lamina revealed that lamin associated domains (LADs) show low gene expression indicating 
a repressive chromatin environment (Guelen et al., 2008). Altered lamina-chromatin interaction 
induced by mutation might therefore change the chromosome organisation in a cell and globally 
affect gene transcription with unpredictable consequences. Similarly, an indirect disruption of 
lamina-chromatin interaction via LEM-domain proteins and BAF may lead to a similar result. 
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Lamin A has also been shown to be involved in the regulation of the Erk1/2 branch of the mitogen 
activated protein kinase (MAPK) pathway (Emerson et al., 2009; Gonzalez et al., 2008). Upon 
mitogen stimulation of serum starved cells, extracellular regulated kinase 1 and 2 (Erk1/2) is 
phosphorylated and in turn phosphorylates and activates c-Fos. Following activation, c-Fos, a 
member of the AP-1 family of transcription factors, dimerises with other AP-1 proteins and 
initiates transcription of AP-1 target genes involved in proliferation, differentiation and apoptosis 
(Andres and Gonzalez, 2009). Lamin A binds to both Erk1/2 and c-Fos and might therefore play 
an important role in modulating Erk signalling (Gonzalez et al., 2008). 
Indeed, the localisation of c-Fos to the nuclear envelope is dependent on A-type lamins (Ivorra et 
al., 2006) and in fibroblasts from EDMD patients, the phosphorylation of Erk1/2 was initially 
delayed and then hyperactivated upon cell stimulation and cells exhibited increased proliferation 
(Emerson et al., 2009). Gene expression analysis in hearts of EMD null mice as well as mice 
expressing the EDMD mutation lamin A-H222P revealed an activation of MAPK signalling which 
precedes the cardiac phenotype. This suggests that activation of MAPK signalling could be 
involved in the pathogenic mechanism of heart disease in EDMD (Muchir et al., 2007a; Muchir et 
al., 2007b). Inhibition of Erk signalling in the H222P mice has been shown to delay the 
development of left ventricular dilatation confirming the involvement of MAPK signalling in the 
development of cardiomyopathy and preparing the way for therapeutic interventions (Muchir et al., 
2009). 
Lamin A does also bind to sterol-regulatory-element binding protein 1 (SREBP1) a transcription 
factor involved in lipid homeostasis, adipogenesis and insulin sensibility. The SREBP1 binding site 
was mapped to the Ig-fold of lamin A which harbours several mutations associated with FPLD2, 
suggesting it might play a role in the pathogenesis of the disease phenotype (Lloyd et al., 2002). 
Various mutations in lamin A inhibited the interaction with SREBP1 (Lloyd et al., 2002) and in 
presence of farnesylated lamin A, SREBP1 was observed to accumulate at the nuclear envelope 
together with a down-regulation of PPARγ (Peroxisome proliferator-activated receptor γ) (Capanni 
et al., 2005). Taken together these results support the theory of an involvement of SREBP1 in 
FPLD pathology. 
Lamin and emerin have been shown to directly interact with MAN1 and could therefore modulate 
TGF-β and BMP signalling (section 1.2.2.6). If altered TGF-β or BMP signalling is involved in 
laminopathies is not known yet. However, BMP signalling could indirectly play a role by affecting 
muscle satellite cells where active BMP signalling is required to maintain proliferation and prevent 
premature differentiation (Ono et al., 2011). 
In addition to the above, microRNAs which are predicted to be involved in several cell signalling 
pathways, including MAPK, TGF-β and Wnt, have recently been implicated in the pathology of 
LMNA associated muscular dystrophy (Sylvius et al., 2011). Interestingly, miR-100, which was 
upregulated in patient samples, induced myogenic differentiation when expressed in C2C12 cells 
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while overexpression of miR-335 induced proliferation (Sylvius et al., 2011), which implies an 
involvement of myoblasts in the disease pathology. 
1.4.2.3 The ‘Cell proliferation/differentiation’ hypothesis 
Defective cell proliferation and differentiation might have several implications in laminopathies 
especially in tissues that are maintained by adult stem cells such as skeletal muscle.  
One key regulator of cell cycle progression is the retinoblastoma protein (pRb). In quiescent cells, 
pRb is hypophosphorylated and bound to E2F transcription factors, thereby inactivating them. In 
proliferating cells, the cyclin D/cdk4 and 6 complex hyperphosphorylates pRb which results in the 
release of E2F and the activation of genes involved in G1/S transition (De Falco et al., 2006). 
Nucleoplasmic A-type lamins have been shown to directly interact with the cell cycle regulator pRb 
in complex with Lap2α, tethering pRb to the nucleoskeleton and modulating its phosphorylation 
(Markiewicz et al., 2002; Markiewicz et al., 2005).  
In mice, loss of Lap2α (Naetar et al., 2008) or lamin A/C (Nitta et al., 2006; Van Berlo et al., 2005) 
is associated with cell cycle progression while in human fibroblasts, loss of Lap2a induces cell cyle 
arrest (Pekovic et al., 2007) for yet unknown reasons. 
The pRb pathway also plays a role in myoblast differentiation. Interaction of pRb and MyoD is 
required for the hypophosphorylation of pRb and subsequent cell cycle exit and differentiation (Gu 
et al., 1993). Lmna-null satellite cell-derived myoblasts display decreased pRb and MyoD protein 
levels as well as reduced differentiation potential in vitro (Frock et al., 2006). Moreover, gene 
expression studies in EDMD patient samples with mutations in LMNA and EMD suggest that key 
interactions between pRb and MyoD at the nuclear envelope fail at the point of cell cycle exit 
leading to poorly coordinated phosphorylation and acetylation steps (Bakay et al., 2006).   
Other lamin A interacting proteins associated with cell cycle progression are cyclin D3 which is 
involved in G1/S transition (Mariappan et al., 2007) and the DNA elongation factor PCNA 
(proliferating cell nuclear antigen) (Shumaker et al., 2008), which suggest that lamin A plays 
additional roles in cell cycle control. 
1.4.2.4 Genotype-Phenotype correlation in laminopathies 
To date more than 300 different mutations have been described in the LMNA gene 
(www.umd.be/LMNA). These include mainly missense mutations but also nonsense mutations, 
insertions, deletions and splice site mutations. However, a clear genoype-phenotype correlation is 
not yet established (reviewed in Scharner et al. (2010)). The elucitation of genotype-phenotype 
correlations using a bioinformatics approach is the aim of chapter 3, where I will highlight the 




1.5 Thesis aim  
Laminopathies are a heterogeneous group of diseases associated with mutations in A-type lamins, 
which together with B-type lamins, form the nuclear lamina: a proteinaceous network underlying 
the nuclear membrane. A-type lamins are encoded by the LMNA gene, and more than 300 
mutations have been described, associated with more than 16 phenotypes. The majority of 
mutations affect striated muscle to cause Emery-Dreifuss muscular dystrophy (EDMD) or 
cardiomyopathy, while others result in lipodystrophy, neuropathy or premature ageing syndromes. 
However, clear genotype-phenotype correlations are not established, the pathogenic mechanisms 
are little understood and therapies are lacking. 
The aim of this thesis is: (1) to advance the current understanding of genotype-phenotype 
correlations in laminopathies by analysing both physical-chemical properties of the amino-acid 
change, and position in the 3D structure of lamin A of a large number of mutations in the context 
of different pathologies (2) to provide insight into the effects of pathogenic Emery-Dreifuss 
muscular dystrophy mutations on nuclear morphology and nuclear protein distribution, as well as 
myogenic cell function such as proliferation and differentiation in overexpression studies, and (3) to 
explore the possibility of using antisense oligonucleotide (AON)-mediated exon skipping as a 
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Chapter 2  
Material and Methods 
 
2.1 Material and reagents 
2.1.1 Chemicals and Plasticware 
Details of chemicals such as their concentration and manufacturer are given in each subsection of 
this chapter when first mentioned. Plasticware used for cell culture and assays were Nunc tissue 
culture plates (ThermoScientific), LabTek 8well Chamber slides (Permanox/Glass) from Nunc 
(ThermoScientific), sterile 15mL and 50mL tubes (Falcon) as well as sterile tissue culture pipettes 
(Falcon). Sterile filters of 0.45μm and 0.22μm pore size were obtained from Millipore. 
2.1.2 Antibodies 
Details of primary antibodies including the concentration they were used at are listed in table 2.1 
below. Details of secondary antibodies are listed in table 2.2. 
Table 2.1 Primary antibodies used in this study 
Antigen Clone Host Supplier Cat. Number Conc. Used 
Emerin (AP8)  Rabbit Generous gift from 
Juliet Ellis 
(Ellis et al., 1998) 
& ImmuQuest 
IF/WB 1:100 
Erk 1/2 (MAPK)  Rabbit Upstate 06-182 WB 1:1000 
pErk 1/2  Rabbit Cell Signalling 9101S WB 1:1000 
GFP  Rabbit Invitrogen A11122 IF 1:500 WB 1:2000 
GFP  Chicken Abcam Ab13970 IF 1:2000 
Lamin A C20 Goat Santa Cruz sc-6214 IF 1:100 
Lamin A/C N18 Goat Santa Cruz sc-6215  IF 1:200 WB 1:1000 
Lamin A/C 131C3 Mouse Abcam ab8984  IF 1:250 
Lamin B M20 Goat Santa Cruz sc-6217 IF 1:200 
Lamin B1  Rabbit Abcam ab16048 IF/WB 1:2000 
Lap2α  Rabbit Novus Biologicals NB 100-676 WB 1:2000 
Myogenin F5D Mouse DSHB  IF 1:10 
Myosin Heavy 
Chain 
MF20 Mouse DSHB  IF 1:500 
PCNA PC10 Mouse Dako M0879 WB 1:1000 
pRb  Mouse BD Biosciences 554136 WB 1:1000 
β-Tubulin E7 Mouse DSHB  WB 1:5000 
V5  Mouse Invitrogen 46-0705 IF 1:1000 
WB 1:5000 




Table 2.2 Secondary antibodies used in this study 
Type Conjugation Host Supplier Cat. Number Conc. Used 
Mouse IgG 488 Goat Invitrogen A11029 1:500 
 488 Donkey Invitrogen A21202 1:500 
 555 Goat Invitrogen A21424 1:500 
 594 Goat Invitrogen A11032 1:500 
 594 Donkey Invitrogen A21203 1:500 
 633 Goat Invitrogen A21052 1:500 
Rabbit IgG 488 Goat Invitrogen A11034 1:500 
 488 Donkey Invitrogen A21206 1:500 
 555 Goat Invitrogen A21429 1:500 
 594 Goat Invitrogen A11037 1:500 
 594 Donkey Invitrogen A21207 1:500 
 633 Goat Invitrogen A21071 1:500 
Goat 488 Donkey Invitrogen A11055 1:500 
 594 Donkey Invitrogen A11058 1:500 
Chicken 488 Goat Invitrogen A11039 1:500 
Rat 594 Goat Invitrogen A11007 1:500 
Mouse IgG HRP Donkey GE Healthcare NA931V 1:5000 
Rabbit IgG HRP Sheep GE Healthcare NA934V 1:5000 
Goat IgG HRP Donkey Abcam ab19 (old) 1:5000 
Goat IgG HRP Rabbit Abcam ab6741 1:50,000 
 
 
2.1.3 Buffers and Solutions 
1M Tris Buffer 
To prepare 1M Tris buffer, 60.6g of Trizma-base (Sigma) were dissolved in 500mL ddH2O before 
adjusting the pH with 5M HCl (pH7.4 or 8.0 depending on the application) and autoclaving. 
EDTA solution 
For a 500mM stock solution of EDTA, 14.6g of EDTA (Sigma) were dissolved in 100mL ddH2O 
and sterile filtered. 
TE-buffer 
To prepare TE-buffer, 10mM Tris-HCl (Sigma) and 1mM EDTA (Sigma) were dissolved in 





A 50x concentrated stock of TAE (Tris-acetate-EDTA) agarose gel electrophoresis buffer was 
prepared by dissolving 242g Tris base in water, adding 57.1mL glacial acetic acid, and 100mL of 
500mM EDTA (pH8.0) solution, and bringing the final volume up to 1 litre. 
Phosphate buffered saline (PBS) 
The PBS working solution was prepared by dissolving 1 PBS-tablet (Oxoid) in 100mL ddH2O and 
was autoclaved subsequently. Each tablet contained 0.8g NaCl, 0.02g KCl, 0.115g Na2HPO4 and 
0.02g KH2PO4. 
PBST 
To make PBST, 0.1% (v/v) Tween20 was added to 1x PBS. 
Paraformaldehyde Solution (4% PFA) 
To prepare 4% (w/v) PFA, 4g of paraformaldehyde (Sigma) were dissolved in 80mL ddH2O at 
65°C under constant stirring in a fume hood. After adding a few drops of 1M NaOH to raise the 
pH and dissolve the PFA completely, the solution was immediately cooled down to room 
temperature on ice. One PBS tablet (Oxoid) was added and the pH was adjusted to 7.4 with 1M 
HCl before topping up to 100mL with ddH2O. The PFA was stored frozen at -20°C. 
Cell suspension buffer 
Cell suspension buffer contains 10mL of 5M NaCl (Sigma), 5mL of 1M Tris-HCl (pH 7.5) and 
1mL of 500mM EDTA (pH 8.0) made up with ddH2O to 500mL and was autoclaved before use. 
The suspension buffer was stored at 4°C. 
Gel loading buffer (2x) 
Double concentrated (2x) gel loading buffer (Laemmli, 1970) contains 2ml 10% (w/v) SDS, 1mL 
Glycerol, 0.625mL 1M Tris-HCl (pH6.8) and 1.375mL ddH2O and was stored at room temperature 
(RT). 
Suspension buffer P1 
The suspension buffer contains 50mM Tris (pH8.0), 10mM EDTA (pH8.0) and 100μg/mL 




Alkaline lysis buffer P2 
Alkaline lysis buffer contains 200mM NaOH (BDH) and 1% (w/v) SDS (Sigma) and was stored at 
RT. 
Neutralisation buffer P3 




2.2 Methods and Protocols 
2.2.1 Mouse work 
2.2.1.1 Maintenance of Lmna mouse colony 
Mice were kept and maintained by the Biological Services Unit (BSU) at King’s College London 
under project license PPL70/7092 and according to standard regulations and guidelines as 
prescribed in the Animals (Scientific Procedures) Act 1986. The Lmna-mice on a C57BL/6 
backround (Sullivan et al., 1999) were a kind gift from Carlos Lopez-Otin (University of Oviedo, 
Spain). 
2.2.1.2 Genotyping by PCR 
Adult Lmna mice were tagged for identification by ear punching and a piece of tail was collected for 
genotyping as wild-type, heterozygotes or homozygotes for the null allele. To genotype embryos, a 
piece of the yolk sac was used. Total genomic DNA was extracted by digesting the tissue samples in 
100μL DNA extraction buffer (Direct PCR Tail or Direct PCR Yolk Sac; Viagen) supplemented 
with 20μg proteinase K (Roche) at 55°C overnight. The samples were heat inactivated at 85°C for 
45min and spun down. For the PCR, 1μL of the supernatant was mixed with 4μL 5x GoTaq buffer 
(Promega), 0.5μL dNTPs (10mM; Fermentas), 0.5μL of each primer (P1, P2 and P3, see table 2.3), 
0.1μL Taq Polymerase (Promega) and 13μL ddH2O. 
Table 2.3 Genotypeing primers used in this study. All listed oligonucleotides were obtained from Sigma. 
ID Primer Name Primer sequence (5’>3’) 
Genotyping Primers 
P1 Lmna wild type-Fwd CGATGAAGAGGGAAAGTTCG 
P2 Lmna wild type-Rev GCCGAATATCATGGTGGAAA 
P3 Lmna mutant-Rev CCATGGACTGGTCCTGAAGT 
 
The DNA was amplified on a Techne TC-512 thermocycler under following conditions: Initial 
denaturation for 5min at 95°C, followed by 35 cycles of 95°C/15sec, 58°C/30sec, 72°C/1min and 
5min extension at 72°C. The PCR products together with a 10kb DNA ladder (SmartLadder; 
Eurogentech) were separated by gel electrophoresis on a 1% (w/v) agarose gel (Fisher Scientific) 
supplemented with 0.5μg/mL Ethidium Bromide (Sigma) and visualised under UV-light. 
The PCR reaction yields 2 different amplicons depending on the genotype of the animal. The 
shorter band at approx. 520bp corresponds to wild-type Lmna allele, a larger band of 750bp 
corresponds to the mutant null Lmna allele. 
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2.2.2 Cloning of construct used in this thesis 
2.2.2.1 General Cloning method 
Constructs were generally cloned by PCR amplification of the cDNA with primers containing 
recognition sites for restriction enzymes. Upon digest of the vector and insert with the restriction 
enzyme under conditions recommended by the supplier (NEB and Promega), the DNA fragments 
were either purified using spin columns (Qiagen) or extracted from the agarose gel using a gel 
extraction kit (Qiagen). The DNA concentration was measured using a Nanodrop 
spectrophotometer. Vector and insert were then incubated in the presence of T4 ligase (NEB) over 
night at 16°C at a molar ratio of 1:3 (Vector:Insert). One microlitre of the ligation reaction was 
transformed into One Shot TOP10 competent cells (Invitrogen) by a 45sec heat shock. The 
bacteria were allowed to recovered for one hour at 37°C in SOC medium (Invitrogen) and plated 
on selective agar plates containing 100μg/mL ampicillin or kanamycin as appropriate. Colonies 
were grown in 2mL LB-broth under selection conditions before extracting plasmid DNA by 
miniprep. Positive colonies were identified by restriction mapping and grown for 16hrs in 100mL 
selective LB medium. Plasmid DNA was extracted using a midiprep kit (Qiagen) and sent for 
sequencing. 
2.2.2.2 Plasmid DNA miniprep 
To extract plasmid DNA, 1mL of bacteria culture was transferred into a 1.5mL Eppendorf tube 
and spun at 10,000g for 1min to pellet the cells. The pellet was resuspended in 100μL suspension 
buffer P1 and lysed by adding 100μL alkaline lysis buffer buffer P2. Protein together with genomic 
DNA was precipitated by adding 100μL neutralisation buffer P3 and spun down at 13.000g for 
5min. The supernatant was transferred into a new Eppendorf tube and the plasmid DNA was 
precipitated by adding 0.7 volumes of Isopropanol (VWR). After pelleting the DNA by 
centrifugation (13,000g for 5min) it was washed with 70% ethanol, dried, and resuspended in 
100μL TE-buffer. For sequencing, plasmid DNA obtained by miniprep was purified on a spin 
column (Qiagen) and eluted with ddH2O. 
2.2.2.3 pMSCV-IRES-eGFP 
All constructs used in this study were cloned into the pMSCV-IRES-eGFP (MIG) retroviral 
expression vector, described by Zammit et al. (2006b). Briefly, an internal ribosomal entry site 
(IRES) together with eGFP and an SV40 polyadenylation signal was cloned into the murine stem 
cell viral vector (pMSCV; Clonetech) to create a bicistronic retroviral expression system. The 
original viral vector is ecotropic and replication incompetent for safety reasons. A map of this 





Figure 2.1 Map of the pMSCV-IRES-eGFP vector. Unique restriction enzymes and main features of the vector are 
indicated. LTR, Long terminal repeat; Ψ, Psi packaging signal; MCS, Multiple cloning site; IRES, Internal ribosomal 
entry site; Col E1 Ori, Origin of replication; Amp (r), Ampicillin resistance gene. 
 
2.2.2.4 Wild-type lamin A and mutant lamin A variants in MIG 
Wild-type lamin A (Motsch et al., 2005) and mutant lamin A (R25P, R190dup, R249W, S295P, 
S303P, N496I and R541P, kindly provided by Juliet Ellis) were amplified using lamin A specific 
primers with restriction enzyme sites XhoI and BamHI (primers P9 and P10, table 2.4) under 
following conditions: 200ng (diluted in 2μL) plasmid DNA template was mixed with 5μL 10x Pfx 
Amplification buffer (Invitrogen), 1.5μL dNTPs (10mM; Fermentas), 1μL MgSO4 (50mM; 
Invitrogen), 1.5μL of each primer (P9 and P10, see table 2.4), 0.5uL  Platinum Pfx DNA 
Polymerase (Invitrogen) and 37μL ddH2O. 
The DNA was amplified on a Techne TC-512 thermocycler under following conditions: Initial 
denaturation for 5min at 95°C, followed by 35 cycles of 95°C/15sec, 55°C/30sec, 68°C/2min and 
5min extension at 68°C. The PCR products together with a 10kb DNA ladder (SmartLadder; 
Eurogentech) were separated by gel electrophoresis on a 1% agarose gel (Fisher Scientific) 
supplemented with 0.5μg/mL ethidium bromide (Sigma) and visualised under UV-light. 
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PCR fragments were purified on a spin column (Qiagen) and digested using restriction enzymes 
XhoI and BamHI under standard conditions before they were ligated with the digested MIG-vector 
(see above). 
Table 2.4 Cloning primers used in this study. All listed oligonucleotides were obtained from Sigma. 
P3 Lmna mutant-Rev CCATGGACTGGTCCTGAAGT 
Lamin A Sequencing Primers 
P4 Lamin A-cDNAseq 1 Fwd CCGAGTCTGAAGAGGTGGTC 
P5 Lamin A-cDNAseq 2 Rev CACGCAGCTCCTCACTGTAG 
P6 Lamin A-cDNAseq 3 Fwd TCTGCTGAGAGGAACAGCAA 
P7 Lamin A-cDNAseq 4 Fwd GTGGAAGGCACAGAACACCT 
P8 Lamin A-cDNAseq 5 Fwd GAAGCTTCGAGACCTGGAGG 
PCR Cloning Primers 
P9 XhoI-lamin A-exon 1 Fwd TATCTCGAGCAACATGGAGAC (start codon in bold) 
P10 Lamin A-exon 12-BamHI Rev TTCTAGGATCCTTACATGATGC (stop codon in bold) 
P11 Lamin A-Δexon 3 Rev CTTGGCCACCTGGCCCC 
P12 Lamin A-Δexon 5 Rev  CTTGGCAGAATAAGTCTTCTC 
P13 Lamin A-Δexon 3 Fwd GAGCTGCGTGAGACCAAGC 
P14 Lamin A-Δexon 5 Fwd CTGGCAGCCAAGGAGGCG 
Mutagenesis Primers 
P15 N195K-Fwd GGTGGATGCTGAGAAGAGGCTGCAGACCATGAAGG 
P16 N195K-Rev CCTTCATGGTCTGCAGCCTCTTCTCAGCATCCACC 
 
2.2.2.5 Creation of lamin A-N195K by site directed mutagenesis 
To create lamin A-N195K, wild-type lamin A was mutated using the QuickChange Site-Directed 
mutagenesis kit (Agilent) according to manufacture’s instructions. In principle, the plasmid to be 
mutated (lamin A-wt in MIG) was amplified by two complementary primers containing the 
mutation (lamin A-N195K mutagenesis primers P15 and 16, table 2.4) resulting in nicked circular 
strands. The non-mutated parental plasmid was then digested with DpnI (target sequence: 5´-
Gm6ATC-3´) which is specific for methylated and hemimethylated DNA. DNA isolated from 
almost all E. coli strains is dam methylated and therefore susceptible to Dpn I digestion which 
allows the selection for mutation-containing synthesised DNA. The nicked vector containing the 
mutation was then transformed into XL1-Blue supercompetent cells (Agilent) and sent for 
sequencing to confirm the mutation. 
2.2.2.6 Creation of lamin A constructs with internal deletions 
The deletion of 48 amino acid fragments corresponding to exons 3 and 5 was carried out as follows 
(illustrated in Fig. 2.2 below): lamin A was amplified with 2 primer pairs (see table 2.4) amplifying 2 
lamin A fragments on either side of the sequence to be removed. The fragments were purified on a 
spin column (Qiagen) and analysed on an agarose gel to confirm their correct size. The two 
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corresponding fragments were then phosphorylated with T4 polynucleotide kinase (Sigma) in 
presence of 0.1mM ATP (Sigma) and blunt ligated with T4 ligase (NEB). The ligation reaction was 
purified with a spin column (Qiagen) and digested with both enzymes introduced with primers P9 
(XhoI) and P10 (BamHI). The digest was separated on an agarose gel and the band with the correct 
size (1885bp) was cut. After extraction of the DNA with a gel extraction kit (Qiagen), it was re-
amplified under the same conditions as above, using primer P9 and P10. The amplicon was purified 
on a spin column, digested and ligated with the MIG backbone under standard conditions (see 
above). The presence and accuracy of the deletion was confirmed by sequencing. 
   
 
Figure 2.1 Cloning strategy to create lamin A-Δ3 and Δ5 by PCR. The fragment to be deleted (exon 3 or 5) is 
shown in red. Primers are indicated by arrows (see table 2.3) Coloured primers contain restriction sites XhoI (blue) 
and BamHI (red). Step1: Two sequences excluding exons 3 or 5 were amplified. Step 2: The amplicons were 
phosphorylated, blunt ligated and digested with XhoI and BamH1. The black arrowhead indicates the correct ligation 
product (1885bp) which was excised from the gel. Step 3: Excised DNA bands were re-amplified using primer pair 
P9/P10 and cut with XhoI and BamHI before ligation with the MIG vector.  
2.2.3 Cell culture protocols 
2.2.3.1 Single Fibre Isolation and Culture 
Single fibres were isolated as per protocol by (Collins and Zammit, 2009; Rosenblatt et al., 1995). 
The extensor digitorum longus (EDL) of young adult mice (6-8 weeks of age) in a Bl-6 background 
was isolated intact and incubated in 0.2% (w/v) collagenase (Sigma) in DMEM-Glutamax (Gibco) 
supplemented with 1% (v/v) Penicillin/Streptomycin (Sigma) for 1hr 30min at 37°C. Muscles were 
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transferred into deep plastic dishes treated with 5% (w/v) BSA (in ddH2O; Sigma) to prevent 
attachment. Single fibres were liberated by trituration with heat polished Pasteur pipettes and 
incubated in plating medium (DMEM-Glutamax supplemented with 10% horse serum (PAA), 
0.25% (v/v) chick embryo extract (MP Biomedicals) and 1% (v/v) Penicillin/Streptomycin) for 
24hrs. At T24 (24 hours after isolation), once satellite cells have been activated and entered cell 
cycle, fibres were exposed to viral particles (without polybrene) and fixed at 48hrs and 72hrs 
respectively (24hrs and 48hrs post infection respectively). 
2.2.3.2 Isolation and culture of plated satellite cells 
To prepare satellite cells, single fibres were isolated as described above. Debris from damaged 
fibres, tendons and connective tissue were removed through three washing steps by transferring 
intact fibres into new culture dishes. Clean fibres were then transferred into 10cm dishes (coated 
with 0.5mg/mL matrigel (BD Biosciences) for 45min at 37°C) filled with satellite cell medium 
consisting of DMEM (Gibco), 20% (v/v) FBS Gold (PAA), 10% (v/v) horse serum (Gibco), 1% 
(v/v) chicken embryo extract (MP Biomedicals), 1% (v/v) Penicillin/Streptomycin (Sigma), 2mM 
L-glutamine (Sigma) and 10ng fibroblast growth factor (PeproTech). After 3 days satellite cells have 
migrated off the fibres and started to proliferate. At this point the fibres are removed by repeatedly 
flushing medium across them with a sterile pipette tip and the satellite cells are subcultured into 6-
well plates for retroviral infection. To infect plated satellite cells, they are subjected to retroviral 
particles for 6hrs in presence of 4µg/mL polybrene (Sigma). Infected cells were subcultured into 
matrigel coated chamber slides and analysed 24-72hrs post infection. To assay the myogenic 
potential, satellite cells were induced to differentiate by changing to differentiation medim (2% 
(v/v) horse serum in DMEM) and analysed 24-48hrs later.  
2.2.3.3 Isolation and Culture of primary Mouse Embryonic Fibroblasts (pMEFs) 
Primary MEFs were isolated according to Xu (2005). Lamin A/C heterozygous female mice were 
set up for mating with a Lamin A/C heterozygous male and sacrificed 13.5 days post coitum (dpc) 
to collect E13.5 embryos. The embryos were dissected under a stereomicroscope in the laminar 
flow hood and transferred into a new dish containing ice cold sterile PBS. At the same time part of 
the yolk sack was collected for genotyping (for genotyping protocol see section 1.2.1.2). After 
removing the brain and internal organs, the body of the embryo was minced in 1mL ice cold 
Trypsin-EDTA (Gibco) and transferred into a 15mL sterile Falcon tube. The minced embryos were 
kept on ice for 1hr to allow the Trypsin-EDTA to penetrate the tissue pieces before incubating 
them at 37°C for 20min. The digested embryonic tissue was then triturated to obtain a single cell 
suspension and filtered through a 100μm cell strainer to remove larger, undigested tissue pieces. 
The cells of one embryo were resuspended in 30mL MEF medium and plated into three 10cm cell 
culture dishes to allow attachment of embryonic fibroblasts overnight. Cells at this stage were 
designated passage number P0. On the next day, unbound cells were removed by rinsing the plates 
3 times with PBS. The remaining cells were left in culture for an additional day to reach confluence. 
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Cells were then trypsinised, counted and frozen for future use. MEFs were cultured in DMEM 
(Gibco) supplemented with 10% FBS Gold (PAA), 1% (v/v) Penicillin/Streptomysin (Sigma), 
2mM L-glutamine (Sigma) and 0.1mM β-Mercaptoethanol (Sigma). The cells were frozen in 
DMEM supplemented with 30% (v/v) FBS, 1% (v/v) Penicillin/Streptomycin, 2mM L-glutamine 
and 10% (v/v) DMSO (Sigma) and stored in liquid N2. 
2.2.3.4 Production of Retrovirus 
Non-replicating viral particles were produced in HEK-293T (maintained in DMEM/10%FBS) cells 
by transiently co-transfecting 4μg of the retroviral constructs, together with 4μg of an ecotropic 
packaging plasmid. To do so, plasmid DNA was diluted in 1.8mL OptiMEM medium (Gibco) 
together with 8μL Plus-Reagent (Invitrogen) and 24μL Lipofectamine LTX (Invitrogen). After 
30min incubation at RT the transfection mixture was added to subconfluent (approx. 70%) HEK-
293T cells, grown in a T75cm2 flask. No penicillin was added to the medium at this stage. After 12-
16hrs the medium was changed and the supernatant (5mL at each time point) was harvested 48, 60 
and 72 hours after transfection. 
2.2.3.5 C2C12 myoblast culture 
The C2C12 myoblast cell line (Blau et al., 1983; Yaffe and Saxel, 1977) was grown and maintained 
in DMEM (Gibco) supplemented with 10% FBS Gold (PAA) 1% (v/v) Penicillin/Streptomycin 
(Sigma) and 2mM L-Glutamine (Sigma). For viral infection, cells were incubated in growth medium 
supplemented with 4µg/mL polybrene to support viral uptake. To induce differentiation by serum 
withdrawal, cells were washed with PBS before exposing them to DMEM supplemented with 2% 
horse serum (Gibco) 1% Penicillin/Streptomycin and 2mM L-Glutamine. 
2.2.3.6 Cell Cycle analysis by Flow Cytometry 
Cells were grown in 6 well plates and harvested by trypsinization 48 hours after infection. After 
fixation in 70% ethanol, cells were incubated with 40µg/mL propidium iodide (PI) (Sigma), 
40µg/mL RNAseA (Roche) and 0.1% NP40 (Sigma) in TE buffer pH8.0 for 30 minutes at 37°C. 
Cells were then stored at 4°C protected from light until analysis by flow cytometry. To determine 
the proportion of GFP positive cells, cells were fixed with 4% PFA, washed twice with PBS and 
stored at 4°C protected from light until analysis by flow cytometry.  
2.2.3.7 BrdU Incorporation 
To label cells in S-phase, they were pulsed with 10μM BrdU (Sigma) for 2hrs prior fixation with 4% 
PFA. 
2.2.3.8 Immunocytochemistry 
Myofibers were collected from growth plates with a fire polished Pasteur pipette and transferred 
into a 2mL Eppendorf tube. They were washed with PBS, fixed with 4% PFA (10min at RT) and 
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transferred into shallow plastic dishes (4cm diameter). After permeabilisation with 0.5% (v/v) 
Triton X-100 (Sigma) in PBS (10 min at RT), they were blocked with 5% (v/v) normal goat serum 
(Dako) and 5% normal swine serum (Dako) for 1hr at RT. Fibres were incubated with primary 
antibodies (diluted in PBS containing 0.025% (v/v) Tween-20 and 0.5% (v/v) serum; see table 2.1) 
overnight at 4°C, washed three times with PBS+0.025% (v/v) Tween-20 and incubated with the 
secondary antibody (diluted in PBS+0.025% Tween-20; see table 2.2) for 1hr at RT protected from 
light. After a further washing of the fibres, they were transferred onto glass slides, mounted with 
Vectashield mounting medium containing DAPI to mark all nucei (Vector Labs) and stored at 4°C 
in the dark. 
Plated cells were processed in the chamber slides. They were washed with PBS, fixed with 4% PFA 
(10min at RT) and permeabilised with 0.5% (v/v) Triton X-100 (Sigma) in PBS (10 min at RT) and 
blocked with 2.5% (v/v) normal goat serum (Dako) and 2.5% (v/v) normal swine serum (Dako) 
for 1hr at RT. Where a primary antibody raised in goat was used, cells were blocked with 5% (v/v) 
normal swine serum. Subsequently, cells were incubated with primary antibodies (diluted in PBS 
containing 0.025% (v/v) Tween-20 and 0.5% (v/v) serum; see table 2.1) overnight at 4°C, washed 
three times with PBS+0.025% (v/v) Tween-20 and incubated with the secondary antibody (diluted 
in PBS+0.025% (v/v) Tween-20; see table 2.2) for 1hr at RT protected from light. To stain the 
DNA, cells were exposed to 300nM DAPI (Sigma) for 10min at RT, washed, mounted with 
FluoromountG (Southern Biotech) and stored at 4°C in the dark. 
To stain for BrdU, cells were fixed and permeabilised as above. To unmask the BrdU epitope, cells 
were treated with 3M HCl diluted in ddH2O for 10mins, rinsed with 0.5% (w/v) BSA/PBS and 
neutralised by rinsing them twice with 100mM Borate (pH8.5). After two washes with 
PBS+0.025% (v/v) Tween-20, the primary anti-BrdU antibody was applied diluted in PBS 
containing 0.025% (v/v) Tween-20 and 0.5% (w/v) BSA and incubated over night at 4°C. After 3 
washes with PBS+0.025% (v/v) Tween-20, cells were incubated with the secondary antibody 
(diluted in PBS+0.025% (v/v) Tween-20) for 1hr at RT. The finished slides were stained for DNA 
and mounted as above. 
2.2.4 Immunoblotting protocol 
2.2.4.1 Total protein extraction 
Cells were rinsed with PBS, scraped off and harvested in an Eppendorf tube by centrifugation at 
13.000 rpm for 1 min. The cell pellet was resuspended in 40-100μL of suspension buffer 
(depending on the pellet size) and lysed by adding an equal amount of 2x gel loading buffer. The 
suspension buffer was supplemented with protease and phosphatase inhibitors just before use: 
complete Mini Protease Inhibitor Cocktail (Roche), 10mM Sodium Orthovandate (Sigma), 10mM 
Sodium pyrophosphate (Sigma) and 50mM Sodium Fluoride (Sigma). The samples were heated to 
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100°C on a heat block and boiled for 10min before they were sonicated two times for 10sec (10μm 
amplitude) by inserting a probe directly into the sample. Insoluble compounds were spun down at 
13.500 rpm for 5min. The supernatant was transferred into a new tube and stored at -20°C after a 
small aliquot for protein estimation was taken. 
2.2.4.2 Protein estimation  
The protein concentration was estimated using the photometric Bio-Rad Dc Protein Assay 
according to the manufacturer’s instructions. Briefly, each protein sample was diluted 1:2 to 1:20 
(depending on the pellet size) in ddH2O and analysed in triplicates in a flat bottom 96-well plate. 
After adding 25μL Reagent A and 200μL Reagent B (BioRad Dc protein Assay solution) to each 
well containing 5μL sample, the plate was incubated for 20min in the dark at RT. The absorbance 
at 620nm was measured with a Multiskan Ex spectrophotometer (Thermo) and the concentration 
was determined using a BSA (Promega) standard curve in the range of 0.2 - 1.0mg/mL, which was 
processed in parallel. After determining the total protein concentration, samples were diluted to 0.5-
2μg/μL protein in 1x gel loading buffer. To each sample 150mM Dithiothreitol (Sigma), and 1x 
RunBlue loading buffer (Expedeon) was added and then stored at -20°C. 
2.2.4.3 SDS-Polyacrylamide Gel Electrophoresis 
Samples were separated on RunBlue precast denaturing gels (Expedeon) by 1D SDS 
Polyacrylamide Gel Electrophoresis (SDS-PAGE) using the RunBlue Electrophoresis system 
(Expedeon). Samples were boiled for 2min before they were loaded onto the gel at a range between 
5 and 50μg total protein per lane. The protein size was determined by a standard protein ladder 
(RunBlue 2-Color SDS Marker (Expedeon)). The electrophoresis was carried out with 1x Tris-
Glycine Electrophoresis buffer (Expedeon) at a constant voltage of 120V. Once the samples have 
entered the separation gel, the voltage was increased to 180V and left running until the colour 
indicator had migrated off the gel. 
2.2.4.4 Immunoblotting 
To transfer the protein bands onto a PVDF membrane, the semidry iBlot system (Invitrogen) was 
used. Membranes were then washed in PBS, blocked with 5% (w/v) BSA (Sigma) in PBST for 1 
hour at RT before the primary antibody was added and incubated over night at 4°C on a laboratory 
shaker. Subsequently, the membranes were washed 3 times for at least 10 min. with PBST and 
incubated with the corresponding HRP conjugated secondary antibody diluted in 1% BSA/PBST 
for 1 hour at room temperature. All primary and secondary antibodies used are listed in tables 2.1 
and 2.2. After a further three washes with PBST and a final rinse with PBS, the membranes were 
incubated for 5 minutes with ECL Western Blotting Detection Reagents (GE Healthcare). In the 
darkroom, an X-ray film was exposed for several seconds up to 5min, and developed using an 
automated film processor. Films were labelled and scanned for permanent recording. 
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2.2.5 Microscopy and picture analysis 
Micrographs of single fibres were taken on a Zeiss Axiovert 200M using the Zeiss Axiovision 
software. Micrographs of plated cells were captured with a Zeiss Axioplan 2 using Openlab v3.1.7. 
Pictures were exported to .tiff files and compiled using Adobe Photoshop CS4. The Cell Counter 
plugin for Image J v.1.43 (http://rsbweb.nih.gov/ij/) was used to quantify cells and/or nuclei. 
To quantify the morphological abnormalities of nuclei such as elongation or lobulation, I measured 
the perimeter and the area of lamin B stained nuclei and calculated the nuclear roundness or 
contour ratio (4π area/ circumference2) (Goldman et al., 2004). The contour ratio (CR) of a circle is 
1, and the value gets smaller with an increased degree of lobulation. To calculate the perimeter and 
area of the nuclei, they were outlined using the polygon selection tool and measured with ImageJ. 
Confocal micrographs were taken at the Zeiss LSM at 63x magnification. Laser voltage and gain 
was adjusted for each fluorophore. Pictures were converted using the LSM Toolbox plugin (Image 
J) and the fluorescence intensity was measured using the Plot Profile tool (Image J). 
2.2.6 Bioinformatics analysis 
2.2.6.1 Structure representation and visualisation 
Structures of the central rod domain (PDB# 1X8Y, (Kapinos et al., 2011)) and Ig-fold doamin 
(PDB# 1IVT (Krimm et al., 2002)) were visualised with the molecular visualisation system PyMOL 
version 1.3.  
2.2.6.2 Calculation and visualisation of electric surface potential 
To visualise the electrostatic surface potential of the Ig-fold structure, it had to be converted to 
allow the inclusion of parameters such as charge and radius information. This was done with the 
online server PDB2PQR available at http://kryptonite.nbcr.net/pdb2pqr/ (Dolinsky et al., 2007). 
The forcefield chosen was PARSE which has been optimised for solvent calculation and is 
therefore the best choice for visualization of protein electrostatics. To assign the charge to the 
structure electrostatics calculation was performed using the Adaptive Poisson-Boltzmann Solver 
(APBS) software package (Baker et al., 2001) which is integrated into the PyMOL software package. 
Once completed, the electrostatic surface potential was visualised with PyMOL with the trajectory 
colour range (colour intensity) for the electrostatic potentials set from -5000 (red, negative charge) 
to +5000 (blue, positive charge). 
2.2.6.3 In silico mutagenesis 
To perform in silico mutagenesis the corresponding mutagenesis plugin in PyMOL was used. The 
plugin can be used to replace any residue in the structure. Once the residue to be mutated and the 
new amino acid are selected, a choice of rotamers is presented. Rotamers are permitted different 
configurations of the new amino acid within the structure (residue side-chains can only take a 
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specified series of preferred conformations with respect to the peptide bond). Since the 3D 
orientation of amino acids in the rest of the structure is not changed, mutated residues might 
physically interfere with neighbouring residues, especially if the new residue is physically larger than 
the original amino acid. PyMOL displayed the points of contact between the new residue and 
remaining structure for each rotamer. In this analysis the least disruptive rotamer (the rotamer with 
the least number of contact points with the rest of the structure) was chosen because it is the 
orientation likely to be found in the structure. The isoelectric surface potential of each new Ig-fold 
mutated isoform was calculated and visualised as described above. 
2.2.7 Statistical analysis and graph representation 
Curves and bar charts were created using Microsoft Excel, figures were created and arranged with 
Adobe Illustrator CS4. Chi-square statistics and Student’s t-test were used to determine a significant 
statistical difference between samples whereby p<0.05 was considered significant (*) and p<0.01 






Chapter 3  
Genotype-Phenotype Correlations in Laminopathies 
 
3.1 Introduction 
As of December 2010, the universal mutation database (www.umd.be/LMNA) lists 303 different 
mutations in the LMNA gene in 1560 patients. However, there are only a handful of mutations 
where the genotype-phenotype link is consistent and well understood. For the vast majority of 
mutations in the LMNA gene the correlation with the resulting phenotype remains a mystery 
(Scharner et al., 2010).  
According to the current understanding, the proposed pathological mechanisms of LMNA 
mutations can be classified according to the protein modification/functional consequence the 
mutations result in, which is (1) protein degradation (2) lamin A filament formation (3) 
function/integrity of lamin A interacting proteins (4) accumulation of farnesylated lamin A 
(Worman and Bonne, 2007). However, for the majority of mutations it is unknown how exactly 
they affect the protein structure or function. 
Clinical phenotypes resulting from LMNA mutations include a large spectrum of disorders ranging 
from cardiomyopathy to premature ageing. However, upon careful inspection, the clinical disorders 
can be grouped according to the tissue they affect, which is either striated muscle, adipose tissue, 
peripheral nerve or multiple systems with signs of accelerated ageing. This classification is for the 
most part robust although other and overlapping phenotypes have been described (Worman, 2012) 
(section 1.4.1). 
The majority of mutations seem to be randomly distributed throughout the protein with no clear 
association between the type of mutation, its location and the resulting phenotype. This is 
highlighted in figure 3.1, which illustrates mutations associated with a range of phenotypes and their 
location in the lamin A protein (www.umd.be/LMNA). However, each disease category has one or 
more mutations with a good correlation between the genotype and the resulting phenotype. 
I will introduce mutations where the genotype-phenotype link is very consistent for a large number 
of patients and mutations where we have a clear understanding about the effects these mutations 
have on the protein and the resulting phenotype. I will then highlight what is known about 
mutations with no obvious correlation with the phenotype and summarise attempts by fellow 






Figure 3.1 Mutations reported in the LMNA gene and their associated phenotype. A schematic of the lamin A 
protein and selected mutations resulting in EDMD (blue), LGMD1B (purple), L-CMD (red), DCM-CD (green), FPLD 
(gold), ARCMT2 (brown) and progeroid syndrome (black) are shown. 
 
3.1.1 LMNA mutations with a predictive genotype-phenotype link 
A small number of LMNA mutations are at mutation ‘hot-spots’ and almost always result in the 
same phenotype in a large number of cases. One such example is the de novo mutation 
c.1824C>T/p.G608G which is always associated with HGPS. The mutation results in a cryptic 
splice donor site in the lamin A-specific exon 11, and deletion of the last 50 codons of exon 11 (De 
Sandre-Giovannoli et al., 2003; Eriksson et al., 2003). The resulting truncated protein (termed 
progerin) retains the CAAX box but lacks the endoproteolytic cleavage site so cannot be processed 
by Zmpste24, and is incorporated into the nuclear lamina carrying the C-terminal farnesyl group. 
Two unrelated patients with severe forms of HGPS have recently been reported carrying two new 
mutations (c.1968+1G>A and c.1821G>A), but both cause a more frequent use of the splice 
donor site that is activated in typical HGPS patients (Moulson et al., 2007). Other splice defects 
leading to the loss of LMNA exon 11 also result in the accumulation of farnesylated prelamin A 
and severe progeroid syndrome (Navarro et al., 2004). Hence, mutations resulting in prelamin A 
accumulation have a strong predictive character and novel mutations that result in similar defects 
are likely to produce a premature ageing phenotype. However, not all patients with a premature 
ageing phenotypes show signs of farnesylated prelamin A accumulation (Agarwal et al., 2008; 
Verstraeten et al., 2006), suggesting that there are other mechanisms involved (Fig. 3.1).   
There are other mutations that also have a very strong predictive character, however without a clear 
understanding of the underlying pathogenic mechanism. For example the missense mutation 
p.R482W is reported in 141 individuals, 125 (88.7%) of these suffers from FPLD, 10 (7.1%) suffer 
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from FPLD with a skeletal muscle involvement and 29 relatives of affected individuals are 
asymptomatic. Although SREBP1, a dual role transcription factor regulating cholesterol 
biosynthesis and adipogenesis has been shown to bind to lamin A, it remains unknown if an 
alteration of this interaction by R482W is the underlying mechanism of FPLD (Lloyd et al., 2002). 
Two other mutations with a strong predictive character are p.R453W which causes EDMD in 
44/45 individuals who carry this mutation and p.S143P causing DCM-CD in 20/30 individuals who 
carry this mutation (10 asymptomatic relatives with p.S143P are described). For some mutations 
with a high predictive character and a large number of patients a founder effect is evident. For 
example the p.S143P mutation is common among Finnish DCM patients and haplotype analysis 
strongly suggests a founder effect for this mutation (Karkkainen et al., 2004). 
Another example is the LMNA mutation p.R298C which is found in 44 (55%) patients who suffer 
from autosomal recessive Charcot-Marie-Tooth disease type 2A (AR-CMT2A) and 29 (36.3%) 
unaffected relatives (www.umd.be/LMNA). All of these individuals belong to large consanguineous 
families in northwest Algeria and east Morocco and form the only population in the world with this 
particular LMNA mutation. The identification of a common ancestral haplotype in 21 unrelated 
families in this region supports the idea of a founder mechanism (De Sandre-Giovannoli et al., 
2002; Tazir et al., 2004). 
3.1.2 LMNA mutations with an non-predictive genotype-phenotype link 
Out of 206 missense mutations reported in the UMD database, only 20 (9.7%) mutations have been 
reported in more than 10 individuals, generally as a result of screening large families of patients with 
LMNA mutations (Garg et al., 2002; Jakobs et al., 2001; van Tintelen et al., 2007). The other 186 
mutations have each been found in less than 10 individuals (often in only one or two), mainly due 
to mutation screening of specific patient cohorts (Brown et al., 2001; Perrot et al., 2009; Pethig et 
al., 2005; Scharner et al., 2011). Pathologies associated with these mutations mainly affect striated 
muscle (AD-EDMD, LGMD1B and DCM-CD) and adipose tissue (FPLD2). Mutations associated 
with each of the pathologies are distributed throughout the gene (Fig. 3.1) although mutational ‘hot 
spots’ have been described such as the Ig-fold domain for FPLD2 mutations and the central rod 
domain for DCM-CD mutations (Perrot et al., 2009; van der Kooi et al., 2002; Worman and Bonne, 
2007). 
3.1.3 Proposed genotype-phenotype links 
So far there have been several suggestions for a genotype-phenotype link in laminopathies. 
However some of these correlations are based on a very small number of mutations and therefore 
merely indicate certain trends or are only valid for a subset of mutations. Below is a summary of 
proposed correlations between mutations in the LMNA gene and the resulting disease phenotype.   
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3.1.3.1 Mutations resulting in a premature translation termination codon (PTC) are 
associated with cardiomyopathy and late onset neuromuscular disease 
Bonne et al. first attempted a genotype-phenotype correlation by mutation-type in LMNA (Bonne 
et al., 2000). Of the 53 patients analysed, all 12 with isolated heart involvement carried a nonsense 
mutation in p.Q6X of the head domain, indicating a link between lamin A/C haploinsufficiency 
and cardiac disease. In the remaining 41 patients with muscle weakness though, attempts to 
correlate disease severity with the protein domain affected by the missense mutations, proved 
inconclusive. Interestingly Lamin A/C haploinsufficiency also causes dilated cardiomyopathy in 
mouse. Wolf et al. (2008) reported early-onset programmed cell death of atrio-ventricular (AV) 
nodal myocytes, cardiac dilation and progressive electrophysiological disease in aged lmna+/– mice. 
Whether haploinsufficiency is the primary cause for cardiomyopathy remains controversial. Geiger 
et al. (2008) have shown that truncated lamin A/C protein with a nonsense mutation in LMNA 
exon 6 (p.R321X) is detectable after proteasome inhibition and conclude that small amounts of 
truncated protein may interfere with normal lamin A function. Truncated lamin protein was also 
found in patients diagnosed with Heart-hand syndrome who suffer primarily from cardiac disease 
(Renou et al., 2008). Here, the inclusion of the last 11 nucleotides of intron LMNA intron 9 
resulted in a frameshift and a PTC. Nuclei from patient fibroblasts displayed an abnormal 
morphology and intranuclear lamin A foci while lamin B and emerin was localised normally (Renou 
et al., 2008). In contrast, cardiac biopsies from DCM-CD patients with a heterozygous nonsense 
mutation in LMNA (p.E111X) showed reduced lamin A/C expression by Western blot.  Truncated 
form of the protein was not detected, supporting haploinsufficiency as a probable disease 
mechanism (Arbustini et al., 2002).  
Davies et al. proposed another theory of how LMNA mutations result in cardiomyopathy which 
supports haploinsufficiency as the disease mechanism in principle (Davies et al., 2011). 
Interestingly, mice homozygous for nonfarnesylated premature lamin A only (lmnanPLAO/nPLAO) also 
develop cardiomyopathy (Davies et al., 2010). These mice express lamin A where the cysteine of 
the CAAX box is mutated to a serine. As a result, prelamin A is not farnesylated and does not 
undergo the first or second cleavage step while lamin C is not expressed. To demonstrate if the 
cardiomyopathy is caused by a toxic protein or a less active protein, lmnanPLAO/– mice were 
generated (Davies et al., 2011). If a toxic protein is the cause of the disease, the phenotype should 
be reduced in these mice. However, if the cardiomyopathy in lmnanPLAO/nPLAO mice was caused by a 
hypoactive protein, the phenotype is expected to be more severe. The results were very clear; 
lmnanPLAO/– had a greatly shortened survival, demonstrating that the cardiomyopathy is caused by 
the presence of non-functional lamin A protein. The authors therefore conclude that LMNA 
mutations can be divided into two categories – those yielding a toxic lamin and those yielding a 
functionally hypoactive lamin. Why the presence of non-functional lamin protein does not affect 
other tissues remains to be answered (Davies et al., 2011). 
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In human, Benedetti et al. separated neuromuscular patients according to the age of disease onset 
(Benedetti et al., 2007). The type of LMNA mutation differed, such that 89% (17/19) early-onset 
patients carried missense mutations and in-frame deletions, while only 63% (5/8) of late-onset 
patients did. The remaining three late-onset patients had frameshift mutations. Interestingly, 
variants associated with early-onset were primarily found in the Ig-like-fold (35%) and in coil 2A 
(24%) while variants associated with late-onset mainly occurred in coil 2B (60%) (Benedetti et al., 
2007). These results indicate that the underlying disease mechanism may be more associated with 
the functional properties of the affected protein domain, rather than the type of mutation. 
3.1.3.2 Mutations in the Ig-fold have different consequences at a molecular level  
In 2002 the 3D structure of the Ig-fold domain was solved independently by Krimm et al. (2002) 
and Dhe-Paganon et al. (2002). In the more extensive study of the two, Krimm et al. characterised a 
number of mutations located on the Ig-fold domain and found that mutations associated with 
muscle-specific diseases are found in conserved hydrophobic and buried polar residues. In contrast, 
mutations associated with FPLD are located on three residues close in space, solvent accessible and 
lead to a diminution of the conserved positively charged character of a site defined by the three 
mutated residues (Krimm et al., 2002). They concluded that mutations located in the centre of the 
Ig-fold domain (which are more likely to destabilize the entire structure) are associated with a 
skeletal muscle phenotype while mutations associated with FPLD are located on the surface of the 
Ig-fold domain and destroy the positive charge of a potential interaction site. The structure of the 
Ig-fold with the FPLD mutation p.R482W was solved in 2009 (Magracheva et al., 2009). 
Superposition of wild-type and mutated molecules showed that the two structures are very similar. 
The mutant protein however forms intercalated dimers by interchanging their β-strand g’. Although 
not seen by others, this allosteric effect might point towards a different mechanism by which 
R482W results in disease. 
Mutations associated with progeroid phenotypes located in the Ig-fold domain have also been 
shown to cluster in a ‘hot-spot’ (Verstraeten et al., 2006). Importantly, the authors highlight the fact 
that the progeria hot spot is physically separated from the FPLD hot spot identified by (Krimm et 
al., 2002). The authors hypothesise that progeria mutations in the Ig-fold destabilise the nuclear 
lamina, leading to pathology (Verstraeten et al., 2006), although the effects of the mutations on the 
surface charge of the Ig-fold were not analysed. 
3.1.3.3 Mutations in Lamin A vs. mutations in Lamin A/C 
Since LMNA is alternatively spliced, another way to classify LMNA mutations is whether they 
affect both lamin A and lamin C or just one protein. Of the 12 exons in LMNA, exons 11 and 12 
are specific to lamin A, which is produced by alternative splicing of exon 10. The lamin C protein 
ends at exon 10 and has six unique C-terminal residues (Lin and Worman, 1993) (Fig. 1.4). Lamin C 
function is not well understood. Lamin A has been shown to required for the nuclear localisation of 
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lamin C, and has therefore been interpreted as being the more important protein (Vaughan et al., 
2001). However, the apparent normal phenotype of the lmnaLCO/LCO mouse, where lamin C is the 
only A-type lamin present, suggests that prelamin A and lamin A are dispensable (Fong et al., 
2006b). Similarly, mice expressing only lamin A (mature form or pre-form) are also normal, which 
confirms a redundancy between A-type lamins (Coffinier et al., 2010; Davies et al., 2010). 
Expectedly given its size, only 2 mutations, p.R571S causing DCM (Fatkin et al., 1999) and 
p.R571C causing muscular dystrophy with axonal neuropathy (Benedetti et al., 2005) have been 
associated with the lamin C-specific tail. Exon 12 encodes 8 amino acids that are cleaved during 
posttranslational modification of prelamin A, so unless mutations affect prelamin A processing, 
they would not be expected to effect lamin A function. Interestingly, few mutations occur in lamin 
A-specific exon 11 and those that do are less associated with skeletal muscle involvement and more 
with lipodystrophy, premature ageing and neuropathy (www.umd.be/LMNA).  
3.1.4 Effect of modifying genes and single nucleotide polymorphisms on 
phenotypic variability in laminopathies 
A large number of LMNA mutations show a high degree of inter- and intra-familial variability 
(Bonne et al., 2000). For example, patients carrying the p.R644C mutation have a range of clinical 
conditions incuding DCM, LGMD1B, atypical HGPS, lipodystrophy etc. which suggests that the 
genetic background contributed to disease phenotype (Brown et al., 2001; Csoka et al., 2004; 
Mercuri et al., 2005; Rankin et al., 2008). 
The LMNA gene contains many single nucleotide polymorphisms (SNPs) with no pathologic 
phenotype: of 40 on the Leiden Open Variation Database (www.dmd.nl/lmna_seqvar.html), 75% 
(30/40) are silent mutations, and the rest are missense mutations affecting the head (one), central 
rod (three) or tail (six) domains. Depending on the context however, these mutations can cause 
disease: p.T528M or p.M540T alone appear non-pathogenic, but when inherited together, they 
result in HGPS but without prelamin A accumulation (Verstraeten et al., 2006). SNPs can also alter 
the clinical condition diagnosed: while the mutation p.S583L normally causes FPLD2, when present 
with T528M it results in FPLD1 (Savage et al., 2004). 
In some patients, mutations in modifying genes such as emerin or desmin have been shown alter 
the EDMD phenotype caused by the LMNA mutation, providing evidence for epistasis (Muntoni 
et al., 2006). Furthermore, approx. 60% of all EDMD patients have no mutations in LMNA, EMD 
or FHL1 which suggests that there are additional genes involved in EDMD pathology (Gueneau et 
al., 2009; Meinke et al., 2011). Mutations in nesprins for example have been found in patients with 
an EDMD phenotype (Zhang et al., 2007). However, it has not been excluded that the missense 
mutations are in fact polymorphisms in these patients and thus not EDMD-causing. 
In summary, an influence of the genetic backround and modifying mutations on the phenotypic 




The aim of this chapter is to investigate genotype-phenotype links in laminopathies applying a very 
general approach including all mutations listed in the UMD database. By grouping mutations 
according to the resulting phenotype and statistically analysing general characteristics of mutations 
in these groups (such as the severity of the amino acid change or the position of these mutations 
within the protein structure) I aim to identify commonalities within each group. This will allow me 
to make predictions about the phenotypic outcome of a novel mutation and perhaps propose novel 





3.3.1 The LMNA mutation dataset 
The LMNA mutation dataset used for this meta-analysis was obtained from the Universal Mutation 
Database (www.umd.be/LMNA) last updated on 20.12.2010. The dataset lists 303 different 
LMNA mutations and 1560 patients (probands initially screened for mutations in LMNA and their 
and relatives) and provides genetic and clinical information for each patient. Unfortunately the 
dataset was not complete and contained errors so I added, removed, changed and combined data. 
Below are examples of changes made to the dataset I generated for my study, to illustrate what kind 
of errors were found and corrected. 
I removed one patient entry from the database because the nucleotide change c.1073T>A did not 
match the protein modification reported (p.M358K). The missense mutation p.R343Q was not 
included in the analysis because none of the four entries with this mutation (1 proband and 3 
relatives) was reported to have a phenotype. According to the original publication by Vytopil et al., 
the LMNA mutation p.R343Q was found in a group that served as negative controls for their study 
(Vytopil et al., 2002). Similarly the frameshift mutation p.A170PfsX7 was not included in this study 
because both patient entries reported with this mutation did not display a phenotype (Doh et al., 
2009). Entries with different nucleotide changes that result in the same protein modification were 
combined in the analysis. 
The clinical information available for each patient reported in the database varies. It ranges from a 
general diagnosis to very detailed description of the phenotype. To standardise the patient 
information available and prepare it in the context of genotype-phenotype correlations, I grouped 
patients into six phenotype categories based on the tissue affected: (1) ‘skeletal muscle’, (2) ‘cardiac-
only’, (3) ‘premature ageing’, (4) ‘lipodystrophy’ and (5) ‘neuropathy’. For a list of diseases 
belonging to each category refer to table 1.1. Patients that suffer from more than one disease or any 
other disease that does not fall in categories 1-5 are grouped into category (6) ‘Other/Combined’. 
3.3.2 Normalising the data entries 
More than half (56.1%) of the mutations listed in the UMD dataset have multiple patient entries. 
Although in most cases, entries for a specific mutation are reported to have the same phenotype, 
there are other cases where one mutation is associated with multiple phenotypes likely due to 
genetic background or modifying mutations. To explore genotype-phenotype correlations, each 
mutation needs to be associated with a phenotype. In order to avoid artificial errors by assigning 
every mutation against a single phenotype, I have devised a phenotype weighing method to 
normalise the data. Each mutation was assigned a Phenotype Outcome Index (POImut) which 
represents the association of a mutation with a specific phenotype. Similarly, each amino acid 
residue was assigned a Phenotype Outcome Index (POIres), which represents to what extent a given 
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residue is associated with a phenotype. This normalising method is described in detail below and is 
illustrated in figure 3.2. 
3.3.2.1 Mutation Phenotype Outcome Index (POImut) 
To accurately represent the number of mutations that cause a specific phenotype, I have assigned a 
phenotype outcome index to each mutation. The index represents the percentage of patients with 
this phenotype for each mutation (it is therefore a numerical representation of the fraction of that 
mutation that contributes to a particular phenotype). The total phenotype outcome index for 
each mutation will always add up to one and is defined as the normalised number of 
mutations (hereafter mutationsN) associated with that phenotype. If more than one patient is 
reported for a given mutation, the mutation can contribute to multiple groups of phenotypes.  
This is best explained by giving the following example (illustrated in Fig. 3.2): There are 3 patients 
reported with missense mutation p.Y45C. Out of these 3 patients, 2 patients have been diagnosed 
with EDMD (EDMD is classified as a ‘skeletal muscle’ phenotype). The third patient has been 
diagnosed with DCM-CD (DCM-CD is classified as a ‘cardiac-only’ phenotype). The missense 
mutation p.Y45C therefore was assigned: (i) a ‘skeletal muscle’ POImut of 0.67 (2/3 patient entries 
with this mutation) and (ii) a ‘cardiac-only’ POImut of 0.33 (1/3 patient entries with this mutation). 
Therefore, the p.Y45C mutation is associated with both a skeletal muscle phenotype and a cardiac-
only phenotype to various degrees represented by the POImut.  
 
 
Figure 3.2 Calculation of the Phenotype Outcome Index for mutations (POImut) and residues (POIres). (A) For 
residues with a single reported mutation the POImut (red) is the same as the POIres (blue) and represents to what 
degree a mutation is associated with a phenotype. (B) For residues with more than one reported mutation, the POIres 
reflects the phenotype outcome of all patients reported on that residue and gives an indication to what degree that 
the residue is associated with a phenotype.  
 
3.3.2.2 Residue Phenotype Outcome Index (POIres) 
Most of the data presented here are based on individual mutations and therefore uses POImut to 
weigh the phenotype. However some data are based on the properties of specific amino acid 
residues such as the heptad repeat position of residues in the central rod domain or the surface 
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exposure of residues in the Ig-fold domain. Because a number of residues in lamin A/C harbour 
multiple mutations, the phenotype was weighed by assigning each residue with a POI (POIres). If 
there is only one mutation reported on a residue the POIres is the same as the POImut (Fig. 3.2A). 
However, if multiple mutations occur on the same residue, their phenotype outcome is combined 
to calculate the POIres for this residue (Fig. 3.1B). The total POIres for a single residue is always 
one and defined as the normalised number of unique residues associated with that 
phenotype (hereafter residuesN). 
Following is an example of calculating the POIres for a unique residue with multiple mutations 
(illustrated in Fig. 3.2B): for residue R89, 2 patients are listed where the arginine is mutated to a 
cysteine (p.R89C). Both patients are reported to have a ‘skeletal muscle’ phenotype. In 5 other 
patients however, the arginine is mutated to a leucine (p.R89L), resulting in a ‘cardiac-only’ 
phenotype in all these 5 patients. When these two mutations are considered individually, their 
POImut would be 1.0 for (a) the ‘skeletal muscle’ phenotype and (b) the ‘cardiac-only’ phenotype, 
respectively. The POIres for residue R89 however takes all seven patients with mutations on that 
residue into account, resulting in a ‘skeletal muscle’ POIres of 0.29 (2/7 patient entries with 
mutations on this residue) and a ‘cardiac-only’ POIres of 0.71 (5/7 patient entries with mutations on 
this residue). 
3.3.3 Breakdown of the LMNA mutations from the UMD dataset 
All together 1560 patients with 303 different pathogenic protein modifications, intronic mutations 
and silent mutations have been reported so far and are listed in the UMD dataset. I have sorted the 
data according to the type of mutation and the resulting phenotype and the results are summarised 
in figure 3.3.  
The types of mutation have been classified into 5 different categories (Fig. 3.3A):  
1. Missense mutations (206 or 67.9%) resulting in a single amino acid change.  
2. Nonsense mutations (45 or 15.1%) resulting in a premature stop codon at the mutated 
amino acid or after a frame shift of various length. This group also contains mutations or 
deletion of the start codon (p.M1?) which is likely to result in a non-coding mRNA. 
3. Intronic mutations (23 or 7.5%) represent the third largest group.  
4. In-frame insertions and deletions of one or more amino acids (18 or 5.9%) 
5. Silent mutations (11 or 3.6%) form the smallest category  
Out of 1560 patients only 1338 were reported to have a clinical phenotype. The remaining 222 
patients (exclusively relatives of probands) were asymptomatic at the point of data entry.  In this 
study asymptomatic cases were not included for the following reason. Being relatives of probands 
they were usually tested either together with the symptomatic proband or shortly after the 
pathogenic mutation was discovered. It is therefore very likely that most, if not all of the 
asymptomatic cases had not yet developed a phenotype at the time of testing. It could also be that 
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the genetic background of relatives protected/delayed onset of the relevant laminopathy symptoms. 
It is important to note, that it is not possible to predict the phenotype these cases might develop 
solely based on the probands phenotype. Assigning asymptomatic cases with a hypothetic or 
predicted phenotype would therefore artificially inflate the strength of the dataset.  Furthermore, 
including asymptomatic relatives would incorporate the risk of reducing the statistical power of the 
dataset by diluting the phenotypic value for each mutation. 
The majority of LMNA mutationsN result in a skeletal muscle phenotype (137.4 or 42.5%) closely 
followed by a cardiac only phenotype (96.5 or 34.7%). The third most common phenotypic group 
includes the premature ageing disorders caused by 30.0 (9.9%) mutationsN. Lipodystrophy disorders 
are caused by 17.4 (5.7%) mutationsN while only 3.0 (1.0%) mutationsN cause neuropathy. The 
remaining 18.8 mutationsN (6.2%) cause other or combined phenotypes such as Insulin Resistance 
Syndrome (IRS) or a combination of FPLD and DCM-CD etc. (Fig. 3.3B). 
In general, all phenotypic groups are predominantly caused by missense mutations. When analysing 
the different phenotypic categories for mutational biases I observed an interesting correlation in the 
‘cardiac-only’ phenotype (Fig. 3.3C and D). When the proportions of the different types of 
mutations which cause the ‘cardiac-only’ phenotype is compared to the distribution of all mutations 
in the UMD dataset, it is significantly different. In total 395 ‘cardiac-only’ patients with 96.5 
different mutationsN are listed in the UMD dataset. Out of those 96.5 mutationsN 27.2 (28.1%) led 
to protein truncations, which is twice as many as would be expected statistically if they were 
randomly distributed. In contrast, when mutations resulting in a ‘skeletal muscle’ or ‘premature 
ageing’ phenotype are broken down into mutation type, an expected number of missense 
mutations, truncations, etc. is found. In other words, I have shown that patients who have an 
LMNA mutation that results in the truncation of the protein are more likely to develop DCM-CD 
compared to patients with missense mutations. In fact, when truncation mutations are considered 
only, the vast majority (60.4%) result in a ‘cardiac-only’ which confirms results obtained by others 
(Benedetti et al., 2007; Bonne et al., 2000) suggesting that mutations resulting in lamin A truncation 
primarily cause DCM-CD. However, if the truncation mutations result in protein expression which 
interferes with lamin A function or a loss of lamin A expression from the affected allele remains to 
be determined for the majority of the mutations (Geiger et al., 2008; Renou et al., 2008). 
Although this analysis gives a good overview about the type of mutation that results in a certain 
phenotype, this correlation is very general. In order to allow more detailed predictions about the 
phenotypic outcome of a particular mutation, the mutations need to be examined in the context of 









Figure 3.3 Breakdown of LMNA mutations from the UMD dataset. A total of 303 mutations are included in this 
study. (A) Breakdown of the dataset according to the type of mutation reported. (B) Breakdown of the dataset 
according to the clinical phenotype. (C) Number of mutationsN resulting in a specific laminopathy. The vast majority of 
mutations result in either a skeletal muscle phenotype or a cardiac-only phenotype. The next most common group of 
diseases are the premature ageing syndromes followed by lipodystrophy and neuropathy. (D) Relative percentages 
of mutationsN resulting in a specific phenotypic group. The proportion of different mutation types resulting in a 
‘cardiac-only’ phenotype is significantly different to the global distribution with protein truncations being over-
represented in this category. n.d. not determined; n.s. not significant; **p<0.01 (Chi-Square statistics) 
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3.3.4 Folded regions of the lamin A protein harbour more pathogenic missense 
mutations than unstructured regions  
A large portion of the lamin A protein is folded into defined secondary and tertiary structures, 
including alpha-helices, and beta-sheets. To determine if mutations in these folded regions are 
statistically more likely to result in a pathogenic phenotype, I separated the protein into two regions: 
(1) one I termed the ‘unstructured region’, which includes the loosely organised globular head 
domain and the globular tail domain excluding the Ig-fold domain and is formed by 193 amino 
acids (2) and the second, the ‘folded region’, which includes the α-helices of the central rod 
domain, the linker and hinge regions of the central rod domain as well as the Ig-fold of the tail 
domain and consists of 471 amino acids (Fig. 3.4A). 
Once I specified the different regions of the lamin A protein, I grouped all 206 missense mutations 
according to their location to either unstructured or folded regions (Fig. 3.4B and C). Out of 206 
missense mutations, 169 (82.0%) are located in the folded regions while only 37 (18.0%) are located 
in the unstructured regions of the lamin A protein. The 206 different missense mutations affect 154 
unique residues. When the data was normalised for unique residues (eliminating mutations located 
on the same residue) the distribution remained almost the same with 124 (80.5%) residues located 
in the folded region and 30 (19.5%) residues located in the unstructured region. If these values are 
compared to the expected values (assuming random mutational events approx. 71% would be 
found in the folded region), I found that a significantly larger proportion of missense mutations are 
located in folded regions even after normalising the data for unique residues. 
Since it is statistically more likely that an amino acid change in the folded region results in a 
pathogenic phenotype, this result suggests that the folded domains of the lamin A protein play a 
more important role in lamin A function than unstructured region. This however, does not take 
into consideration mutations that have never been described due to embryonic lethality (which 
might be located in the unstructured region of the protein). In terms of total numbers of missense 
mutations and unique residues, both mutations in the central rod domain and the Ig-fold domain 
are equally likely to result in a pathogenic phenotype. So although folded domains are more 
affected, the central rod domain and Ig-fold domain contribute equally to this result. 
To find out if mutations resulting in a certain phenotype are randomly distributed throughout the 
lamin A protein, the observed frequencies of phenotypes have been compared to the frequencies of 
phenotypes of all reported missense mutations. The result shows that mutations in the unstructured 
region of the lamin A protein result in a significantly different distribution of phenotypes when 
compared to all missense mutations. This is due to a reduced number of mutations resulting in a 
‘skeletal muscle’ and ‘cardiac-only’ phenotype. Mutations resulting in ‘lipodystrophy’ and 
‘other/combined’ phenotypes however, were overrepresented in the unstructured region of the 
lamin A protein. In contrast, mutations in the central rod domain or Ig-fold domain (analysed 




Figure 3.4 Separation of unstructured regions and folded domains in lamin A. (A) Schematic diagram of the 
lamin A protein with unstructred regions highlighted in green and folded regions highlighted in blue. The folded region 
includes the central rod domain and the Ig-fold domain while the unstructured region includes the head and tail 
domain and an unfolded region between the central rod and Ig-fold domain. (B) Absolute number of missense 
mutations located in unstructured or folded domains of the protein before and after removing mutations on residues 
with multiple reported mutations. (C) Relative percentage of missense mutations in unstructured regions or folded 
domains of the protein showing significantly more mutations located in the folded domains of the protein (before and 
after the removal of residues with multiple reported mutations). (D) Distribution of phenotypes caused by missense 
mutations located in unstructured region and folded domains of the lamin A protein compared to all reported 
missense mutations. The central rod domain and Ig-fold domain are analysed individually. Only mutations located in 
the unstructured region of the lamin A protein result in a phenotype distribution that is significantly different from the 




Interestingly, the proportion of mutations resulting in a cardiac phenoptype is slightly elevated in 
the central rod domain (when compared to the Ig-fold domain and all missense mutations 
combined) which confirms results by others who suggest that the central rod domain is a hot-spot 
for DCM mutations (Perrot et al., 2009). 
A possible explanation could be that DCM mutations differentially affect lamin A binding partners 
such as c-Fos and Erk1/2 which have been shown to bind to the central rod domain (Gonzalez et 
al., 2008). Further evidence for this hypothesis is provided by lamin A mouse model where 
upregulation of the Erk1/2 signalling cascade has been shown to be involved in the development 
of cardiomyopathy (Muchir et al., 2007b; Muchir et al., 2009). 
In summary, folded domains of the lamin A protein (the central rod domain and Ig-fold domain) 
harbour significantly more missense mutations than the unstructured region suggesting that these 
domains play a more important role in lamin A function/interaction with binding partners. At the 
same time, the proportion of mutations that cause a ‘skeletal muscle’ and ‘cardiac-only’ phenotype 
is reduced and ‘lipodystrophy’ and ‘other/combined’ phenotypes are overrepresented in 
unstructured regions of lamin A for reasons that are yet unclear. 
3.3.5 Classification of the type of amino acid change 
Even though all the mutations analysed are missense mutations, some result in amino acid changes 
in which the new amino acid is structurally/chemically similar to the original, while others 
introduce amino acids that confer quite different chemical side chains compared to the original 
residue. Amino acids can be classified into 4 groups according to the polarity of their side chain: (a) 
amino acids with nonpolar aliphatic and aromatic side chains (Gly, Ala, Val, Leu, Ile, Met, Phe, 
Trp); (b) amino acids with uncharged polar side chains (Ser, Thr, Asn, Gln, Tyr, Cys); (c) amino 
acids with positively charged side chains (Lys, Arg, His) and (d) amino acids with negatively charged 
side chains (Asp, Glu). Proline with its cyclic structure is generally considered a special amino acid 
(for amino acid structures see appendix 3). 
To address the question of whether a larger number of pathogenic missense mutations arise from 
more drastic changes in the residue properties, I classified the missense mutations into 2 categories 
according to the chemical and physical properties of the amino acid change. 1) ‘Drastic changes’ of 
amino acid side chain characteristics are changes from nonpolar to charged or vice versa, a change 
of charge and changes to/from proline. 2) ‘Moderate changes’ of amino acid side chain 
characteristics are all other changes and include nonpolar to nonpolar, nonpolar to polar, charged 
to the same charge etc. (Fig. 3.5A). 








Figure 3.5 Classification of all missense mutations by the type of amino acid change. (A) Classification of the 
amino acid changes into 2 groups according to their chemical and physical properties. ‘Drastic’ amino acid changes 
are changes from hydrophobic to charged or vice versa, a change of charge and changes to/from proline. ‘Moderate’ 
amino acid changes are all other possible mutations. (B) Number of ‘drastic’ and ‘moderate’ missense mutations 
reported in the UMD database. Half of all missense mutations are classified as ‘drastic’. (C) Relative percentages of 
‘drastic’ and ‘moderate’ missense mutations reported along the entire lamin A protein or on specific protein domains. 
Taking all reported missense mutations into consideration, there are significantly more classified ‘drastic’ than would 
be expected statistically. (D) Relative percentages of ‘drastic’ and ‘moderate’ missense mutations for each 
phenotypic group. All three major phenotypic groups (skeletal muscle, cardiac-only and premature ageing) are 
caused by a significantly larger proportion of ‘drastic’ amino acid changes than expected. Expected frequencies 
represent relative percentages of all possible missense mutations (157 in total). n.d. not determined; n.s. not 






To determine if the number of drastic missense mutations found in the UMD dataset can be 
expected by chance, I compared it to the proportion of drastic amino acid changes of possible 
missense mutations. In theory any of the 20 standard amino acids can be mutated to any of the 
remaining 19 to qualify as a missense mutation, equating to a total of 380 different mutations. 
However, virtually all LMNA missense mutations listed in the UMD dataset arise from single 
nucleotide changes. This study therefore considers only those missense mutations that can arise 
from a single nucleotide change. For example the codons UAU and UAC encode for Tyr while the 
codons AAA and AAG encode for Lys. If only a single nucleotide is changed, a Tyr residue cannot 
be mutated to a Lys residue and vice versa. Excluding such mutations results in a total of 157 
missense mutations, that can be caused by a single nucleotide change. Out of those 157, 21 (13.4%) 
missense mutations cause a drastic change in amino acid property while the remaining 136 (86.6%) 
missense mutations result in a moderate change in amino acid property (Fig. 3.5A). 
If ‘drastic’ and ‘moderate’ amino acid changes are equally likely to cause a phenotype (assuming 
random mutational events) one would expect the proportion of ‘drastic’ missense mutations in the 
UMD dataset to be close to 13.4%. However, out of 206 missense mutations 103 (50%) classify as 
‘drastic’ and 103 (50%) classify as ‘moderate’ amino acid changes (Fig. 3.5B). A significantly larger 
proportion of drastic amino acid changes is also found in each of the three sub-regions of the lamin 
A protein (Fig. 3.4C) which shows, not surprisingly, that ‘drastic’ amino acid changes are more 
likely to result in a phenotype than ‘moderate’ amino acid changes.  
The question remains if all phenotypic groups arise equally from a larger proportion of ‘drastic’ 
mutations. To address this, I calculated the relative percentages of all reported ‘drastic’ and 
‘moderate’ missense mutations grouped by phenotype (Fig. 3.5D). The result shows that three 
major phenotypic groups (skeletal muscle, cardiac-only and premature ageing syndromes) but not 
lipodystrophy,  are caused by a significantly larger proportion of missense mutations classified as 
‘drastic’ than what we would expect if we assume the occurrence of random mutational events.  
The number of mutations resulting in ‘neuropathy’ and ‘other/combined’ phenotypes is too small 
for statistical analysis. 
3.3.6 Missense mutations in the central rod domain 
The central rod domain of lamin A is formed of four α-helices two linker regions and one hinge 
region all of which engage in a coiled-coil dimerization with a second lamin A protein (see section 
1.3.4.1). Sequences of α-helical coiled-coils display a periodicity of seven amino acids (heptad 
repeats) with nonpolar amino acids occupying heptad positions a and d. These hydrophobic 
residues form a hydrophobic seam running along the centre of the coils, stabilising the interaction 
(Parry et al., 2008). A typical example of a heptad repeat sequence (taken from the lamin A central 
rod domain) is illustrated in figure 3.6. If mutations on hydrophobic residues do destabilize α-
helical coiled-coils, it can be hypothesised that the residues lining the inner surface of the coiled-coil 
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(a and d) are likely to be more sensitive to changes than those located on the outside of the coiled-
coil. The lamin A central rod domain contains a total of 42 heptad repeat units. If pathogenic 
mutations would be distributed randomly throughout the central rod domain, we would expect 
approximately 2/7 (28.8%) of all mutations to fall on hydrophobic residues (a and d). 
To test if this is true, all missense mutations and unique residues located within the 4 α-helices of 
the central rod domain were sorted according to their corresponding heptad repeat position and 
were plotted on a graph (Fig. 3.7A). Interestingly, missense mutations are not over-represented on 
hydrophobic heptad positions (a and d). When the proportion of mutationN and unique residuesN 
on the seven heptad repeat positions were compared to the expected numbers, no significant 
difference was found (Fig. 3.7B). This might suggest that (a) either the stability of the α-helical 
coiled coil is not affected by mutations on hydrophobic heptad positions or (b) that destabilizing 
the α-helical coiled coils are not the underlying mechanism of phenotypes arising from mutations in 
the central rod domain. 
Although the global analysis did not point to hydrophobic residues as being more susceptible to 
changes it was unclear if this is true for each individual phenotype. The next step was therefore to 
find out if all the major disease phenotypes are caused by an expected number of mutations on 
hydrophobic (a and d) or other (b, c, e, f and g) heptad repeat residues or if any of the phenotypes 
is caused by mutations that favour a specific heptad repeat position. Because of the low number of 
mutations in each category, hydrophobic (a and d) and other (b, c, e, f and g) heptad positions have 
been combined and were analysed together (Fig. 3.7C). 
The result however, shows that none of the phenotypes are caused by a larger number of 
hydrophobic residues as statistically expected, although a trend was observed for mutations 
resulting in a skeletal muscle phenotype where one third of all mutations are located on heptad 
position a or d. Unfortuantely, the number of known mutations is currently not large enough to 
yield a conclusive result. However, the result indicates that for skeletal muscle laminopathies, 
heptad repeat positions might be affected to a larger extent, which could potentially lead to 





Figure 3.6 Heptad repeat sequence of the lamin A central rod domain. (A) Two consecutive heptad repeats 
(residues 338-351) from the human lamin A central rod domain are shown with nonpolar amino acids occupying 
heptad positions a and d. Occasionally charged amino acids  are located on position a or d such as lysine 341. In this 
case, lysine 341 forms a salt bridge with a glutamate residue of the neighbouring α-helix, reinforcing the coiled-coil 
(Kapinos et al., 2011). (B) Structural representation of a coiled coil α-helix. Residues located on heptad positions a 
and d are shown in space fill (highlighted in red) and form a seam along the interface of both a α-helices. 
 
 
Figure 3.7 Occurrence of missense mutations on specific heptad repeat positions. (A) Absolute numbers of 
missense mutations (1) and numbers of unique residues with pathogenic missense mutations (2) located on 
hydrophobic (red) and other (grey) heptad repeat positions. (B) Relative percentage of missense mutations located 
on hydrophobic (a and d) and other (b, c e, f and g) heptad positions. Hydrophobic residues (a and d) are marked in 
red in all 3 panels. (C) Relative percentage of missense mutations resulting in a specific phenotype located on 
hydrophobic (a and d) and other (b, c e, f and g) heptad positions. For all major disease phenotypes a statistically 
expected number of mutations is found on both, hydrophobic and other heptad positions; The number of mutations in 
each category is indicated on the x-axes; n.d. not determined; n.s. not significant 
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3.3.7 Missense mutations in the Ig-fold domain 
3.3.7.1 Surface exposure as a potential link between genotype and phenotype 
The Ig-fold domain stretches from residue 428-547 of the lamin A protein and encodes two β-
sheets which fold to form a β-sandwich (see section 1.3.4.2). The 3D structure of the Ig-fold 
domain has been solved independently by Krimm et al. (2002) and Dhe-Paganon et al. (2002). For 
this study, the NMR structure from Krimm et al. (PDB ID 1IVT) was used since it covers a longer 
length of the Ig-fold domain and is thus likely to present a more accurate structure. For a detailed 
description of structure manipulation and graphical representation refer to section 2.2.6. 
My results described above show that in the Ig-fold, the severity of the amino acid change cannot 
be used to predict the phenotypic outcome of the mutation. The question here is, if the spatial 
position of the residues within the Ig-fold, i.e. buried or exposed, can be statistically associated with 
certain phenotypes, which was first proposed by Krimm et al. (2002) for lipodystrophy disorders.  
In order to address the question, I first calculated the Solvent Accessible Surface Area (SASA) for 
each amino acid residue in the protein model of the Ig-fold domain with the Parameter Optimised 
Surfaces (POPS) program (Cavallo et al., 2003; Fraternali and Cavallo, 2002). The SASA of the 
amino acid in the Ig-fold was then compared to the SASA of the same amino acid in the tripeptide 
Ala-Xxx-Ala (isolated form) which was considered to be the maximum SASA (Fraternali F., 
personal communication). Residues are defined as buried when its SASA in the protein is lower 
than 20% of its SASA in the tripeptide Ala-Xxx-Ala. The relative values of surface exposure for 
residues of the Ig-fold are visualised graphically in figure 3.8A with the 20% cut-off indicated as a 
red line. 
In total 38 residues (31.7%) in the Ig-fold domain have a relative surface exposure of less than 20% 
and are therefore considered buried. If mutations on buried and other residues are equally likely to 
result in a phenotype we would expect approximately 32% of all residues that are associated with 
disease to be buried residues. However, out of the 34 residues that cause a phenotype when 
mutated, 17 (50%) are found on buried residues which is significantly more than statistically 
expected (p=0.0215, Chi-square statistics). 
Next, the residues were sorted according to the phenotype they are associated with to analyse if 
buried or exposed residues are more likely to result in a certain phenotype when mutated. 
According to the numbers shown in figure 3.8B the distribution of residues resulting in ‘skeletal 
muscle’ disorders when mutated is significantly different from expected numbers of buried, 
intermediate and exposed residues. Here 10.1 residuesN (61.4%) instead of the expected 5.1 
residuesN (i.e. twice the number) fall within the buried amino acid category. In contrast, a lower 
proportion of residues associated with other phenotypic groups seem to be located on buried 
residues.  Unfortunately, the number of residues associated with the other phenotypic groups was 
not large enough to apply Chi-square statistics. In the entire Ig-fold there are 16.5 residuesN 
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associated with a skeletal muscle phenotype. The other phenotypic groups are associated with 
considerably less residues, in descending order: ‘premature ageing’ (5.3 residuesN), ‘cardiac 
phenotype’ (4.5 residuesN), ‘lipodystrophy’ (4.4 residuesN) and ‘neuropathy’ (1.6 residuesN). 
 
 
Figure 3.8 Parameter Optimises Surfaces (POPS) analysis of the Ig-fold domain. (A) POPS analysis on the 
lamin A Ig-fold domain (PDB ID 1IVT) was performed using the online server available at 
http://mathbio.nimr.mrc.ac.uk/wiki/POPS (Cavallo et al., 2003). The graph displays the relative solvent accessible 
surface area (SASA) of each amino acid residue in the Ig-fold domain (residues 428-547) compared to the SASA of 
the same amino acid in the Ala-X-Ala tripeptide. Residues with less than 20% exposure (indicated by the red line) are 
considered buried. (B) Relative percentages of mutations located on buried/other residues (identified in A) 
associated with a specific phenotype. The results show that mutations causing a skeletal muscle phenotype are 
significantly more likely to fall on a buried residue. Number of mutations in each category is indicated on the x-axes; 
n.d. not determined; ** p<0.01 (Chi-square statistics) 
 
3.3.7.2 Visualising mutations in a spatial context reveals that they cluster for specific 
phenotypic groups  
Since most disease categories are only caused by mutations on a small number of residues in the Ig-
fold, I have chosen a more direct approach to find a correlation between mutation/residue and the 
phenotype. The 3D structure of the lamin A Ig-fold is freely available and can be manipulated in a 
number of ways using different molecular visualisation tools such as PyMOL. The strategy 
employed here was to bring residues that are strongly associated with a certain phenotype into a 
spatial context by highlighting them on the 3D structure of the Ig-fold (Fig. 3.9). The advantages of 
doing this are threefold: 1) By looking at every residue change individually, even a small number of 
mutations can yield strong correlation. 2) Residues that would not be associated with each other by 
looking at the primary sequence are brought into a spatial proximity and this might highlight 
regions of special interest. 3) Amino acids can be mutated in silico to predict chemical and physical 





Figure 3.9 Location of residues associated with a specific phenotype (when mutated) on the 3D structure of 
the wild-type lamin A Ig-fold domain. (A) Backbone of the wild-type lamin A Ig-fold domain viewed from 4 different 
angles, rotated by 90º. The β-sheets forming the β-sandwich are indicated in blue, loops are indicated in grey. (B) 
Representation of the surface of the Ig-fold (white). Amino acid residues associated with a certain phenotype (when 
mutated) are highlighted in colour: skeletal muscle (blue), cardiac-only (red), premature ageing (green), lipodystrophy 
(purple) and neuropathy (orange). (C) Electrostatic surface potential of the Ig-fold. Blue areas indicate a positive 
surface potential while red areas represent negative surface charge of the protein.  
 
Figure 3.9A shows the backbone structure of the Ig-fold in four orthographic views to help with 
the three dimensional orientation. Figure 3.9B shows the surface representation of the Ig-fold in 
the same orientation as the backbone structure above. In addition, residues showing a strong 
association with a certain phenotype are highlighted in different colours. In figure 3.9C the 
electrostatic surface potential of the Ig-fold is shown.  
Residues visualised in figure 3.9B are those with a very high association (phenotype outcome index 
>0.9) with particular phenotype. The result clearly shows that residues that do cause a certain 
phenotype when mutated cluster together on the surface of the 3D structure of the Ig-fold which 
confirms results obtained by others (Krimm et al., 2002; Verstraeten et al., 2006). Residues in blue 
are associated with a skeletal muscle phenotype and are mainly located on a negatively charged 
phase of the β-fold. Residues associated with premature ageing (green) and lipodystrophy (purple) 
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are located in regions on the opposite phase of the structure. For residues associated with a ‘cardiac 
only’ phenotype (red) no specific region could be identified and only one residue located on a loop 
was strongly associated with neuropathy (orange). 
Another interesting observation is that all regions that contain mutations carry either a strong 
negative charge or a strong positive charge while regions with a neutral electrostatic surface 
potential seem to be free of pathogenic amino acid changes (Fig. 3.9B and C).  
From previous results (Fig. 3.4) we saw that mutations causing ‘premature ageing’ and 
‘lipodystrophy’ syndromes are over-represented in the Ig-fold. This, and the fact that mutations 
causing these phenotypes cluster together in specific regions of the 3D structure of the Ig-fold 
strongly suggests that there is a specific interaction at this point (either with lamin A itself or other 
proteins) that if disrupted, leads to a certain phenotype. To analyse this finding in greater detail, I 
took all of the mutations that are both partially exposed at the surface and fall within a contained 
region of the Ig-fold causing the same phenotype, and re-analysed them on an individual basis. 
3.3.7.3 In silico mutagenesis of the lamin A Ig-fold identifies consistent changes of 
surface charge for some laminopathies 
After the identification of specific regions that seem to be associated with a certain phenotype, the 
question arose if mutations in these regions all cause the same change to the surface charge of the 
Ig-fold. To answer this, I applied in silico the mutagenesis plug-in of the visualisation software 
PyMOL to mimic mutational changes to amino acid residues in the Ig-fold domain.  
After mutating residues in the Ig-fold with PyMOL (see section 2.2.6 for details) the surface 
potential of each isoform was compared to the wild-type structure to establish if mutations in the 
region analysed (for a specific phenotype) alter the surface potential of the Ig-fold in the same way. 
Four regions of the Ig-fold were analysed this way: the skeletal muscle regions 1 and 2 (Fig. 3.10), 
the premature ageing region (Fig. 3.11) and the lipodystrophy region (Fig. 3.12). The summary of 
the findings are summarised in table 3.1. 
Mutations resulting in a skeletal muscle phenotype 
Residues resulting in a skeletal muscle phenotype when mutated cluster to 2 main regions on the Ig-
fold. The first region is located along the front of the Ig-fold and forms a negatively charged ridge. 
The second region clusters between both β-sheets around residue Y481 forming a positively 
charged area (Fig. 3.10). When the electrostatic surface potential of each mutation in cluster 1 is 








Figure 3.10 Change in the electrostatic potential with mutations causing a skeletal muscle phenotype. Shown 
are the Ig-fold backbone, positions of residues subjected to in silico mutagenesis (in yellow) and the electrostatic 
surface potential of wild-type as well as mutated structures. I have identified two main clusters of residues on the Ig-
fold that result in a skeletal muscle phenotype when mutated. Cluster 1 is located on one side of the β-sandwich and 
involves residues. D446, G449, R453, W520 and R545 while cluster 2, located on the opposite β-sheet and involves 
residues W467, Y481 and W514. Coloured arrows indicate areas of the mutated Ig-fold that are affected by each 
amino acid change. 
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Three out of six mutations located in this region cause an increase of positive charge (p.D446V, 
p.W520G and p.W520S), two mutations result in an increase in negative charge (p.G449D and 
p.R453W) and one mutation causes a reduction in the positive charge (p.R545C).  
Mutations in the second cluster identified on the other hand, lead to a very consistent surface 
charge change in this area. All three mutations (p.W467R, p.Y481H and p.W514R) substantially 
increase the positive charge already present in this area (Fig. 3.10, summarised in table 3.1). 
The fact that mutations resulting in a ‘skeletal muscle’ phenotype in region 1 do show such large 
variations in terms of the change to the surface potential they cause is not surprising. As shown 
above, residues associated with a skeletal muscle phenotype are statistically more likely to be buried. 
Notably, a number of residues (including residues G449, W467 and Y481) are buried entirely. This 
result supports the theory proposed by others (Krimm et al., 2002) that mutations giving rise to a 
skeletal muscle phenotype are more likely to disrupt the structural core of the Ig-fold. So instead of 
just disrupting the surface charge, mutations of buried residues might also lead to a destabilisation 
of the overall Ig-fold structure. This however does not mean that all mutations resulting in a 
skeletal muscle phenotype do so by the same mechanism. Here I present strong evidence that there 
are skeletal muscle mutations on the Ig-fold that, although on buried residues, do seem to affect the 
surface charge of region 2 in a very specific way, increasing the positive charge of a potential 
interaction site. 
Mutations resulting in a premature ageing phenotype 
The premature ageing phenotype is currently associated with eight different missense mutations 
affecting residues clustering around residue R527, which is part of positive surface charge patch on 
the back side of the Ig-fold. Six mutations (p.R435C, p.R471C, p.R527C, p.R527H, p.A529T, and 
p.K542N) result in a reduction of the positive charge within this region (Fig. 3.11, summarised in 
table 3.1). 
Two mutations located in the same cluster (p.T528M/p.M540T) have been shown to cause HGPS 
when inherited together, whereas alone, they appear to be non-pathogenic (Verstraeten et al., 2006). 
Interestingly, p.M540T results in a slight increase in the positive charge in this region of the Ig-fold 
which is inconsistent with the other five mutations. In contrast, the second mutation (p.T528M) 
does not affect the surface charge of the Ig-fold domain (not depicted in Fig. 3.11). 
Importantly, all patients with progeroid phenotypes (MADA or HGPS) who carry mutations in this 
cluster have been shown to be homozygous for that mutation (Agarwal et al., 2008; Kosho et al., 
2007; Novelli et al., 2002; Plasilova et al., 2004; Simha et al., 2003; Youn et al., 2010). One further 
patient is compound heterozygous for two mutations located in the cluster (p.R471C/R527C) (Cao 
and Hegele, 2003), both resulting in a reduction of the positive charge in the domain surface. 
Unfortunately, most studies did not test patient cells for prelamin A accumulation. However, those 
86 
 
that did test for it found no evidence of prelamin A accumulation (Agarwal et al., 2008; Verstraeten 
et al., 2006). 
Together, this provides strong evidence for a very consistent genotype-phenotype where 
homozygous or compound heterozygous mutations located in a small cluster on the Ig-fold domain 
all result in progeroid phenotypes.  
 
 
Figure 3.11 Change in the electrostatic potential with mutations causing premature ageing syndromes. 
Shown are the Ig-fold backbone, positions of residues subjected to in silico mutagenesis (in yellow) and the 
electrostatic surface potential of wild-type as well as mutated structures Coloured arrows indicate areas of the 
mutated Ig-fold that are affected by each amino acid change. 
 
Mutations resulting in a lipodystrophy phenotype 
The last cluster I analysed includes mutations that lead to a lipodystrophy phenotype. It is located in 
a region at the back of the Ig-fold, adjacent to the skeletal muscle cluster 2 and includes residues 
R439, G465, R482 and K486 forming a negatively charged patch in this area. Five of the six 
mutations found in this region (p.R439C, p.G465D, p.R482W, p.R482Q and p.K486N) result in an 
increase of the negative charge while one mutation (p.R482L, not shown) results in a reduction of 




Figure 3.12 Change in the electrostatic potential with mutations causing a lipodystrophy phenotype. Shown 
are the Ig-fold backbone, positions of residues subjected to in silico mutagenesis (in yellow) and the electrostatic 
surface potential of wild-type as well as mutated structures. Coloured arrows indicate areas of the mutated Ig-fold 
that are affected by each amino acid change. 
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abbreviations: SASA, solvent accessible surface area; b, buried; * not shown in figures 10-12; The effect on 
electrostatic surface potential was estimated viasually.  
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To summarise the findings above, all the changes identified in the in silico mutagenesis analysis for 
each mutation together with the SASA information has been listed in table 3.1. The results suggest 
that there are defined regions in the Ig-fold that, when mutated, cause a specific change in charge 
that results in either a premature ageing, or lipodystrophy phenotype. 
3.3.7.4 Comparison of mutations on the same/adjacent residue resulting in different 
phenotypes 
Although the clusters of mutations that result in a specific phenotype are in distinct regions of the 
Ig-fold, some residues within or nearby these clusters have been reported to cause a different 
phenotype. For example, direct comparison of two neighbouring mutations (p.R527H, resulting in 
a premature ageing phenotype with p.T528R, resulting in a skeletal muscle phenotype) revealed 
opposing effects on the surface charge in the region. When the Arg527 is substituted with a 
histidine, the positive charge in the region is decreased. When the neighbouring Thr528 however is 
substituted with an arginine, the positive charge is increased (Fig. 3.13A). Another mutation 
reported on Thr528, p.T528K, is also predicted to increase the positive charge and also results in a 
skeletal muscle phenotype. This result suggests that a potential interaction site is affect by opposite 
charge changes which may explains why mutations located on neighbouring residues result in 
different phenotypes. 
However, there are two other crucial differences between these mutations/residues: (1) progeroid 
patients are homozygous for p.R527H (Novelli et al., 2002; Simha et al., 2003) while patients with a 
skeletal muscle phenotype are heterozygous for p.T528R (Vytopil et al., 2003) and p.T528K (Bonne 
et al., 2000; Raffaele Di Barletta et al., 2000). (2) Arg527 is exposed (rel. SASA=0.34) while Thr528 
is buried (rel. SASA=0.17). 
Taken together this supports the hypothesis that buried residues are associated with a skeletal 
muscle phenotype (Krimm et al., 2002). However, it also raises the possibility of a new pathogenic 
mechanism for progeroid phenotypes associated with mutations in the Ig-fold, potentially involving 
lamin A interacting proteins. 
The second example involves neighbouring residues located in 2 different disease regions of the Ig-
fold, the skeletal muscle region 2 and the lipodystrophy region. Residue Y481 is located in the 
positively charged pocket; residue R482 on the other hand is located in the negatively charged area 
adjacent to it. Interestingly, mutations on the two residues result in opposite charge changes that are 
constrained to their respective region. Mutation p.Y481H increases the charge of the positively 
charged pocket and always results in a skeletal muscle phenotype (POI 1.0). Mutation p.R482W 
however increases the negative charge in the adjacent region without affecting the positively 
charged pocket and mainly results in lipodystrophy disorder (POI 0.93) (Fig. 3.13B). This result 
supports the hypothesis that there are specific regions of the Ig-fold that are particularly sensitive 
and result in a certain phenotype when altered. Again, this can also provide an explanation of how 







Figure 3.13 Comparison of mutations on adjacent residues that result in a different phenotype (A) Mutations 
on neighbouring residues R527 and T528 (both located in the premature ageing cluster) are associated with 2 
different phenotypes. Mutation p.R527H strongly reduces the positive charge in this area and causes a premature 
ageing phenotype (POI 1.0). Mutation p.T528R however increases the positive charge in this area and causes a 
skeletal muscle phenotype (POI 1.0). (B) Mutations on neighbouring residues Y481 and R482 are associated with 
two different phenotypes. Mutation p.Y481H increases the charge of a positively charged pocket and always results 
in a skeletal muscle phenotype (POI 1.0). Mutation p.R482W however increases the negative charge in the region 
without affecting the positively charged pocket next to Y481 and mainly results in lipodystrophy disorder (POI 0.93). 






Genotype-phenotype correlations in laminopathies are not well understood for the majority of 
LMNA mutations, although some mutation hot-spots (i.e. p.R482W which is associated with 
lipodystrophy disorders) and specific protein modifications (i.e. retention of the farnesyl group 
which is associated with premature ageing disorders) have been shown to result in consistent 
phenotypes (Worman and Bonne, 2007). The aim of this chapter was to identify genotype-
phenotype links in laminopathies by grouping mutations according to the resulting phenotype and 
statistically analysing general characteristics of mutations in these groups. 
I have shown that a significant proportion (60.4%) of patients with nonsense mutations in LMNA 
develop cardiomyopathy. Nonsense mutations generally result in a premature termination codon 
(PTC) and as a consequence, mRNAs containing PTCs are usually subject to nonsense mediated 
decay, which serves as a quality control mechanism to prevent the accumulation of truncated, 
potentially harmful protein or products of faulty splicing (Maquat, 2005; Rebbapragada and Lykke-
Andersen, 2009). A loss of lamin A/C expression from one LMNA allele would mean that 
haploinsufficiency is a likely explanation for the phenotype.  
Evidence supporting haploinsufficiency was provided by Arbustini et al. (2002), who found reduced 
levels but no truncated form of lamin A/C in cardiac tissue of DCM-CD patients with the 
nonsense mutation p.E111X. Truncated lamin protein was also absent in patient fibroblasts 
heterozygous or homozygous for the nonsense mutation p.Y259X (Muchir et al., 2003). Further, 
lamin A/C heterozygous mice also express reduced levels of lamin A/C which results in cardiac 
dilation and progressive electrophysiological disease (Wolf et al., 2008).  
Whether DCM is caused by lamin A/C haploinsufficiency in man, remains controversial. Geiger et 
al. (2008) found reduced lamin A mRNA levels in explanted myocardial tissue and cultured 
fibroblasts from DCM patients with the nonsense mutation p.R321X. However, protein levels were 
unchanged when compared to wild-type control samples and truncated lamin protein were only 
detected in presence of a proteasome inhibitor. The authors concluded that low amounts of 
truncated protein could interfere with normal lamin A/C function, before it is degraded by the 
proteasome (Geiger et al., 2008). Truncated protein was also found in patients diagnosed with 
Heart-hand syndrome carrying a splice site mutation in LMNA intron 9, indicating that 
haploinsufficiency does not occur for all nonsense mutations (Renou et al., 2008). Importantly this 
could explain why nonsense mutations in different parts of the protein result in different 
phenotypes. Truncated lamin protein of various lengths could have different effects on normal 
lamin A function, or lamin A interacting proteins resulting in a range of phenotypes. 
Although haploinsufficiency appears to be a likely cause in some cardiomyopathy cases, there are a 
number of missense mutations that also result in cardiomyopathy. My result shows that one third 
of all missense mutation in the central rod domain result in cardiomyopathy (Fig. 3.4). This 
supports results by others suggesting that the central rod domain is a hot-spot for DCM-CD 
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mutations (Perrot et al., 2009). Interestingly, c-Fos and Erk1/2 bind to the central rod domain 
(Gonzalez et al., 2008) and upregulation of the Erk1/2 signalling cascade has been shown to be 
involved in the development of cardiomyopathy in mice (Muchir et al., 2007b; Muchir et al., 2009; 
Wu et al., 2011). 
Different pathogenic mechanisms are also evident in other mouse models for cardiomyopathy. 
Mice homozygous for p.N195K develop cardiomyopathy and have a maximum survival time of 17 
weeks (Mounkes et al., 2005). Desmin staining revealed a loss of organisation at sarcomeres and gap 
junction proteins connexin 40 and 43 were mislocalised in lmnaN195K/N195K hearts. In contrast, 
lmna+/– and lmnanPLAO/nPLAO mice have a much longer maximum survival time of up to two years 
and disorganisation of sarcomeres or misocalisation of gap junction proteins was not reported 
(Davies et al., 2010; Wolf et al., 2008). Interestingly, in lmnanPLAO/– mice, the phenotype worsened 
which led to the conclusion that for a subset of mutations, loss of function is the underlying disease 
mechanism for cardiomyopathy (Davies et al., 2011). 
An interesting observation I made was that domains in the lamin protein with defined tertiary 
structures (central rod domain and Ig-fold domain) harbour significantly more mutations than 
unstructured regions. Sequence alignment of lamin A from human, mouse and frog (all 664 or 665 
amino acids long) shows a very high sequence homology especially in the central rod domain and 
the Ig-fold domain (Appendix 2). There are only 33/471 residues (7.0%) in folded regions of lamin 
A (22 in the central rod domain and 11 in the Ig-fold domain) which are partly conserved or not 
conserved (Appendix 2). Out of those, only 2 residues (Gly125 and Ser268) are associated with a 
phenotype in human when mutated, both causing muscular dystrophy (Astejada et al., 2007; 
Scharner et al., 2011). In contrast, unstructured regions allow for larger variation in the sequence. 
Here, 44/193 residues (22.8%) are only partly conserved or not conserved, suggesting that folded 
regions are more important to lamin A function. 
It is therefore unsurprising that structured regions of the lamin A protein appear to be more 
sensitive to amino acid changes and are more likely to result in a phenotype (Fig. 3.4). Furthermore, 
65.5% of all missense mutations in the central rod domain and 40.4% of all missense mutations in 
the Ig-fold domain resulted in a drastic change in the amino acid side chain characteristics. Both 
domains are important in filament formations and mutations disrupting the central rod domain or 
Ig-fold domain potentially interfere with filament formation. 
The question of whether all lamin mutations, or only those that cause a certain phenotype affect 
lamin filament formation was addressed by Yosef Gruenbaum and his team in 2008 (Wiesel et al., 
2008). The ability of lamins to form higher filaments can be assayed in vitro. Wild-type lamins form 
paracrystals when dialysed from urea into a Tris-HCl buffer containing CaCl2 (Karabinos et al., 
2003) or assemble into 10nm branched filaments when diluted in assembly buffer (Foeger et al., 
2006). Analysis of the ability of 14 Ce-lamin mutations (resulting in EDMD, HGPS, DCM and 
FPLD in human) to form paracrystals and filaments in vitro revealed that some of the mutants did 
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not affect paracrystal or filament assembly, some affected either paracrystal or filament assembly 
and some affected both. However, none of these characteristics associated with a specific 
phenotype (Wiesel et al., 2008). Even when I applied my own more detailed analysis to these 14 
mutations and tried to link their inability to form paracrystals or filaments with the severity of the 
amino acid change, the heptad repeat position (residues in the central rod domain) or the surface 
exposure (residues in the Ig-fold domain), I could not detect any obvious correlation. This is very 
interesting and may suggest that the ability or inability to form filaments in vitro does not provide 
common ground for a pathogenic mechanism of lamin mutations. In fact, even proteins with 
severe deletions in the central rod domain (Schirmer et al., 2003), deletion of the entire tail domain 
(Moir et al., 1991) and progerin with its farnesyl group, are able to form paracrystals in vitro (Taimen 
et al., 2009).  
Recently, crystal structures of lamin A coil 2B, harbouring missense mutations associated with 
DCM-CD (p.R335W or p.E347K) have been solved. However, the amino acid substitutions did not 
affect the overall structure of the α-helix, which provides additional evidence that lamin 
dimerisation not affected by these mutations. Although an effect on higher filament assembly or 
protein protein interaction cannot be ruled out; although an effect on higher filament assembly or 
protein protein interaction cannot be ruled out (Bollati et al., 2012). 
The possibility that mutations destabilise the 3D structure of the Ig-fold was first proposed by 
Krimm et al. (2002). I have shown that more than 60% of all residues associated with a skeletal 
muscle phenotype are buried which is significantly different from what would be expected in case 
of a random distribution. However we also know that there are a large number of mutations in the 
Ig-fold that are located on buried residues but do not cause a skeletal muscle phenotype. All Ig-like 
domains have a common 2-plus-2 stranded structural core (strands b, c, e, f, Fig. 1.6) which is 
surrounded by structurally more variable strands (Bork et al., 1994). In the Ig-fold of A-type lamins 
the structural core corresponds to residues number 451-455 (strand b), 468-473 (strand c), 494-499 
(strand e) and 525-531 (strand f) (Krimm et al., 2002). Mutations that disrupt the structural core are 
therefore more likely to destabilize the Ig-fold domain than mutations located in peripheral β-
strands. This could also explain why not all buried residues result in a skeletal muscle phenotype. 
Indeed, out of nine buried residues in the Ig-fold associated with a skeletal muscle phenotype 
(phenotype score ≥0.75) six are located on strands b, c, e and f. One residue (N456) is located at 
the border to strand b. In total 17 buried residues were found to be associated with a phenotype. A 
large number (8/17) buried residues does not cause a skeletal muscle phenotype. Interestingly, six 
of these eight residues are not located on one of the four core strands. Taken together, these results 
confirm the hypothesis stated in 2002, and demonstrate the importance of the location of the 
residue in a spatial context in the 3D structure, while the type of amino acid change does not seem 
to have an important influence on the pathogenicity in this domain. 
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Unfortunately, crystal structures for the Ig-fold domain with mutations on buried core residues are 
not yet available. However, there is in vitro evidence in Xenopus suggesting that the Ig-fold domain 
is involved in lamin polymerisation, and that this function is modified by the presence of an 
EDMD mutation (equivalent to p.R453W in human) (Shumaker et al., 2005). 
For other disease phenotypes caused by missense mutations in the Ig-fold, altered protein 
interaction is a far more likely explanation. Clusters in the Ig-fold associated with a specific 
phenotype have been described before for lipodystrophy disorders (Krimm et al., 2002) and 
progeria disorders (Verstraeten et al., 2006).  
Importantly, my analysis of mutations in the Ig-fold domain also revealed, that mutations located in 
these clusters result in a similar change of charge (section 3.3.7). Mutations in a cluster associated 
with lipodytrophy disorders generally result in an increase in negative charge while mutations in a 
second cluster (located on a different phase of the 3D domain) result in a loss of positive charge 
suggesting the involvement of specific protein interactions for each disease phenotype. 
To date, numerous interaction partners have been described that bind to the tail domain of lamin A 
including emerin, actin, PCNA, SREBP1, etc. (Fig. 1.8). However, none of these interactions has 
been mapped to specific regions of the Ig-fold. One could use docking simulations to try to map 
interaction sites. To do so however, requires the 3D structure of the Ig-fold in presence of different 
mutations and to date, only one Ig-fold structure with a mutation (p.R482W) has been solved 
(Magracheva et al., 2009). The transcription factor SREBP1, involved in lipid homeostasis and 
adipogenesis, has been shown to directly interact with the lamin A tail domain and is a promising 
candidate for FPLD pathology (Capanni et al., 2005; Lloyd et al., 2002). 
Using in silico docking analysis, Rajendran et al. (2011) have attempted to measure the binding 
energy of emerin and SREBP1 bound to the wild-type Ig-fold and compare it to the binding energy 
when bound to the Ig-fold containing the p.R482W mutation. Their results show that both emerin 
and SREBP1 are bound tighter to the mutant Ig-fold than they are to the wild-type Ig-fold. 
Unfortunately the interaction site was restricted to a very narrow region on both binding partners 
to speed up the docking simulation. In addition, this data is contradictory to in vitro data which 
shows a reduced lamin A-SREBP1 interaction in presence of p.R482W as well as other FPLD 
causing missense mutations (Lloyd et al., 2002). 
The by far most striking correlation was seen in a small cluster of mutations resulting in premature 
ageing syndromes (MADA and HGPS). Interestingly, all reported patients with mutations in this 
cluster had one thing in common: both their LMNA alleles were affected by either homozygous 
mutations (Agarwal et al., 2008; Kosho et al., 2007; Novelli et al., 2002; Plasilova et al., 2004; Simha 
et al., 2003; Youn et al., 2010) or compound heterozygous mutations for two mutations (Cao and 
Hegele, 2003; Verstraeten et al., 2006) located within this specific region of the Ig-fold. 
Furthermore, 6/8 mutations resulted in a moderate/strong reduction of a positive charge found in 
this region (Fig. 3.11). 
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A mechanism, similar to that proposed for skeletal muscle disorders involving the destabilisation of 
the structure by these mutations is unlikely, because heterozygous relatives (of homozygous 
patients) are unaffected. Similarly, individuals who carry either p.T528M or p.M540T alone are 
unaffected, but together, they result in HGPS (Verstraeten et al., 2006). Additional evidence is 
provided by analysing Thr528 in more detail. A substitution of Thr528, which is a buried 
hydrophobic residue (rel. SASA=0.17) with methionine, does not result in a drastic change in the 
amino acid characteristic and is therefore less likely to dirupt the structure (table 3.1). However, 
replacing Thr528 with a positively charged and very large arginine residue will have more severe 
consequences on the Ig-fold stability. Indeed, p.T528R has been shown to cause EDMD in all six 
reported patients (www.umd.be/LMNA). 
A common molecular feature of HGPS patients is the accumulation of farnesylated prelamin A 
(Davies et al., 2009). However, prelamin A accumulation was not evident in homozygous (Agarwal 
et al., 2008), and compound heterozygous (Verstraeten et al., 2006) patients, which suggests that a 
different underlying mechanism is involved. The consistent change in charge suggests that a protein 
interaction is involved. Since many of progeroid patients also show lipodystrophy syndromes the 
molecular mechanism might be smililar to that of FPLD. Another potential mechanism could 
involve the accumulation of SUN1, shown to be pathogenic in phenotypes caused by farnesylated 
lamin A and loss of lamin A alike (Chen et al., 2012). 
Although I could identify potential genotype-phenotype links for mutations in the central rod 
domain and Ig-fold domain, a large number of mutations in other parts of the protein do not show 
a clear correlation. For example mutations in unstructured regions result in a larger number of 
lipodystrophy disorders and overlapping phenotypes while the number of striated muscle 
phenotypes (‘skeletal muscle’ and ‘cardiac-only’) is reduced. Unfortunately the functional role of the 
tail domain beyond the Ig-fold domain, apart from its role in the posttranslational processing of 
lamin A, is not well understood. Lamin C lacks the tail domain completely and mice expressing 
lamin C (but not lamin A) are apparently normal, suggesting that the tail region bears no specific 
function (Fong et al., 2006b). Mutations in the tail domain could modulate lamin A processing, 
which was shown for residue R644 (Barrowman et al., 2012), and therby affect the phenotypic 
outcome. 
Another possible explanation is that some of the mutations in the database are not the cause of 
pathogenesis for the diagnosed disease. The LMNA gene contains many single nucleotide 
polymorphisms (SNPs) with no pathologic phenotype (www.dmd.nl/lmna_seqvar.html). Further, 
approx. 60% of all EDMD patients have no mutations in LMNA, EMD or FHL1 which suggests 
that there are additional genes involved in EDMD pathology (Gueneau et al., 2009). Examples are 
mutations in emerin and desmin which have been shown to modulate the disease severity of 
LMNA mutations (Muntoni et al., 2006). Further, mutations in nesprins have been found in 
patients with EDMD phenotype (Zhang et al., 2007). It can therefore not be ruled out that some of 
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the mutations in the database are non-pathogenic SNPs (that may or may not contribute to the 
pathology), especially for mutations where only one patient is reported.  
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3.5 Conclusion  
In this chapter I set out to find correlations between mutations in the LMNA gene and the 
resulting phenotype by grouping mutations according to the resulting phenotype and statistically 
analysing general characteristics of mutations in these groups. My results confirm hypotheses 
postulated by others such as a correlation between truncation mutations and a cardiomyopathy 
phenotype or that buried residues in the Ig-fold are more likely to result in a skeletal muscle 
phenotype. However my results also show novel correlations such as the spatial clustering of 
mutations resulting in a specific phenotype on the Ig-fold domain which correlates with a similar 
change in charge. Further I could show that pathogenic missense mutations in the central rod 
domain generally result in a drastic change in side chain characteristics while pathogenic missense 
mutations in the Ig-fold and the unstructured region of the protein result in a moderate change in 
side chain characteristics. 
In future, well established genotype phenotype correlations in combination with perinatal genetic 
screening for mutations in LMNA may be used to monitor the health status of the patient well 
before the first symptoms arise. That such an approach would be hugely beneficial for patients is 
already evident. The analysis of familial and sporadic DCM cases shows that DCM patients with 
mutations in the LMNA gene have a significantly poorer cumulative survival rate compared to 
non-carriers (Taylor et al., 2003). The most frequent cause of death in patients with DCM is sudden 
cardiac arrest which is usually prevented by implanting a pacemaker. If genetic screening becomes 
more widely available, individuals with LMNA mutations likely to cause DCM could be monitored 
for cardiac defects before symptoms arise, providing them with a better quality of life. 
Similarly, once treatment for other types of laminopathies becomes available, and the phenotypic 
outcome of a specific mutation can be predicted, treatment can start early and again improve life 
expectancy and/or quality of life of patients. Until we reach that point a lot more work has to be 
done to understand the functions of lamins and how mutant lamins affect cell structure and 




Chapter 4  
Novel LMNA Mutations in Patients with Emery-Dreifuss 




As shown in the previous chapter, a lot of mutations have been described on the LMNA gene so 
far and novel pathogenic mutations continue to get published and are collated on a regular basis on 
the Universal Mutation Database (UMD) which can be accessed online at www.umd.be/LMNA. 
The latest novel LMNA mutation is an autosomal recessive EDMD mutation (p.R225Q) located 
on exon 4 in the linker region L12 of the central rod domain, published in April this year (Jimenez-
Escrig et al., 2012). In a collaborative effort with Dr. Charlotte A. Brown formally of Carolinas 
Medical Center in North Carolina (USA) (present address Director, Clinical and Scientific Affairs 
BD Diagnostics, Women's Health and Cancer 4025 Stirrup Creek Dr., Suite 400, Durham, NC 
27703 USA) we have analysed a large cohort of patients from North America with skeletal muscle 
dystrophy and identified 15 novel LMNA mutations (reported in this chapter).  
An increasing number of mutations known on the LMNA gene will help analysis to understand the 
relationship between the type of mutation, their location and the resulting phenotype as discussed 
in chapter 3. However, we also need to understand the effects that different lamin A mutations 
have on cellular and nuclear structure and in cell function. 
Cells isolated from patients with a laminopathy and mice carrying lmna mutations often display 
abnormalities, such as minor deformations, lobulations and herneations. A-type and B-type lamins 
are frequently mislocalised in such nuclei and aggregate in coarse meshworks known as honeycomb 
structures, intranuclear lamin foci or a combination of both (Agarwal et al., 2008; Kandert et al., 
2009; Mounkes et al., 2005; Muchir et al., 2004; Muchir et al., 2003; Vigouroux et al., 2001). The 
reason why certain mutations cause these phenotypes, while other mutations apparently do not 
result in any abnormalities remains a mystery. 
To advance the understanding of the effect of LMNA-mutations on cells, I chose four pathogenic 
LMNA mutations from our study, located on conserved residues throughout the lamin A/C 
protein that can each cause a skeletal muscle phenotype. Because of the observed muscle 
phenotype in patients where these mutations have been found, I have chosen to use C2C12 
myoblasts to express mutant lamins and study their structural and functional effects on the cells.  
The first mutation analysed in this study was p.R25P which results in a drastic amino acid change 
because of the cyclic structure of proline and the loss of a positive charge (see section 3.3.5 for 
details). Residue R25 is conserved down to D. melanogaster and located in the head domain of lamin 
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A/C. To date three pathogenic mutations (p.R25G, p.R25C, p.R25P) in a total of 11 patients have 
been found on residue R25. All patients were diagnosed with a skeletal muscle phenotype (Brown 
et al., 2001; Fokkema et al., 2005; van Tintelen et al., 2007).  
The second mutation used in this study was the severe amino acid substitution p.R249W. The 
mutation eliminates a positive charge and is located in a heptad repeat (position e) on coil 2A in the 
central rod domain of lamin A/C. One further pathogenic mutation, p.R249Q, has been described 
on this residue (Benedetti et al., 2007; Bonne et al., 2000). All patients with mutations on residue 
R249, 28 in total, were diagnosed with a skeletal muscle phenotype. Recently, p.R249W has also 
been found in patients with lamin associated congenital muscular dystrophy (Quijano-Roy et al., 
2008). 
Mutation p.N456I, the third mutation in this study was a severe mutation located on a loop 
connecting strands b and c in the Ig-fold domain. It is a buried residue (rel. SASA=0.09; see section 
3.3.7 for a detailed explanation) and is associated with a skeletal muscle phenotype. There are three 
further pathogenic amino acid substitutions reported on residue N456: p.N456H, p.N456D and 
p.N456K. All four mutations have been shown to cause a skeletal muscle phenotype in a total of 7 
patients (Astejada et al., 2007; Bonne et al., 2000; Quijano-Roy et al., 2008).  
The last mutation included in this study was p.R541P, a severe amino acid change located on strand 
f of the Ig-fold domain. The residue is buried (rel. SASA=0.12) and was found in two patients, one 
diagnosed with a skeletal muscle phenotype (this study) and one diagnosed with DCM (van 
Tintelen et al., 2007). Residue R541 is conserved to Amphioxus and has been shown to be 
pathogenic if mutated to three other amino acids (p.R541S p.R541C p.R541H). All four mutations 
have been diagnosed in a total of 19 patients, 5 (26%) diagnosed with a skeletal mucle phenotype, 
12 (63%) diagnosed with a cardiac-only phenotype and 2 (11%) diagnosed with other phenotypes. 
The effects of these four LMNA mutations on nuclear structure and lamin distribution in myogenic 
cells are the subject of this chapter. Since these results were recently published in the journal 
Human Mutation (Scharner et al., 2011), I have included the paper as a results section of this 
chapter (as permitted under current regulations). 
Figure and table numbers in this chapter remain as in the published manuscript (figure 1, figure 2, 
table 1, etc.). However for clarity and consistency, in the list of figures and tables for the thesis and 
when referred to in other parts of the thesis, figures and tables in this chapter will receive the 





4.2 Authors contributions 
I co-authored the publication with Charlotte A. Brown who was a geneticist at Carolinas Medical 
Center in North Carolina at the time of data collection. Charlotte sequenced DNA samples from 
patients and compiled a list of genetic and clinical information for each patient from patient 
samples and information supplied by co-authors Matthew Bower, Susan T. Iannaccone, Ismail A. 
Khatri, Diana Escolar, Erynn Gordon, Kevin Felice, Carol A. Crowe, Carla Grosmann, Matthew 
N. Meriggioli, Alexander Asamoah and Ora Gordon.  
I selected four different LMNA mutations, cloned them into a retroviral expression vector and 
analysed their effects on nuclei of the myogenic C2C12 cell line. I also produced the figures and 
tables and wrote a draft of the manuscript, which was edited and reviewed by co-authors Viola F. 




The aim of this chapter was to identify and compare the effects of four different pathogenic lamin 
A mutations on nuclear morphology and the localisation of nuclear envelope proteins. The chosen 
mutations (p.R25P, p.R249W, p.N456I and p.R541P) were all identified in patients with skeletal 
muscle dystrophy. Since defective myoblasts might play a role in the pathology of these mutations, 
I have chosen C2C12 myoblasts to study these mutations. It was also important to create 
conditions that closely resemble a physiological environment. I therefore utilised a retroviral 
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ABSTRACT: Mutations in LMNA cause a variety of
diseases affecting striated muscle including autosomal
Emery-Dreifuss muscular dystrophy (EDMD), LMNA-
associated congenital muscular dystrophy (L-CMD), and
limb-girdle muscular dystrophy type 1B (LGMD1B).
Here, we describe novel and recurrent LMNA mutations
identified in 50 patients from the United States and
Canada, which is the first report of the distribution of
LMNA mutations from a large cohort outside Europe.
This augments the number of LMNA mutations known
to cause EDMD by 16.5%, equating to an increase of
5.9% in the total known LMNAmutations. Eight patients
presented with either p.R249W/Q or p.E358K mutations
and an early onset EDMD phenotype: two mutations
recently associated with L-CMD. Importantly, 15 muta-
tions are novel and include eight missense mutations
(p.R189P, p.F206L, p.S268P, p.S295P, p.E361K, p.G449D,
p.L454P, and p.W467R), three splice site mutations
(c.IVS411G4A, c.IVS62A4G, and c.IVS811G4A),
one duplication/in frame insertion (p.R190dup), one
deletion (p.Q355del), and two silent mutations (p.R119R
and p.K270K). Analysis of 4 of our lamin A mutations
showed that some caused nuclear deformations and
lamin B redistribution in a mutation specific manner.
Together, this study significantly augments the number of
EDMD patients on the database and describes 15 novel
mutations that underlie EDMD, which will contribute to
establishing genotype–phenotype correlations.
Hum Mutat 32:152–167, 2011. & 2011 Wiley-Liss, Inc.
KEY WORDS: lamin A; lamin B; emerin; EDMD; LGMD;
L-CMD; nuclear envelope; nuclear lamina; laminopathy;
skeletal muscle
Introduction
Emery-Dreifuss muscular dystrophy (EDMD) manifests in
childhood with slowly progressive muscle weakness with a
scapulohumeroperoneal distribution, associated with contractures
of the Achilles tendon, neck, and elbow. Cardiac involvement is a
consistent feature associated with nearly all patients by the third
decade, initially involving arrhythmias, progressing toward
complete heart block with a substantial risk of sudden death in
middle age [Emery, 1989].
Both X-linked and autosomal forms of EDMD have been
described. Mutations in the EMD gene (Xq28; MIM] 300384)
have been identified in patients with X-linked EDMD (X-EDMD;
MIM] 310300) [Bione et al., 1994]. EMD encodes emerin, a small
integral membrane protein located at the inner nuclear membrane
and a member of the LEM domain proteins [Wagner and Krohne,
2007]. Mutations in the LMNA gene (1q21.3; MIM] 150330),
encoding the A-type lamins, lamin A and C by alternative splicing
(Fig. 1A), have been found in patients with autosomal dominant
(EDMD2; MIM] 181350) [Bonne et al., 1999] and autosomal
recessive (EDMD3; MIM] 604929) [Raffaele Di Barletta et al.,
2000] forms of EDMD. LMNA mutations are also associated with
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a congenital muscular dystrophy termed LMNA-related congenital
muscular dystrophy (L-CMD; MIM] 613205) [Quijano-Roy et al.,
2008]. Lamins A and C are type V intermediate filament proteins,
and together with B-type lamins, are major components of the
nuclear lamina: a proteinaceous meshwork underlying the inner
nuclear membrane, thought to provide a structural framework
for the nuclear envelope and an anchoring site at the nuclear
periphery for interphase chromosomes. Recently, it has been
shown that mutations in the FHL1 gene (Xq27.2; MIM] 300163)
are also associated with EDMD [Gueneau et al., 2009]. FHL1
encodes a LIM domain protein containing two zinc fingers in
tandem, which has been implicated in sarcomere assembly
[Gueneau et al., 2009; McGrath et al., 2006].
Emerin and lamin A/C are thought to have a close functional
relationship, even though the phenotypes caused by EMD and
LMNA mutations are clinically different [Bonne et al., 2003;
Figure 1. Schematic of the LMNA gene and lamin A protein indicating mutations. A: Schematic of the LMNA gene and lamin A protein. Lamin A
is encoded by exons 1–12, whereas lamin C terminates at exon 10 with six unique amino acids at its C-terminal. The alternative splice site for lamin
A is indicated. Sequence variations affecting splice donor or acceptor sites that lead to disease are shown for IVS 4, 6, 7, and 8. Missense
mutations, insertions, and deletions are indicated on the lamin A protein, where the head, central rod, and tail domain (incorporating the nuclear
localization signal [NLS], and Ig-like fold) are indicated. Novel sequence variants are shown above the gene/protein (red) and mutations used for in
vitro investigation are underlined (blue), whereas recurring mutations are shown beneath the gene/protein. Table 2 provides a detailed genetic
description of the sequence variants. B: Illustration of evolutionary conservation of residues associated with novel missense mutations, insertions,
and deletions located in the coding region of LMNA and those used in our in vitro analysis (blue/underlined). Sequences were obtained from the
online databank swissprot (http://expasy.org/sprot/) and aligned with the online tool ClustalW2 (http://www.ebi.ac.uk/clustalw/). Partial sequence
only, with // denoting nonconsecutive sequence, indicating identical residues in all aligned sequences; ‘‘:’’ showing conserved substitutions; and
‘‘.’’ marking semiconserved substitutions. If viewed in color: residues with nonpolar side chains are indicated in red, acidic residues are shown in
blue, basic residues shown in magenta, and amino acids with uncharged polar side chains are indicated in green.
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Meune et al., 2006]. In fact, direct interaction between emerin and
lamin A has been demonstrated by multiple experimental
techniques [Clements et al., 2000; Lee et al., 2001] and emerin
localization has been shown to be affected by mutant lamin A
[Holt et al., 2003]. LMNA mutations have also been detected in
patients with autosomal dominant limb-girdle muscular dystro-
phy with atrioventricular conduction disturbances (LGMD1B;
MIM] 159001) [Muchir et al., 2000]. Atlhough the clinical
phenotype of LGMD1B overlaps with EDMD, there are differ-
ences, for example, LGMD1B is characterized by slowly progres-
sive pelvic girdle weakness, with a sparing of the lower leg muscles.
In addition, contractures and cardiac disturbances tend to occur
later in life in LGMD1B, compared to EDMD patients [Muchir
et al., 2000].
In addition to EDMD, LGMD1B, L-CMD, and isolated dilated
cardiomyopathy and conduction-system disease (CMD1A; MIM]
115200) [Fatkin et al., 1999] that primarily affect striated muscle,
‘‘laminopathies’’ also affect other tissues. Such laminopathies
include Dunningan-type familial partial lipodystrophy (FPLD;
MIM] 151660) [Hegele et al., 2000; Shackleton et al., 2000;
Speckman et al., 2000], autosomal recessive Charcot-Marie-Tooth
Disorder Type 2B1 (CMT2B1; MIM] 605588) [De Sandre-
Giovannoli et al., 2002], mandibuloacral dysplasia (MAD; MIM]
248370) [Novelli et al., 2002; Shen et al., 2003], Hutchinson-
Gilford progeria syndrome (HGPS; MIM] 176670) [De Sandre-
Giovannoli et al., 2003; Eriksson et al., 2003], and autosomal
dominant atypical Werner’s syndrome (WRN; MIM] 150330)
[Chen et al., 2003]. In addition, both intrafamilial and
interfamilial variability of phenotypes associated with LMNA
mutations is a common feature [Shen et al., 2003; Simha et al.,
2003; Speckman et al., 2000; Vytopil et al., 2002].
A clear genotype–phenotype correlation has not been identified
for most laminopathies, although HGPS tends to correlate with C-
terminal splicing defects, while other conditions (i.e., MAD,
WRN, and CMT2B1) result from ‘‘hot spot’’ missense mutations.
For other laminopathies including EDMD, the pathogenic LMNA
mutations are distributed throughout the gene [Scharner et al.,
2010]. The LMNA gene contains 12 exons and encodes both lamin
A and C by alternative splicing, both sharing the first 566 amino
acids [Lin and Worman, 1993]. In addition to their role in the
nuclear lamina, lamins also interact with numerous integral
proteins of the inner nuclear membrane and proteins of nuclear
pore complexes [Schirmer and Foisner, 2007], orchestrating a
number of cellular and molecular processes including nuclear
envelope assembly, maintenance of nuclear architecture, DNA
synthesis, chromatin organization, gene transcription, cell cycle
progression, cell differentiation, and migration and response to
DNA damage [Broers et al., 2006; Prokocimer et al., 2009;
Verstraeten et al., 2007], processes that could be differentially
affected by specific mutations.
This report describes novel and recurrent LMNA mutations
identified in 50 patients referred for clinical testing for a suspected
diagnosis of EDMD or LGMD in the United States and Canada.
This is also the first report of the distribution of LMNA mutations
from a large patient cohort from outside Europe, and augments
the EDMD mutation database by 6%. Importantly, among
these were 15 novel pathogenic LMNA mutations that include
eight missense mutations (p.R189P, p.F206L, p.S268P, p.S295P,
p.E361K, p.G449D, p.L454P, and p.W467R), three splice site
mutations (c.IVS411G4A, c.IVS62A4G, and c.IVS811G4A),
one duplication/in frame insertion (p.R190dup), one deletion
(p.Q355del), and two silent mutations (p.R119R and p.K270K).
Examining four of our LMNA mutations further, we found that
mutations located in various protein domains differentially affect
basic nuclear characteristics including nuclear size, shape, and
protein distribution. Taken together, we provide clinical and in
vitro data to confirm the complex pathogenicity associated with
LMNA mutations, suggesting that genetic background is also a




The 255 patients reported in this manuscript were referred to
either the DNA Diagnostic Laboratory at Carolinas Medical
Center (1996–2001) or the Molecular Diagnostics Laboratory at
the University of Minnesota (2001–2003) from the United States
of America and Canada for mutation analysis of the LMNA gene
(GenBank Accession Number RefSeq NM_170707.2). The clinical
diagnoses of patients referred for testing included muscular
dystrophies of the EDMD, LGMD, congenital, Becker (BMD), and
fascioscapulohumeral (FSHD) types, as well as spinal muscular
atrophy (SMA). This study was approved by the Institutional
Review Board at both Carolinas Medical Center and the University
of Minnesota.
DNA Isolation and Polymerase Chain Reaction
DNA extracted from peripheral blood by either standard
proteinase K/phenol-chloroform extraction procedures on a 341
Nucleic Acid Extractor (Perkin-Elmer, Norwalk, CT) or using a
QIamp DNA Blood Mini Kit (Qiagen, Valencia, CA). Exons 1–12
of LMNA were amplified by PCR as previously described [Brown
et al., 2001]. Primers used for the PCR reaction are listed in Supp.
Table S1.
Sequencing
Amplimers were extracted from agarose gel using a Gel
Extraction Kit (Qiagen) and each exon sequenced directly from
both strands using the Prism Ready Reaction DyeDeoxy
Terminator Cycle Sequencing Kit (Applied Biosystems, Foster
City, CA) with analysis of sequenced products on either an ABI377
or ABI3100 Genetic Analyzer. Generated sequences were com-
pared to the published EMD or LMNA gene sequence using the
Sequence Navigator (Applied Biosystems) or Sequencher (Gene
Codes Corporation, Ann Arbor, MI) software packages. Nucleo-
tide numbering reflects cDNA numbering with 11 corresponding
to the A of the ATG translation initiation codon in the reference
sequence, according to journal guidelines (www.hgvs.org/mutno-
men). The initiation codon is codon 1.
Retroviral Expression Vectors
The retroviral (RV) backbone pMSCV-puro (Clontech, Mountain
View, CA) was modified to replace the puromycin selection gene
with eGFP, to create pMSCV–IRES–eGFP, which served as the RV
control vector [Zammit et al., 2006]. Wild-type [Motsch et al.,
2005] and four mutant human lamin A pEGFP-C1 cDNAs (R25P,
R249W, N456I, and R541P) were subcloned into pMSCV–
IRES–eGFP to generate control pMSCV–laminA–IRES–eGFP and
pMSCV–laminA–R25P–IRES–eGFP, pMSCV–laminA–R249W–
IRES–eGFP, pMSCV––laminA–N456I–IRES–eGFP, and pMSCV–
laminA–R541P–IRES–eGFP, producing either wild-type lamin A
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as a control, or mutant lamin A species, as a bicistronic message
with eGFP (Fig. 2C). Retroviral constructs, together with an
ecotropic packaging plasmid, were transiently cotransfected into
293T cells to produce nonreplicating retrovirus and the super-
natant harvested 48, 60, and 72 hr later.
Cell Culture and Retroviral Infection
C2C12 mouse myoblast cells were grown and maintained in
DMEM-Glutamax (Invitrogen, Paisley, UK) supplemented with
10% FBS (PAA, Somerset, UK) and 1% Penicillin/Streptomycin
(Sigma, Dorset, UK). A total of 20,000 C2C12 cells were plated
into one well of a six-well plate and exposed to retroviral
supernatant (diluted 1:5 in growth medium supplemented with
4 mg/mL polybrene) for at least 12 hr, before they were analyzed at
least 24 hr later.
Morphometric Analysis
To quantify the morphological abnormalities of nuclei such as
elongation or lobulation, we measured the perimeter and the area
of at least 120 nuclei from three independent experiments and
calculated the nuclear roundness or contour ratio (4p; area/
circumference2) [Goldman et al., 2004]. The contour ratio of a
circle is 1, and the value gets smaller with an increased degree of
lobulation. Micrographs of infected C2C12 cells stained for lamin
B were analyzed using the NIH ImageJ software (http://
rsbweb.nih.gov/ij/). To calculate the perimeter and area of the
nuclei, they were outlined using the polygon selection tool and
measured with ImageJ. A two-tailed Student’s t-test was used to
calculate the statistical significance of the result.
Immunostaining
Cells were fixed with 4% paraformaldehyde (PFA) for 10min,
permeabilized with 0.5% Triton X-100 in PBS for 10 min and
blocked with 5% normal goat serum and 5% normal swine serum
(or 5% horse serum and 5% normal swine serum when primary
antibodies raised in goat were used) in PBS/0.025% Tween20 for
1 hr at room temperature. After incubation with primary antibody
in 1% serum (goat anti-lamin A C20 1:100, goat anti-lamin A/C
N18 1:200, goat anti-lamin B [recognizes all forms] M20 1:200
[Santa Cruz Biotechnology, Santa Cruz, CA]; rabbit anti-emerin
AP8 1:100 [Ellis et al., 1998]; rabbit anti-GFP 1:500 [Molecular
Probes, Eugene, OR] and mouse anti-GFP 7.1 and 13.1 1:100
[Roche, Mannheim, Germany]), the cells were washed and
exposed to fluorescently coupled secondary antibodies (Alexa
Fluor, Molecular Probes) at a concentration of 1:500 and mounted
in DAPI containing mounting medium. F-actin was stained by
exposing the PFA-fixed cells to Alexa Fluor 633-conjugated
phalloidin (Molecular Probes) (diluted 1:50 in PBS 1 0.025%
Tween20) for 30min prior washing, and mounting the slides with
DAPI containing mounting medium.
Figure 2. Mutant lamin A species affect nuclear size and shape in myogenic cells. A: Proliferating mouse C2C12 cells infected with control
pMSCV–laminA–IRES–eGFP encoding wild-type lamin A-IRES–eGFP and immunostained for eGFP and lamin A. Cells expressing high levels of
GFP show a increased expression of lamin A wild type (arrowheads) compared to cells expressing low levels of GFP (arrows); Scale bar 100 mm.
B: Western blot of uninfected C2C12 cells and cells infected with pMSCV–IRES–eGFP (RV control), pMSCV–laminA–IRES–eGFP (Lamin A),
pMSCV–laminA–R25P–IRES–eGFP (R25P), pMSCV–laminA–R249W–IRES–eGFP (R249W), pMSCV–laminA–N456I–IRES–eGFP (N456I) and
pMSCV–laminA–R541P–IRES–eGFP (R541P). A representative blot probed for lamin A/C (N19) is shown. The relative quantities of lamin A
normalized to b-tubulin are shown below, and range from 1.5–1.7-fold endogenous lamin A levels in the RV control sample. The endogenous
level of lamin C does not change with constitutive expression of wild-type lamin A or the mutant forms. C: Schematic of the
pMSCV–laminA–IRES-EGFP vector used in this study, indicating the 50 and 30 long terminal repeats (LTR), c; packaging signal, the lamin A (wild-
type or mutant versions) and eGFP cDNAs, separated by an internal ribosome entry site (IRES). D: Nuclear size (cross-sectional area) of
cells with lamin A-R25P and lamin A-R249W increased by 2973.3% and 3474.5%, respectively, compared to lamin A wild-type infected cells.
E: The contour ratio was significantly decreased in nuclei of cells expressing lamin A-R25P (0.8770.006) and lamin A-R249W (0.8570.007),
but not with the other two mutant lamin A species. Values represent the mean7SEM; Po0.05; Po0.01 compared to lamin A wild-type
infected cells. [Color figure can be viewed in the online issue, which is available, at wileyonlinelibrary.com]
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Fluorescence Intensity Measurement
Representative nuclei stained for DAPI, lamin A, and lamin B,
respectively, were analyzed using the ‘‘Plot Profile’’ tool in ImageJ.
The x and y coordinates were imported in MS Excel to compile the
histogram.
Western Blot
Harvested cells were resuspended in suspension buffer (100mM
NaCl, 10mM Tris-HCl pH 7.5, 1mM EDTA) supplemented with
proteinase inhibitors and lysed in loading buffer [Laemmli, 1970].
The protein concentration was determined with the Bio-Rad DC
Protein Assay based on the Lowry method [Lowry et al., 1951].
Samples were immunoblotted with the following antibodies: goat
antilamin A/C N18 1:1000 (Santa Cruz Biotechnology), rabbit
anti-GFP 1:2000 (Molecular Probes), mouse anti-b-tubulin 1:1000
(DSHB, Iowa City, IA), and then probed with HRP-conjugated
secondary antibodies (ECLTM; sheep antimouse or rabbit 1:5000,
GE Healthcare, Uppsala, Sweden; sheep antigoat SO84 1:5000,
Abcam, Cambridge, UK), and developed using ECL from GE
Healthcare. Band intensity was quantified using ImageJ.
Results
Clinical and Genetic Information on 50 Patients
This is the first report on the distribution of LMNA mutations
from a large patient cohort from the United States and Canada.
Among the 255 referrals, 23 patients (9.0%) were found to possess
EMD gene mutations (manuscript in preparation), and 61
individuals (23.9%) were found to have LMNA mutations.
Clinical and genetic information on 11 of the patients with
LMNA mutations has been published previously [Brown et al.,
2001]. The mutations identified in the remaining 50 patients and
their clinical information are presented in Tables 1 and 2.
Among the 50 individuals found to carry a LMNA mutation, 37
different mutations (in 36 patients) were detected, scattered
throughout the gene (Fig. 1A and Tables 1 and 2). The majority of
LMNA mutations identified here are missense mutations (27/37;
73.0%), with an additional two mutations being small in-frame
insertions or deletions (2/37; 5.4%). Seven mutations were found
to be deleterious mutations at conserved donor or acceptor splice
site sequences (5/37; 13.5%) or silent mutations (2/37; 5.4%).
Importantly, the bases associated with the silent mutations are
located on the first or last base of the exon, so could affect splicing
efficiency. The final mutation in patient 2974 was the only frame
shift mutation, presumably encoding both truncated lamin A and
lamin C protein species (1/37; 2.7%). This patient had a
predominantly cardiac phenotype with only mild skeletal muscle
weakness developing at age 50. These results are consistent with
the phenotypes of other patients found to possess truncating
mutations [Benedetti et al., 2007]. The most common previously
reported LMNA mutation, c.1357C4T (p.R453W), was also the
most frequent in our study group, being found in six (12.0%) of
the patients. Two mutations were found to be confined to the
lamin A protein, p.G602S, and p.R644C, suggesting that altera-
tions in the far C-terminus of the lamin A protein alone is
sufficient to cause EDMD2. A few of the patients with p.R249W,
p.E358K or p.N39S presented at o1–2 years old (Table 1),
which is below the average onset age for a severe EDMD2 case
(32 months). Interestingly, these mutations have recently been
reported to be associated with the congenital muscular dystrophy
L-CMD, presenting from birth to 1 year.
Five patients (33, 7975, 1412, 6388, and 2660) had mutations
located in noncoding regions at the exon–intron or intron–exon
junctions affecting the universally conserved GT and AG di-
nucleotides. Therefore, these mutations likely affect pre-mRNA
splicing although RNA analysis was not performed. These patients
with intronic splice-site mutations presented with an EDMD
phenotype (Table 1). A further three patients (91, 778, and 2018)
had two silent mutations located on either the first or last
nucleotides of an exon, which could also modify splicing.
Of the 45 patients for whom a family history was available, there
was an approximately even split between cases that appeared to be
familial in origin (21/45 [46.7%]) compared to cases that appeared
to be sporadic (24/45 [53.3%]). Indeed, for our commonest
mutation for which we have information (p.R453W), two cases
were familial and three cases were sporadic. DNA analysis was only
performed on the family members of three cases classed as sporadic
(patients 6537, 3734, and 778), which confirmed the de novo origin
of mutations in these individuals. It is possible of course, that
apparently sporadic cases may have relatives who are currently
asymptomatic gene mutation carriers.
Novel Pathogenic LMNA Mutations
Of these 37 LMNA mutations, 15 are novel pathogenic LMNA
mutations (highlighted in red in Fig. 1A and B and Tables 1 and 2),
not previously published or listed in any of the following
databases: The Universal Mutation Database (UMD) (http://
www.umd.be/), Human Intermediate Filament Database (http://
www.interfil.org/) [Szeverenyi et al., 2006] and the Leiden Open
Variation Database (LOVD) (http://www.dmd.nl/). This augments
the number of LMNA mutations known to cause EDMD by
16.5%, equating to an increase of 5.9% in the total known LMNA
mutations. These 15 mutations include eight missense mutations
(p.R189P, p.F206L, p.S268P, p.S295P, p.E361K, p.G449D, p.L454P,
and p.W467R), three splice site mutations (c.IVS411G4A,
c.IVS62A4G, c.IVS811G4A), one duplication/in frame inser-
tion (p.R190dup), one deletion (p.Q355del) and two silent
mutations (p.R119R and p.K270K). The majority of patients
carrying novel mutations (13/15) show symptoms associated with
EDMD, whereas patient 2018 carrying the silent mutation
c.810G4A (p.K270K), was initially diagnosed with BMD, prior
to screening for LMNA mutations. Patient 91 carrying the silent
mutation c.357C4T (p.R119R) presented with an LGMD1B
phenotype with cardiac involvement. Of the 12 mutations located
in the coding region of LMNA, four are in coil 1B, five are in coil
two of the central rod domain, and the remaining three are located
on conserved residues in the Ig-like fold of the tail of the lamin
A/C protein (Fig. 1).
The LMNA gene is well conserved with 33% homology of the
coding region between Drosophila melanogaster and Homo sapiens.
The majority of our novel missense mutations and one insertion
(7/10) affect residues highly conserved between species from
Caenorhabditis elegans to Homo sapiens, while the remaining two
missense mutations and one deletion (p.R189P, p.S268P, and
p.Q355del) are all located in the central rod domain, and affect
residues that are less conserved between species (Fig. 1B).
Effects of Lamin A Mutants on Myogenic Cells
Having described pathogenic LMNA mutations in patients, we
next sought to gain insight into the effects of several mutant
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human lamin A species on myogenic cells. We chose four
mutations from this (p.R249W and p.R541P) and our previous
study (p.R25P and p.N456I) [Brown et al., 2001] that span the
LMNA gene and affect different domains of the protein. The
majority of pathogenic lamin A mutations are dominant, with
usually only one allele being affected in patients. This suggests that
in cases that are not caused by haploinsufficiency, the amount of
mutated protein that is necessary to create a phenotype is
relatively small. Importantly, patient myoblasts are not readily
available and a commonly used DNA delivery method is
cell transfection, which results in dramatic overexpression (up to
25-fold) of mutant lamin A [Bechert et al., 2003].
Retroviral infection is efficient in mouse C2C12 myogenic cells
with an infection rate of 498% routinely obtained (data not
shown). Retroviral-mediated constitutive expression of wild-type
lamin A clearly shows the coexpression of lamin A and eGFP
(Fig. 2A–C), with cells with higher levels of eGFP generally also
expressing higher levels of lamin A (Fig. 2A). In addition to efficiently
targeting498% cells, retroviral-mediated constitutive expression also
has the advantage that the levels of exogenous proteins are generally
only moderately elevated compared to endogenous proteins. Western
blot analysis confirmed increased levels of exogenous wild-type and
mutant lamin A was only on average 1.3–1.7-fold higher than
controls (Fig. 2B) resembling a more physiological condition.
Endogenous expression level of lamin C was not affected (Fig. 2B).
The Presence of Lamin A-R25P and Lamin A-R249W
Results in Abnormal Nuclear Morphology
We observed large differences in nuclear size depending on the
lamin variant expressed. Although a small increase in the nuclear
cross-sectional area was observed in cells treated with the RV
control, the average nuclear size was further significantly increased
in the presence of lamin A-R25P (29% increase) and lamin
A-R249W (34% increase) compared to lamin A wild-type-infected
cells (Fig. 2D). Constitutive expression of lamin A wild type did
not have an effect on nuclear size. The dramatic increase in
nuclear size coincides with changes in nuclear morphology.
Normal ovoid nuclear morphology was observed when cells were
infected with RV control (contour ratio 0.9570.003) or lamin A
wild-type (0.9570.002). The presence of either lamin A-R25P or
lamin A-R249W, however, resulted in abnormal nuclear morphol-
ogy with simple or multiple lobules of the nuclear envelope. The
contour ratio was significantly smaller in cells expressing lamin
A-R25P (0.8770.006) and lamin A-R249W (0.8570.007), reflect-
ing these nuclear distortions (Fig. 2E). Changes in both nuclear size
and contour ratio occurred concomitantly. This effect was mutation
specific however, because the presence of lamin A-N456I or lamin
A-R541P did not alter nuclear size or shape.
Mutant Lamin A Protein Species Are Mislocalised in the
Nucleus
Abnormalities in mutant lamin A protein distribution were also
observed (Figs. 3 and 4A–C). Although all the mutant lamin A
proteins were present to some degree at the nuclear periphery,
there was frequent disorganization of the lattice, with evidence of
lamin A capping, particularly in lamin A-R25P and lamin
A-R249W-expressing nuclei (lamin A mislocalization is shown
by arrows in Fig. 3). There were also more lamin A-positive
nuclear speckles present, with a greater size distribution compared
with cells expressing lamin A wild type. Prominent lamin A
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Table 2. Summary of LMNA Mutations and Encoded Protein




acid change Mutation type
Protein domain
affected Ref. for published mutations
.Novel mutations
91 c.357C4T 2 p.R119R Silent Coil 1b Novel
3734 c.566_567delinsCC 3 p.R189P Missense Coil 1b Novel
2952 c.568_570dup 3 p.R190dup Duplication (In frame
insertion)
Coil 1b Novel
8542 c.618C4G 3 p.F206L Missense Coil 1b Novel
8434 c.802T4C 4 p.S268P Missense Coil 2b Novel
2018 c.810G4A 4 p.K270K Silent Coil 2b Novel
778 c.810G4A 4 p.K270K Silent Coil 2b Novel
33 c.IVS411G4A (c.81011G4A) IVS 4 Splice site Novel
6298 c.883T4C 5 p.S295P Missense Coil 2b Novel
116 c.1064_1066del 6 p.Q355del In frame deletion Coil 2b Novel
2785 c.1081G4A 6 p.E361K Missense Coil 2b Novel
7975 c.IVS62A4G (c.1159-2A4G) IVS 6 Splice site Novel
342 c.1346G4A 7 p.G449D Missense Tail (Ig-fold) Novel
9106 c.1361T4C 7 p.L454P Missense Tail (Ig-fold) Novel
7461 c.1399T4C 8 p.W467R Missense Tail (Ig-fold) Novel
2660 c.IVS811G4A (c.148811G4A) IVS 8 Splice site Novel
.Recurrent mutations
6537 c.116A4G 1 p.N39S Missense Coil 1a [Benedetti et al., 2007;
Quijano-Roy et al., 2008]
5182 c.134A4G 1 p.Y45C Missense Coil 1a [Bonne et al., 2000]
563 c.448A4C 2 p.T150P Missense Coil 1b [Felice et al., 2000]
7897 c.745C4T 4 p.R249W Missense Coil 2a [Quijano-Roy et al., 2008]
61 c.745C4T 4 p.R249W Missense Coil 2a same as above
8281 c.745C4T 4 p.R249W Missense Coil 2a same as above
3 c.745C4T; c.1930C4T 4; 11 p.R249W; p.R644C Missense Coil 2a; Tail
(Lamin A
specific)
[Quijano-Roy et al., 2008; Csoka et al., 2004;
Genschel et al., 2001;
Mercuri et al., 2005; Muntoni et al., 2006;
Pasotti et al., 2008;
Perrot et al., 2009; Rankin et al., 2008]
9696 c.746G4A 4 p.R249Q Missense Coil 2a [Benedetti et al., 2007; Bonne et al., 2000;
Boriani et al., 2003;
Brown et al., 2001; Ki et al., 2002;
Muchir et al., 2004;
Raffaele Di Barletta et al., 2000;
Rudenskaya et al., 2008;
Vytopil et al., 2003]
167 c.746G4A 4 p.R249Q Missense Coil 2a same as above
1943 c.812T4C 5 p.L271P Missense Coil 2b [Kichuk Chrisant et al., 2004]
2111 c.881A4C 5 p.Q294P Missense Coil 2b [Bonne et al., 2000]
149 c.907T4C 5 p.S303P Missense Coil 2b [Onishi et al., 2002]
2570 c.1072G4A 6 p.E358K Missense Coil 2b [Benedetti et al., 2007; Bonne et al., 2000, 2001;
Mercuri et al., 2004;
Quijano-Roy et al., 2008]
8419 c.1072G4A 6 p.E358K Missense Coil 2b same as above
26 c.1072G4A 6 p.E358K Missense Coil 2b same as above
2631 c.1157G4A 6 p.R386K Missense Coil 2b [Bonne et al., 2000; Boriani et al., 2003]
5653 c.1157G4A 6 p.R386K Missense Coil 2b same as above
7309 c.1357C4T 7 p.R453W Missense Tail (Ig-fold) [Benedetti et al., 2007; Bonne et al., 1999;
Bonne et al., 2000;
Brette et al., 2004; Colomer et al., 2002;
Fidzianska and Glinka, 2006;
Golzio et al., 2007; Muchir et al., 2004;
Raffaele Di Barletta et al., 2000;
Vytopil et al., 2003]
565 c.1357C4T 7 p.R453W Missense Tail (Ig-fold) same as above
2975 c.1357C4T 7 p.R453W Missense Tail (Ig-fold) same as above
5176 c.1357C4T 7 p.R453W Missense Tail (Ig-fold) same as above
1283 c.1357C4T 7 p.R453W Missense Tail (Ig-fold) same as above
68 c.1357C4T 7 p.R453W Missense Tail (Ig-fold) same as above
1412 c.IVS72A4G (c.13812A4G) IVS 7 Splice site [Quijano-Roy et al., 2008]
6388 c.IVS71G4T (c.13811G4T);
c.1381G4T
IVS 7/exon 8 p.D461Y Splice site; Missense Tail (Ig-fold) [Bakay et al., 2006]
2974 c.1526dup 9 p.T510YfsX42 Frame shift Tail (Ig-fold) [Arbustini et al., 2005]
7288 c.1580G4C 9 p.R527P Missense Tail (Ig-fold) [Benedetti et al., 2007; Bonne et al., 1999, 2000;
Brown et al., 2001;
Raffaele Di Barletta et al., 2000;
van der Kooi et al., 2002]
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evident in many cells expressing the lamin A-N456I and lamin
A-R541P mutant proteins (lamin A-N456I, 25.974.0%; lamin
A-R541P, 9.073.5%) than with the other mutants (Fig. 4A
and C). Lamin A speckles observed in lamin A-N456I infected cells
were generally larger in size compared to those observed in lamin
A-R541P infected cells (Fig. 4A). When the fluorescence intensity
of lamin A together with that of DAPI was plotted on a histogram,
lamin A-positive foci did not costain with the chromatin (Fig. 4B).
Nuclear lamin A foci were not analyzed in cells infected with RV
control because the fixation protocol used to preserve cellular
morphology resulted in endogenous mouse lamin A being weakly
detected (Fig. 3), compared to the robust immunostaining to the
human lamin A species encoded by RVs.
Endogenous Lamin B Mis-localization in the Presence
of Lamin A-R25P and R249W
To investigate whether other endogenous nuclear envelope
components were mislocalized in the presence of the mutant
lamin A proteins, we analyzed the expression of several
components of the nuclear envelope by immunocytochemistry
(Figs. 3 and 4D–F). Lamin A and C directly bind emerin in vitro
[Vaughan et al., 2001] and have been shown to colocalize with
mutant lamin A [Ostlund et al., 2001]. We therefore determined if
the expression of our constructs had an effect on emerin
localization, and if lamin A-N456I, in particular, could cause
nuclear foci that strongly immunostain for emerin. However, none
of the lamin A mutants induced nuclear foci that contained
emerin, confirming previous descriptions [Capanni et al., 2003;
Muchir et al., 2004] (Fig. 3). F-actin staining by standard
immunofluorescence microscopy appeared normal, except in cells
expressing the p.R25P mutation, where fewer stress fibers were
observed (Fig. 3).
The localization of lamin B, however, was changed by the
expression of two mutant lamins. In nuclei of cells expressing
lamin A-R25P and lamin A-R249W, B-type lamins were lost from
one or more poles in some cells (Fig. 3, arrowed and Fig. 4D),
which was particularly severe with the p.R249W mutant. The
DAPI staining pattern implies the nuclei remain intact, but the
redistribution of lamin B is suggestive of nuclear membrane
herniation. Figure 4D shows a detailed micrograph of lamin B
stained cells infected with either lamin A wild-type, lamin A-R25P
or lamin A-R249W. Fluorescent intensity profiles of DAPI and
B-type lamin staining across a central axis of the nuclei were
calculated (Fig. 4E). Whereas the signal for lamin B in cells
expressing lamin A wild type (shown by the histogram) remained
constant across the nucleus, in the presence of lamin A-R249W,
where the central axis bisects one of the poles, the fluorescence
intensity gradually reduced to background levels as the pole was
approached. Nuclei of cells infected with lamin A-R25P showed an
intermediate phenotype between lamin A wild type and lamin
A-R249W. Although a mean of less than 6% of nuclei infected
with lamin A wild type, lamin A-N456I, and lamin A-R541P were
affected, the number of nuclei with a polar loss of lamin B was
significantly higher in presence of lamin A-R25P (19.672.7%) and
especially lamin A-R249W (32.773.3%), with cells containing the
R249W mutation being the most severely affected (Fig. 4F).
Discussion
In this study we report 16 patients with novel, and 34 patients
with recurring LMNA mutations, increasing the known LMNA
mutation database by 5.9% (The Universal Mutation Database;
UMD). Because laminopathies are rare diseases, this significant
increase in patient data will hopefully aid genotype–phenotype
correlations.
Variable expressivity of the EDMD phenotype is noted in many
families illustrating the importance of the genetic background for
clinical presentation. One example of highly variable expressivity
in EDMD2 is demonstrated by the family of patient 7309, found
to be heterozygous for the common p.R453W lamin A/C
mutation. The proband was initially diagnosed with a mild form
of LGMD1B at age 6, and at age 26, he had mild proximal muscle
weakness, contractures, and cardiac involvement. The probands
father died of heart failure at age 61, at which time he had neck
and elbow contractures, but minimal, if any, muscle weakness. The
proband’s paternal grandmother was not considered to be affected
with EDMD until an autopsy performed at age 88 revealed a
skeletal muscle myopathy consistent with this disorder, but a
cardiac muscle biopsy exhibited no significant pathology. Another
example of the phenomenon of variable expressivity is demon-
strated by patient 33, who was found to be heterozygous for an
intron 4 splice junction mutation. Although both patient 33 and
his sister were known to be affected with EDMD2 upon referral
for genetic testing, neither of their parents showed any clinical
Table 2. Continued




acid change Mutation type
Protein domain
affected Ref. for published mutations
1527 c.1583C4A 9 p.T528K Missense Tail (Ig-fold) [Benedetti et al., 2007; Bonne et al., 2000;
Fokkema et al., 2005;
Raffaele Di Barletta et al., 2000]
1200 c.1583C4G 9 p.T528R Missense Tail (Ig-fold) [Fokkema et al., 2005; Vytopil et al., 2003]
2257 c.1583C4G 9 p.T528R Missense Tail (Ig-fold) same as above
2743 c.1621C4A 10 p.R541S Missense Tail [Sylvius et al., 2005]
198 c.1622G4C 10 p.R541P Missense Tail [van Tintelen et al., 2007]
853 c.1804G4A 11 p.G602S Missense Tail
(Lamin A
specific)
[Bakay et al., 2006; Young et al., 2005]
51 c.1930C4T 11 p.R644C Missense Tail
(Lamin A
specific)
[Csoka et al., 2004; Genschel et al., 2001;
Mercuri et al., 2005;
Muntoni et al., 2006; Pasotti et al., 2008;
Perrot et al., 2009;
Rankin et al., 2008]
LMNA GenBank Accession Number RefSeq NM_170707.2; Nucleotide numbering reflects cDNA numbering with 11 corresponding to the A of the ATG translation initiation
codon in the reference sequence, according to journal guidelines (www.hgvs.org/mutnomen). The initiation codon is codon 1.
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signs of this disorder. Molecular testing indicated that their father
carried the splice junction mutation and shortly after receiving
this information, presented with cardiac arrhythmia.
Two patients were found to have a missense mutation within
codon 541. Patient 198, with a predicted p.R541P mutation within
lamin A/C was diagnosed with LGMD1B. She has two affected
children: a daughter diagnosed with mild LGMD1B and a son
with a severe form of EDMD. A p.R541S mutation was detected in
patient 2743, who required a heart transplant at age 13 due to
severe DCM. Other members of this family possessing the p.R541S
mutation were diagnosed with either dilated cardiomyopathy or
LGMD1B, whereas female mutation carriers had an unusual
habitus due to loss of adipose tissue.
We previously reported patient 1325 who is heterozygous for
both p.E358K and p.R624H mutations [Brown et al., 2001]. We
hypothesized that the compound heterozygous mutations found
in this patient may account for her particularly severe phenotype,
with the lamin A-specific mutation being either recessive or
dominant with incomplete penetrance, as it was detected in her
clinically unaffected father. Of note, three other patients in this
study were found to be heterozygous for just the p.E358K
mutation, and all appear to be severely affected with EDMD,
making the role of the second, lamin A-specific mutation, in
patient 1325 unclear. In this study, two compound heterozygous
patients were found, both presenting with an early onset
phenotype (marked by superscript b in Table 1). Patient 6388,
with a severe form of EDMD, was compound heterozygous for
c.IVS1G4T and p.D461Y, two mutations that have been
described before in a patient with early onset EDMD [Bakay
et al., 2006]. A second severely affected patient (patient 3) was also
found to be a compound heterozygote carrying p.R249W and
p.R644C mutations. Interestingly, our study population included
patients carrying each of these sequence alterations individually,
with patient 8281 being heterozygous for the p.R249W alteration
and patient 51 being heterozygous for the lamin A-specific
p.R644C mutation. As the two latter patients with single
Figure 3. Distribution of nuclear envelope-associated components in myogenic cells infected with mutant lamin A. Cells infected with
pMSCV–IRES–eGFP (RV control), pMSCV–laminA–IRES–eGFP (Lamin A), pMSCV–laminA–R25P–IRES–eGFP (R25P), pMSCV–laminA–R249W–IR-
ES–eGFP (R249W), pMSCV–laminA–N456I–IRES–eGFP (N456I), and pMSCV–laminA–R541P–IRES–eGFP (R541P) were immunostained for nuclear
envelope components (lamin A, lamin A/C, lamin B, emerin; Scale bar5 10mm) and F-actin (red) (eGFP-positive infected cells are indicated by
arrowheads; Scale bar5 50mm). A representative selection of nuclei and cells are shown. Lamin A-positive nuclear speckles and lamin A capping
(arrows) as well as a loss of lamin B from nuclear poles was evident to varying degrees in a mutant-dependent fashion. The localization of emerin
was normal in all instances. [Color figure can be viewed in the online issue, which is available, at wileyonlinelibrary.com]
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mutations are affected with early age-of-onset disease, both of
these mutations appear to act in a dominant fashion. This paradox
suggests further studies are required to determine the true reason
behind modifying effects, if any, of compound heterozygosity on
clinical phenotype.
In 2008, Quijano-Roy et al. reported a new form of congenital
muscular dystrophy associated with 11 different mutations in the
LMNA gene [Quijano-Roy et al., 2008]. Notably, affected patients
presented with muscle weakness between birth and the first year of
life (rather than at an average age of 32 months as seen for
EDMD2). L-CMD patients additionally display a dropped head,
also not observed in EDMD2. The muscle weakness in L-CMD
expresses as selective axial weakness and wasting of the
cervicoaxial muscles with a predominantly proximal upper and
distal lower limb involvement. Of 50 patients reported in our
study, 14 (marked by superscript a in Table 1) associated with 11
different singular mutations originating from familial and
sporadic origin, expressed a severe EDMD-like phenotype
characterised by an onset of o3 years of age or early cardiac
involvement. Three mutations (p.N39S, p.R249W, and p.E358K)
with an early onset were also reported to cause L-CMD [Quijano-
Roy et al., 2008]. Three further mutations described here (c.IVS4
11G4A, p.G449D, and p.W467R) causing early onset EDMD are
novel. The remaining five mutations (p.R249Q, p.S303P, p.R527P,
p.T528R, and p.R644C) have been previously described as causing
EDMD [Benedetti et al., 2007; Bonne et al., 1999, 2000; Boriani
et al., 2003; Brown et al., 2001; Fokkema et al., 2005; Muchir et al.,
2004; Onishi et al., 2002; Raffaele Di Barletta et al., 2000; van der
Kooi et al., 2002; Vytopil et al., 2003] with R644C causing a large
variety of phenotypes including EDMD [Brown et al., 2001; Csoka
et al., 2004; Mercuri et al., 2005; Rankin et al., 2008]. We conclude
that additional mechanisms must contribute to the disease
severity at presentation such as modifier genes or digenism.
Patients with mutations in both EMD and LMNA genes present
with a more severe phenotype [Ben Yaou et al., 2007], but all our
patients were also screened for EMD mutations and found to be
negative.
Taking the entire lamin A protein, approximately 50% of all
pathogenic mutations affect residues that are conserved from man
to C. elegans. Although mutations in the conserved residues are
Figure 4. Nuclear abnormalities in myogenic cells infected with mutant lamin A. A: Prominent lamin A foci distributed throughout the nucleus
were frequently observed in cells infected with lamin A-N456I and lamin A-R541P. Nuclei with representative lamin A foci are shown. Scale
bar5 10mm. B: The fluorescence intensity of DAPI and lamin A along the central axis indicated by a dashed line in A is shown in the adjacent
histogram. C: Quantification of nuclei with prominent lamin A foci distributed throughout the nucleus. Values represent the mean7SEM;
Po0.05, Po0.01 compared to wild-type lamin A infected cells (wild type). D: Loss of lamin B expression from one or multiple poles is
frequently observed in cells expressing lamin A-R25P and lamin A-R249W. Scale bar5 10 mm. E: The fluorescence intensity of DAPI and lamin B
along the central axis indicated by a dashed line in D is shown in the histogram. F: Quantification of nuclei where a polar loss of lamin B
expression was observed. Values represent the mean7SEM; Po0.05, Po0.01 compared to wild-type lamin A infected cells.
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more likely to cause a phenotype, to date, no clear genotype–
phenotype correlation has been established. Six of eight novel
amino acid substitutions described in this report affect highly
conserved residues of the lamin A protein. Two affected residues
reported to be pathogenic (p.R189 and p.S268) are located in the
central rod domain of lamin A and are not conserved in evolution.
Interestingly, both nonconserved residues are mutated to a proline
and located adjacent to pathogenic residues. These are p.R190,
associated with DCM when mutated to Trp or Gln [Perrot et al.,
2009; Sylvius et al., 2005], and p.Y267, associated with EDMD and
DCM when mutated to His or Cys [Carboni et al., 2008; Vytopil
et al., 2003]. Proline is not found in the center of a straight
a-helix, due to its helix breaking attributes [Richardson and
Richardson, 1988]. Interestingly, 9/30 (30%) of all pathogenic,
nonconserved residues in the central rod domain, are substituted
to a proline. Eight of these cause either EDMD or DCM, while one
(p.A57P) has been reported to cause WRN [Chen et al., 2003].
Our data therefore confirms the assumption that the introduction
of a proline is more likely to be pathogenic irrespective of amino
acid conservation.
Eight patients were found to have mutations located on the
exon–intron or intron–exon junctions, suggesting they may affect
pre-mRNA splicing. In five (33, 7975, 1412, 6388, and 2660), the
universally conserved GT and AG di-nucleotides are affected. The
majority of intronic splice site mutations published so far are
associated with DCM or LGMD1B [Chrestian et al., 2008; Muchir
et al., 2000; Otomo et al., 2005] while others have been shown to
result in EDMD [Bakay et al., 2006]. In our study, however, all
patients with intronic splice site mutations presented with an
EDMD phenotype (Table 1). We also had three patients with
mutations located on either the first nucleotide of exon 2 or the
last nucleotide of exon 4. Patient 2018, who presented with DCM,
and patient 778, who presented with an EDMD phenotype with
cardiac involvement, both had the last nucleotide of exon 4
mutated to an A (c.810G4A; p.K270K). In patient 91, who
presented with an LGMD phenotype with cardiac involvement,
the first nucleotide in exon 2 is mutated to a T (c.357C4T;
p.R119R) (Fig. 1A). Such mutation types are very rare mutational
events and only one other such mutation has been described so far
in the LMNA gene. It is located on the last nucleotide of exon 2
(c.513G4A; p.K171K) and was found in four patients diagnosed
with LGMD1B [Todorova et al., 2003]. mRNA analysis on these
patients showed that this results in a partial skipping of the canonical
50 splice site in intron 2 and the alternative use of a cryptic GT donor
site within intron 2 leading to an insertion of 15 additional amino
acids between exon 2 and 3 [Todorova et al., 2003].
Cells isolated from patients with LMNA mutations, or cells
overexpressing mutant lamin A, often display aberrant localization
of nuclear envelope proteins and changes in nuclear morphology.
In our study, we observe both phenomena: constitutive lamin
A-R25P and lamin A-R249W expression caused severe changes in
nuclear shape and size, while lamin A-N456I and lamin A-R541P
resulted in nuclear lamin A-positive foci. Nuclear foci staining for
lamin A are frequently described when overexpressing mutant and
lamin A wild type in vitro [Bechert et al., 2003; Holt et al., 2001;
Ostlund et al., 2001]. In contrast, such foci are not very common
in primary cells isolated from patients with LMNA mutations
[Emerson et al., 2009; Markiewicz et al., 2002; Muchir et al., 2004;
Taimen et al., 2009; Vigouroux et al., 2001; Zhang et al., 2007],
suggesting that lamin A-positive foci formation can be attributed
to lamin A overexpression. Patient fibroblasts that do show lamin
A-positive foci usually carry FPLD but also EDMD causing
mutations in the Ig-fold domain [Capanni et al., 2003; Muchir
et al., 2004]. We see similar effects using mouse C2C12 myogenic
cells. Cells expressing lamin A-R25P and lamin A-R249W do not
form nuclear foci staining for lamin A. However, constitutive
expression of the lamin A variants with a mutation in the Ig-like
fold (lamin A-N456I) and adjacent to the Ig-like fold (Lamin
A-R541P) induces lamin A foci formation in 25 and 10% of all
infected nuclei, respectively. Although nuclear foci appear to be
smaller in cells infected with lamin A-R541P, these results may
suggest that the molecular mechanism inducing these foci and
perhaps the underlying disease mechanism, is similar for the two
mutations in the tail domain of lamin A analyzed in this study.
In contrast, constitutive lamin A-R25P and lamin A-R249W
expression in mouse myogenic cells caused severe changes in
nuclear shape and size. Nuclear blebbing is a type of nuclear
distortion commonly found in progeria and other laminopathies
[Eriksson et al., 2003; Goldman et al., 2004; Jacob and Garg, 2006;
Taimen et al., 2009]. Khatau et al. [2009] report that the nuclear
morphology can be regulated by a perinuclear actin cap, which is
disrupted in cells from lmna/ and lmnaL530P/L530P mice. To test
if the abnormal nuclear morphology we observed was associated
with a misarranged actin-cytoskeleton, we stained infected C2C12
cells for F-actin. However, although there were perturbed F-actin
stress fibers with lamin A-R25P, as has been described previously
for other mutations in patient fibroblasts [Emerson et al., 2009],
confocal imaging did not reveal differences in the perinuclear
actin cap associated with this, or any of our other mutant lamin A-
species (data not shown). This suggests that there might be other
factors involved in nuclear deformation in this case. One
possibility of nuclear deformation is a misregulation of nesprin
or other members of the LINC complex which physically connects
the nuclear lamin with the cytoskeleton [Razafsky and Hodzic,
2009]. The expression pattern of these interaction partners will be
the subject of future investigations.
Interestingly, aberrant nuclear morphology in both mutants
(lamin A-R25P and lamin A-R249W) is accompanied by a polar
loss of lamin B expression in a mean of 20% and 33% of nuclei
respectively. The same phenomenon has been observed by others
in cells from HGPS patients with the p.E145K mutation [Taimen
et al., 2009] and in fibroblasts isolated from FPLD patients
[Vigouroux et al., 2001]. Mouse embryonic fibroblasts from
mouse embryos homozygous for a truncated, nonfunctional form
of lamin B1 show severely misshaped nuclei also, suggesting that
the loss of lamin B1 is a causative event for the observed nuclear
lobulation [Vergnes et al., 2004]. How mutated lamin A affects
lamin B localization is unclear, and if a correction of lamin B
expression can restore a normal nuclear morphology remains to
be determined. It would also be very interesting to see if there are
any LMNA single nucleotide polymorphisms (SNPs) that can
affect lamin B localization and nuclear morphology.
Generally, patient fibroblasts with mutations associated with
severe forms of laminopathies such as MAD (p.L59R, p.R527C,
and p.R527H) [Agarwal et al., 2008; Nguyen et al., 2007; Novelli
et al., 2002], WRN (p.R133L, and p.L140R) [Caux et al., 2003;
Chen et al., 2003], and FPLD (p.R439C) [Verstraeten et al., 2009]
all show the most profound changes in nuclear morphology.
Taimen et al. [2009] have shown that nuclei of dermal fibroblast
isolated from HGPS patients with the lamin A-E145K mutation
show drastic changes in morphology and are severely lobulated. It
has been suggested that the underlying mechanism of the
pathogenicity of HGPS causing lamin A-E145K is a disrupted
filament formation [Taimen et al., 2009]. However, mutant lamin
A variants that caused an effect on nuclear morphology in our
study result in either typical EDMD2 (lamin A-R25P) or an early
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onset/L-CMD phenotype (lamin A-R249W), but whether they
affect filament formation to differing degrees is unknown.
A-type lamins are expressed in mouse satellite cells: the resident
stem cells of skeletal muscle [Gnocchi et al., 2009]. Therefore,
perturbed lamin function does not only affect the myonuclei of
muscle fibers, but could also compromise satellite cell-mediated
muscle maintenance and repair. A disrupted nuclear morphology
is likely to affect basic cellular processes, such as proliferation and
differentiation of myoblasts [Gnocchi et al., 2008]. It is generally
accepted that mutations in lamin A can affect cell cycle kinetics
[Emerson et al., 2009; Johnson et al., 2004]. Fibroblasts from
HGPS patients demonstrate a decreased cell growth rate [Gold-
man et al., 2004] and fibroblasts isolated from EDMD but not
DCM patients have been shown to have an increase in cell
proliferation [Emerson et al., 2009]. However, it has also been
reported that cell cycle progression is dependent on nuclear size
[Roca-Cusachs et al., 2008; Yen and Pardee, 1979]. It is therefore
likely that cells expressing lamin A-R25P and lamin A-R249W
show altered cell cycle progression and proliferation.
In conclusion, we describe 15 novel LMNA mutations that
underlie a striated muscle phenotype, increasing the LMNA
mutation spectrum by 6%. These will contribute toward
formulating more accurate genotype–phenotype correlations in
the laminopathies. Our analysis of 4 LMNA mutations shows that
mutations located in the head and central rod domain perturb
lamin B polarization and nuclear morphology, while the two
mutations in the Ig-fold domain and adjacent to the Ig-fold
domain, increase the incidence of lamin A-positive nuclear foci.
We conclude that although the molecular mechanisms underlying
the LMNA-generated pathogenic cascade in a particular tissue, with
respect to intrinsic cellular processes such as cell cycle, cell
signalling, etc., may be similar for a given laminopathy, the disease
penetrance and clinical variability within a phenotype may arise
from the combined contribution of genetic background, digenism
and environmental factors.
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In this chapter I set out to study the effects of four pathogenic lamin A mutations on C2C12 
myoblasts. I have found that even moderate expression levels achieved by the retroviral expression 
system used, induce an obvious but variable phenotype in presence of all four mutations. In 
presence of missense mutations located in the head (p.R25P) and central rod domain (p.R249W) 
nuclei were severely dysmorphic and showed mislocalised lamin B expression. In contrast, 
mutations located in the Ig-fold domain (p.N456I and p.R541P) resulted in lamin A positive 
nuclear foci, while the nuclear morphology in their presence was not affected. Together, these 
results demonstrate that mutations manifesting in similar phenotypes can have very different effects 
on a cellular level, suggesting that different pathogenic mechanisms are at play. To pinpoint 
potential mechanisms, the effects of mutant lamin on functional aspects of myoblasts such as 
proliferation and differentiation must be investigated, which will be covered in the next chapter of 




Chapter 5  
Functional Effects of Four Mutant Lamin A Variants on the 
Proliferation and Differentiation Capacity of Myogenic Cells 
 
5.1 Introduction 
The vast majority of all reported LMNA mutations (77.2%) result in disease phenotypes affecting 
skeletal and/or cardiac muscle (www.umd.be/LMNA). The most common disease is Emery-
Dreifuss muscular dystrophy (EDMD), characterised by the clinical triad consisting of joint 
contractures (primarily of elbow and Achilles tendons), slowly progressive muscle weakness of the 
upper proximal and lower distal musculature (humero-peroneal distribution) and cardiac 
involvement (see section 1.1.3 for details). However, how mutations in LMNA cause muscle 
dystrophy is largely unknown.  
Ever since LMNA mutations have been described to cause EDMD, research has been conducted 
to elucidate the pathogenic mechanism. From this research three non-mutually exclusive 
hypotheses emerged: the ‘mechanical stress’ hypothesis and the ‘gene expression’ hypothesis and 
the ‘cell proliferation/differentiation’ hypothesis (Broers et al., 2006; Worman, 2012) (refer to 
section 1.4.2 for details).   
Abnormalities in nuclear structure, caused by lamin mutations, could lead to an increased 
susceptibility to cellular damage by physical stress. Muscle is especially subject to high forces and 
constant mechanical stress. Some of the force transmitted through the cytoskeleton could directly 
affect the nuclear envelope via the LINC (linker of nucleoskeleton and cytoskeleton, see section 
1.2.2) complex (Mellad et al., 2011; Padmakumar et al., 2005). This could potentially result in 
damage of a nuclear envelope compromised by the presence of mutant lamin or the absence of 
emerin. Indeed, ultrastructural analysis of skeletal muscle from patients with autosomal dominant 
EDMD and X-linked EDMD reveals widespread damage of nuclear envelopes and leakage of 
chromatin into the cytoplasm (Fidzianska and Hausmanowa-Petrusewicz, 2003; Fidzianska et al., 
1998), providing evidence in favour of this as a potential pathogenic mechanism for certain LMNA 
mutations. 
Lamins are able to directly and indirectly interact with chromatin and transcription factors and 
might therefore affect cell/tissue function by indirectly modulating gene expression and regulation 
(Wilson and Foisner, 2010; Zastrow et al., 2004). One such example is the regulation of Erk1/2 
signalling. Upon extracellular stimulation, Erk1/2 is phosphorylated and activates c-Fos which 
stimulated cell cycle entry and the transition to S-phase. Lamin A binds to both Erk1/2 and c-Fos 
(Gonzalez et al., 2008) and mutant lamin A has been shown to affect Erk1/2 phosphorylation and 
proliferation (Emerson et al., 2009). 
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Lamins have also been shown to directly interact with the cell cycle regulator pRb in complex with 
Lap2α, tethering pRb to the nucleoskeleton (Dechat et al., 2000; Markiewicz et al., 2002). Mutant 
lamins that disrupt this complex potentially affect cell cycle exit: a necessary step for myogenic 
differentiation (Markiewicz et al., 2005). 
Functional tissue of skeletal muscle, the muscle fibre, is post-mitotic, however muscle retains a 
well-characterized stem cell compartment (satellite cells) responsible for homoeostatic myonuclear 
turnover, hypertrophy and repair (Zammit, 2008). Thus, next to mutations that weaken the 
structural support of myonuclei and satellite cells, skeletal muscle may additionally be vulnerable to 
mutations that also affect cell cycle and/or differentiation of myogenic stem cells. Genetic ablation 
using Cre-lox technology of satellite cells in adult mice has been shown to completely block 
regenerative myogenesis demonstrating their absolute requirement to regenerate muscle damaged 
after acute injury (Lepper et al., 2011). A defective satellite cell pool can therefore potentially 
contribute to the disease pathology or accelerate disease progression (Gnocchi et al., 2008; Morgan 
and Zammit, 2010). 
One example where defective satellite cells have been shown to play an indirect role in disease 
progression is Duchenne muscular dystrophy (DMD). Excessive myofibre damage caused by the 
lack of dystrophin protein induces chronic rounds of degeneration and repair, eventually leading to 
a decline in the regenerative capacity of muscle (Webster and Blau, 1990). In likely combination 
with an increasingly hostile microenvironment, this constant demand for a large number of satellite 
cells ultimately leads to their exhaustion, resulting in a progression of the dystrophic phenotype. 
Indeed the dystrophic phenotype is worse in mice where telomerase is inactivated, presumably 
largely due to its effects to limit satellite cell proliferation (Sacco et al., 2010). EDMD patients do 
not show these repeated rounds of degeneration-regeneration, and so if lamin mutations affect 
satellite cell function it is likely by affecting muscle homeostasis and repair. 
In general, mutant lamins could affect satellite cells on multiple levels (intrinsic and extrinsic) 
leading to an impaired proliferation or differentiation capacity. For example, satellite cell derived 
myoblasts from mice lacking A-type lamins display decreased pRb and MyoD protein levels as well 
as reduced differentiation potential in vitro (Frock et al., 2006). Cells isolated from EDMD patients 
carrying various LMNA mutations show a delayed cell cycle progression by prolonging S-phase 
(Emerson et al., 2009). Myogenic differentiation also requires a timely exit from the cell cycle which 
involves remodelling of the nucleoskeleton and the relocation of nucleoplasmic A-type lamins to 
the nuclear envelope, a process disrupted by mutant lamin A-W520S (Markiewicz et al., 2005). 
Similarly, C2C12 cells fail to dephosphorylate pRb and exit cell cycle in the presence of lamin A-
R453W and as a consequence do not fuse to form myotubes (Favreau et al., 2004). 
Evidence that satellite cells are affected in vivo is provided by ultrastructural studies. Recently, Park 
et al. (2009) have analysed muscle sections from EDMD and LGMD1B patients and found that 
50% of all satellite cell nuclei and 90% of all myonuclei displayed abnormal chromatin organisation. 
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Interestingly, abnormalities in nuclear morphology were only detected in approx. 20% of all 
myonuclei but not in satellite cells (Park et al., 2009).  
Taken together, the important role of satellite cells in muscle homeostasis and repair makes them 
an attractive target to contribute to the pathology of EDMD.  In the previous chapter, I examined 
the effects of four mutations on nuclear structure and localisation of proteins including lamin B. 
Here I investigated whether these structural defects had effects on myogenic cell function. The 
effects on myoblast proliferation and differentiation of the four lamin A mutations described in 
chapter 4 (lamin A-R25P, R249W, N456I and R541P compared to wild-type lamin A as a control) 





In chapter 4, I overexpressed four mutant lamin A variants (lamin A-R25P, R249W, N456I and 
R541P) found in patients with a skeletal muscle phenotype. Given the vastly different nuclear 
abnormalities these four mutant lamin A variants caused in C2C12 myoblasts, I also sought to 
investigate their effects on functional properties of myogenic cells including proliferation and 
differentiation.  
I hypothesise that the muscle phenotype observed in EDMD patients is, in part, caused by 
dysfunctional satellite cell pool that either fails to efficiently expand due to proliferation/cell cycle 
defects or to differentiate and form myotubes. This leads to a significant failure in muscle 
homeostasis and repair in response to the muscle wasting caused by the effects of the mutation in 
myonuclei, and so exaggeration of the dystrophic phenotype. 
Testing this hypothesis, required the analysis of myogenic cells in the presence of mutant lamin A. 
However, EDMD is a rare disease and patient myoblasts are not readily available. I therefore again 
overexpressed the same four mutant lamin A proteins in mouse immortalised satellite cell-derived 
myoblasts (C2C12 cells) by retroviral infection to examine how the nuclear structural changes affect 
proliferation and differentiation. In addition, I also used primary mouse satellite cells to confirm 




5.3.1 Colony Growth is reduced in cells expressing lamin A-R25P and R249W 
The first functional analysis performed was to test the effects of mutant lamin A variants on cell 
proliferation and cell cycle in C2C12 myoblasts. To analyse the proliferative capacity of C2C12 cells 
I first performed a colony growth assay. The constructs used in this study (see section 2.2.2 for 
details) express full length human lamin A as well as eGFP from the IRES-eGFP in the retroviral 
backbone. Infected cells were seeded at low density 24 hours post infection which allowed the 
formation of individual colonies. The number of cells per eGFP positive colony was counted 24, 48 
and 72hrs in culture and is shown for each mutation in figure 5.1.  
Retroviral overexpression of wild-type lamin A in C2C12 did not have an effect on colony growth. 
The colony size is similar to that of cells infected with the control RV at all three time points. After 
24 hours in culture none of the mutant lamin A variants resulted in a significant change in colony 
size. However, at the two later time points (48hrs and 72hrs after seeding) colony size was 
significantly smaller in the presence of lamin A-R25P and R249W, indicating a lower proliferative 
potential as compared to wild-type lamin A infected cells. In contrast, the presence of lamin A-
N456I and R541P did not have an effect on colony growth at any of the time points analysed. 
 
 
Figure 5.1 Colony growth is reduced in C2C12 myoblasts infected with lamin A-R25P and R249W. Colony size 
is significantly smaller in the presence of lamin A-R25P and R249W at 48hrs and 72hrs after passaging. Numbers 
represent the average number of cells/colony from 3 independent infections (at least 35 colonies were counted in 
total per time point), error bars show S.E.M where an asterisk denotes significant difference (* p<0.05, ** p<0.01) 
from wild-type lamin A infected cells using a student’s t-test. 
124 
 
To test if the reduced colony growth is associated with a reduced proliferation rate, C2C12 cells 
were pulsed with bromodeoxyuridine (BrdU) for 2 hours to quantify the number of cells in S-phase 
(Fig. 5.2A). The proportion of infected cells (eGFP positive) that immunostained for BrdU in 
presence of each lamin A-variant is shown in figure 5.2B. However, the number of BrdU positive 
cells was not statistically different in the presence of lamin A-R25P and R249W when compared to 
wild-type lamin A infected cells, despite the decreased number of cells in the colony assay (Fig. 5.1). 
Similarly, lamin A-N456I and R541P do not have a significant effect on the number of BrdU 
positive cells.  
 
 
Figure 5.2 BrdU incorporation in proliferating C2C12 cells is not affected in the presence of different lamin A 
mutants. (A) Proliferating C2C12 cells stained for BrdU after a 2hr pulse 72 hours post infection. A representative 
picture for each construct is shown. (B) Quantification of the proportion of infected cells (eGFP positive) that 
immunostained for BrdU in the presence of mutant lamin A variants from 5 independent experiments. n.s. not 
significant compared to wild-type lamin A infected cells using a student’s t-test. 
 
Overexpression of HGPS causing missense mutations (R133L and L140R) in human fibroblasts 
has been shown to increase replicative senescence by telomere shortening (Huang et al., 2008). 
Similarly, signs of premature senescence have been found in patient myoblasts harbouring the 
EDMD mutation p.R545C (Kandert et al., 2009). To test if senescence is the cause of the reduced 
colony growth in the presence of lamin A-R25P and R249W, cells were stained for senescence 
associated (SA) β-gal. However, none of the C2C12 cells infected with any of the four lamin A 
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variants stained positive for SA β-gal, ruling out senescence as the cause for the discrepancy seen 
between the colony growth assay and BrdU staining (data not shown).     
5.3.2 Mutant lamin A-variants do not affect the cell cycle in C2C12 cells  
BrdU is a marker of DNA synthesis and allows visualising cells currently in S-phase. However the 
number of cells in S-phase does not reveal potential defects in other parts of the cell cycle such as 
G1 or G2/M. In order to find out if other elements of the cell cycle are affected by any of the four 
mutant lamin A variants tested in this study, I performed cell cycle analysis by flow cytometry. To 
do so, proliferating C2C12 cells infected with mutant lamin variants were stained with propidium 
iodine (PI) and fixed with ethanol before flow cytometry. Unfortunately ethanol fixation cannot be 
used for the analysis of GFP expression as it allows GFP to leak out of the cell resulting in reduced 
fluorescence intensity. Therefore all cells stained with PI were included in the cell cycle analysis 
(50,000 cells per sample). To assess the potential influence of non-infected cells on the result, the 
infection efficiency was quantified for each of the samples by fixing half the cells with 4% PFA and 
processing them in parallel. On average 99.8% of the cells were GFP positive (Fig. 5.3) ruling out 
any influence of non-infected cells on the result. 
The results show that little debris (fragmented cells)  was present in the sample (as judged by the 
number of events in the bottom left corner of figure 5.3A and 5.4A respectively) and that the 
majority of C2C12 cells infected with the control RV are single cells (Fig. 5.4B, gated subset). The 
same result was obtained with all other samples (data not shown). Cell cycle distributions of cells 
infected with the control RV and different lamin A variants are shown in figure 5.4C. The 
proportion of cells in each phase of the cell cycle was quantified using the FlowJo software using 
the Watson model (Watson et al., 1987) and is summarised in table 5.1. On average, 37.9% of all 
cells infected with wild-type lamin A were found in G1-phase, 43.3% were found in S-phase and 
15.9% were found in G2/M-phase. When these values were compared to other samples, no 
significant difference was found. The Root Mean Square (RMS) value which is a measure of how 
well the chosen model fits the curve is similar for all samples. 
Table 5.1 Proportion of infected C2C12 cells in different phases of the cell cycle. 
 RMS % G1 p-value % S p-value % G2/M p-value
Control RV 11.2 (2.3) 39.5 (2.67) 0.44 41.5 (2.12) 0.29 15.7 (1.00) 0.85 
Lamin A-wt 9.2 (0.1) 37.9 (1.87) Ref 43.3 (1.38) Ref 15.9 (0.61) Ref 
R25P 9.8 (1.6) 37.1 (1.01) 0.53 43.3 (0.76) 1.00 16.4 (0.59) 0.31 
R249W 10.4 (1.0) 37.1 (2.29) 0.66 43.5 (1.48) 0.91 16.0 (0.23) 0.80 
N456I 9.7 (1.2) 37.7 (2.08) 0.92 43.7 (1.65) 0.78 15.6 (0.35) 0.55 
R541P 8.9 (0.3) 38.3 (0.81) 0.77 42.2 (1.99) 0.68 16.0 (0.40) 0.77 
Values represent the mean (S.E.M.) from 3 independent experiments. The Root Mean Square (RMS) is a measure of 






Figure 5.3 Quantification of eGFP positive C2C12 cells after retroviral infection with mutant lamin A variants 
demonstrates very high infection efficiencies. (A) Forward scatter (FSC) vs. side scatter (SSC) plot of non-
infected C2C12 cells. (B) GFP intensity (FL1) of non-infected cells gated in panel A which served as a negative 
control. (C) Histograms of infected cells (grey curve) compared to non-infected cells (white curve). Percentages of 










Figure 5.4 Cell cycle analysis of C2C12 cells infected with mutant lamin A variants. (A) Side-scatter/Forward 
Scatter plot to identify debris which would be located in the bottom left corner. (B) FL2-A (peak area) vs. FL2-W 
(peak width) plot indicates cells in different phases of the cell cycle (amount of DNA). Single cell population is gated 
and was used for cell cycle analysis.  (C) Cell cycle analysis of infected C2C12 cells by flow cytometry. The DNA 
content was stained with propidium iodine and the percentages of G1, G2/M and S-phase was determined using 






To substantiate the lack of phenotype in C2C12 cells infected with pathogenic lamin A variants, I 
also analysed the expression of a number of cell cycle markers shown to be mis-regulated in Lmna-
null cells or presence of mutant lamin A (Fig. 5.5). Sub-confluent C2C12 cells were infected over-
night, sub-cultured and harvested while in proliferation 72hrs post infection. Total protein extracts 
were prepared as described in section 2.2.4 in the presence of protease and phosphatase inhibitors 
and separated on a 4-20% denaturing gradient gel. The gel was blotted onto a PVDF membrane 
using the Invitrogen iBlot system and probed with antibodies against pRb, p21, PCNA, Erk1/2 and 
pErk1/2. Antibody details can be found in tables 2.1 and 2.2. β-tubulin served as a loading control 
and a standard 2-colour protein ladder (Expedeon) was used to estimate the size of the bands.  
 
 
Figure 5.5 Western blot analysis of cell cycle markers in proliferating C2C12 cells expressing mutant lamin A 
proteins. (A) Western blot analysis of proliferating C2C12 cells infected for 72hrs with either control-RV, wild-type 
lamin A or mutant lamin A variants. A non-infected control sample (lane 1) was also included. Levels of cell cycle 
regulators pRb (110-116kDa), p21 (21kDa) and the DNA replication elongation factor PCNA (29kDa) did not 
obviously change in presence of mutant lamin A. (B) Total Erk1 (p44 MAPK, 44kDa) and Erk2 (p42 MAPK, 42kDa) 
as well as phosphorylated pERK1/2 in proliferating C2C12 cells. The expression level of phosphorylated p42 MAPK 
(Erk1) appears to be slightly reduced in the presence of lamin A-R25P. 
 
The retinoblastoma protein (pRb) forms a complex with nucleoplasmic lamin A and Lap2α which 
has been shown to be disrupted in presence of mutant lamin A affecting cell cycle dynamic 
(Markiewicz et al., 2002; Markiewicz et al., 2005). When the cell receives cues to exit cell cycle, the 
cdk inhibitor p21 is up-regulated and pRb is rapidly hypophosphorylated which inactivates E2F 
transcription factors, leading to cell cycle arrest (Guo et al., 1995). Hence, if cells exit the cell cycle 
in the presence of any of the four mutants, pRb as well as p21 levels would be expected to increase. 
However, there was no obvious change in pRb levels and p21 levels in the presence of all four 
lamin A mutants which confirms results obtained by cell cycle analysis. Similarly, levels of the DNA 
replication elongation factor PCNA, which is involved in DNA repair and cell cycle control, and 
129 
 
has been shown to bind the Ig-fold of lamin A (Shumaker et al., 2008), was not obviously altered by 
any of the mutations. 
Erk1/2 activation has been shown to be misregulated during cell cycle entry in human fibroblasts 
from EDMD patients carrying mutations in LMNA (Emerson et al., 2009). Upon serum 
stimulation, Erk1/2 phosphorylation was initially delayed followed by hyperphosphorylation. 
Phosphorylated Erk1/2 is necessary to activate the transcription factor c-Fos which initiates cell 
cycle dependent genes and promotes S-phase progression (Gonzalez et al., 2008). In proliferating 
asynchronous C2C12 cells infected with mutant lamin A variants, p42/p44 MAPK (Erk1/2) levels 
as well as phosphorylated p42/p44 (pErk1/2) levels are similar to those in wild-type lamin A 
infected cells (Fig. 5.5B). In all cases, levels were very similar by eye and the band intensity was 
therefore not quantified. Although in cells expressing lamin A-R25P, a slight decrease of p42 
MAPK (Erk2) expression level was noted. 
5.3.3 Myogenic commitment is increased in C2C12 cells in presence of Lamin A-
N456I 
Next to analysing proliferation and cell cycle, I assayed the effect of pathogenic lamin A mutants on 
the differentiation potential of myogenic cells. Myogenic differentiation can be separated into 
multiple different stages (see Fig. 1.2). Two of these stages were analysed in the presence of mutant 
lamin A namely, myogenic commitment (marked by the expression of myogenin) and sarcomeric 
assembly (marked by the expression of myosin heavy chain) during myotube formation.  
To study myogenic differentiation, I have used C2C12 myoblasts which are maintained in a 
proliferative state in serum containing medium and at sub-confluency. Differentiation of C2C12 
cells is induced by contact inhibition and/or serum deprivation (Blau et al., 1983; Yaffe and Saxel, 
1977). To analyse the effect of mutant lamin A on myogenic commitment in C2C12 cells, cells were 
infected and seeded into chamber slides. When they reached 80-90% confluence (usually 72hrs post 
infection) they were induced to differentiate by serum deprivation with culture medium containing 
2% (v/v) horse serum. By doing so, C2C12 are induced all at the same time which makes this is a 
very precise and sensitive method to detect potential alterations in myogenic progression caused by 
mutant lamin A. 
Results summarised in figure 5.6 show that 43.5% of all infected cells (wt-lamin A) express 
myogenin. This is statistically similar to cells infected with control RV (43.1%), lamin A-R25P 
(43.9%), R249W (45.6%) and R541P (42.3%). The only lamin A variant resulting a statistically 
significant change was lamin A-N456I. The pathogenic mutation located in the Ig-fold significantly 
increased (+5.7%, p=0.0099) the proportion of myogenin positive cells after 24 hours in 
differentiation medium when compared to wild-type lamin A infected cells (Fig. 5.6D). This is 







Figure 5.6 C2C12 myoblasts commitment to differentiation is increased in the presence of lamin A-N456I. (A) 
Representative images showing infected C2C12 cells after 24hrs in differentiation medium co-immunostained for 
eGFP and myogenin. (B) Quantification of the proportion of infected (eGFP positive) cells which are positive for 
myogenin. Values represent the average of three separate experiments. A total of at least 3000 cells (in 3 field of 
views) were counted for each replicate. Error bars represent he S.E.M.; * p<0.05, ** p<0.01 when compared to wild-





5.3.4 Myogenic differentiation in C2C12 cells is unaffected by Lamin A-mutants 
As described above, C2C12 cells are a well-established murine satellite cell-derived myoblast line 
used to study myogenesis in vitro. When induced to differentiate by serum deprivation, C2C12 cells 
exit the cell cycle and express myogenin. They then continue to fuse to form multinucleated 
myotubes and start to express myosin heavy chain, a marker for sarcomere assembly and terminal 
differentiation (Fig. 5.7A). To see if the accelerated myogenic commitment of cells infected with 
lamin A-N456I affects later stages of myogenic differentiation, C2C12 cells were infected and 48 
hours later switched to differentiation medium and further cultured for 48 hours before fixation 
and co-immunostaining for MyHC, a marker for terminal differentiation and eGFP.  
In addition to serum deprivation C2C12 cells are also induced to differentiate by contact inhibition. 
A small difference in cell density at the start of the experiment or variability in proliferation might 
therefore affect the onset of differentiation and skew the result. To assess a potential influence of 
cell density on my result, I performed a statistical analysis to see whether the average number of 
cells per picture analysed was significantly different between different samples. However, no 
difference was found, ruling out an influence of cell density on the obtained result (data not 
shown). Furthermore, immunostaining showed that cells did not express myogenin at the time that 
they were induced to differentiate by switching to differentiation medium. 
The differentiation index (defined as the proportion of nuclei in MyHC positive cells) of cells 
infected with wild-type lamin A was 44.0% after 48 hours in differentiation medium. When 
compared to cells infected with control RV or other lamin A variants, no significant changes were 
found. The only noticeable although non-significant increase was caused by lamin A-N456I which 
resulted in a differentiation index 3.6% higher (p=0.085) than that of cells infected with wild-type 
lamin A (Fig. 5.7B). Similarly the fusion index (defined as the proportion of nuclei in myotubes 
with 2 or more nuclei) was slightly (but again not significantly) raised in presence of lamin A-N456I 
(+4.0%, p=0.084) compared to wild-type lamin A infected cells. All other lamin variants and the 
control RV did not have a noticeable effect on the fusion index (Fig. 5.7C). 
Interestingly, examination of myonuclei at higher magnification revealed small differences in 
nuclear morphology across different constructs (Fig. 5.8). Myonuclei in myotubes formed by cells 
infected with control RV and wild-type lamin A have a round/ovoid appearance and are aligned in 
a bead-like fashion. Similarly lamin A-N456I and R541P does not seem to cause drastic changes in 
nuclear morphology in myotubes. In contrast, abnormal myonuclear positioning is evident in 
presence of lamin A-R25P and R249W which suggests that there are different mechanisms involved 









Figure 5.7 Quantification of Differentiation index and Fusion index in C2C12 cells expressing different lamin 
A mutants. (A) Representative images showing infected C2C12 cells after 48hrs in differentiation medium. A 
significant proportion of cells have fused into large multinucleated myotubes expressing myosin heavy chain. (B) 
Average Differentiation index (%) representing the proportion of nuclei in MyHC positive cells. (C) Average fusion 
index (%) representing the proportion of nuclei in multinucleated (≥2 nuclei) myotubes. Values represent average 
indices obtained from 4 independent experiments, error bars represent the S.E.M.; A total of at least 2800 cells (in 2 
field of views) were counted for each replicate;  n.s. not significant when compared to wild-type lamin A infected cells 




Figure 5.8 Morphological abnormalities are evident in myonuclei of C2C12 cells infected with lamin A-R25P 
and R249W. Representative selection of pictures showing infected C2C12 cells after 48hrs in differentiation medium. 
White arrowheads indicate nuclei where morphological abnormalities are evident in presence of lamin A-R25P and 
R249W. In presence of control RV, lamin A-wt, N456I and R541P, myonuclei generally have a round appearance 
and are arranged in a bead-like fashion.  
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The arrangement of nuclei is irregular with a less well defined boundary between individual nuclei 
and some of the nuclei show signs of deformation. It is likely that these abnormal myonuclei are 
characterised by mislocalisation of lamin B and therefore more susceptible to physical damage 
which would support the ‘mechanical stress’ hypothesis. However, lamin A and lamin B staining is 
not available for these cells because the antibodies used at the time the experiments were conducted 
(lamin A/C N18 and Lamin B M20, both goat polyclonal Abs from Santa Cruz) highly cross 
reacted with a sarcomeric protein, interfering with nuclear staining. 
5.3.5 Myogenic commitment is also increased in satellite cells in presence of lamin 
A-N456I 
Myogenic commitment was also assayed in primary mouse satellite cells cultured on single 
myofibres (Collins and Zammit, 2009; Zammit et al., 2004). This model allows the analysis of 
satellite cells in their niche as they activate, enter cell cycle and commit to differentiation. Quiescent 
satellite cells express Pax7, and induce MyoD as they activate. Satellite cells first co-express 
myogenic markers Pax7 and MyoD while proliferating and later diverge where some down-regulate 
MyoD and enter quiescence (self-renewal) while others commit to differentiation and start to 
express myogenin (Zammit et al., 2004; Zammit et al., 2006b). In contrast to C2C12 cells which are 
polyploid cells which express very low levels of the satellite cell marker Pax7, primary satellite cells 
provide a much better and physiologically relevant system to study lamin mutations. 
To test the effects of lamin A variants on the myogenic commitment in satellite cells, single 
myofibres were isolated from hind limbs of adult wild-type C57BL/6 mice using standard 
procedures, entailing careful dissection of extensor digitorum longus (EDL), digestion in 
collagenase and gentle trituration to separate myofibres (Collins and Zammit, 2009; Rosenblatt et 
al., 1995). Single floating myofibres were incubated in growth medium for 72 hours (Fig. 5.9A). 
During the isolation process, satellite cells present underneath the basal lamina are activated. 
Medium used to culture single fibres is enriched with growth factors, pushing satellite cells to 
proliferate before spontaneously committing to differentiation by inducing the expression of 
myogenin. To analyse myogenin expression in presence of mutant lamin A, satellite cells were 
infected using retroviral particles after 24 hours in culture and further cultured for another 48 
hours. After 72 hours in culture (48 hours post infection, p.i.) the myofibres with their associated 
satellite cells still attached were fixed and co-immunostained for eGFP and myogenin (Fig. 5.9B). 
The results show that there was some variation in the total number of GFP positive cells/myofibre 
48hrs post infection (Fig. 5.9C). This could be due to infection efficiency or loss of satellite cells 
during the staining procedure. Importantly, no significant difference was found when fibres 
exposed to wt-lamin A are compared to the number of GFP positive cells on fibres exposed to 







Figure 5.9 Satellite cell commitment to differentiation is increased in the presence of lamin A-N456I (A) 
Schematic representation of the single fibre model. Myofibres were isolated from EDL muscle of adult C57BL/6 mice 
and the satellite cells infected in a floating culture. (B) Myogenin expression (red) in infected wild-type satellite cells 
(green) in single EDL fibre cultures. The insert shows two infected satellite cells that are positive for myogenin. (C) 
Quantification of the number of eGFP positive cells per myofibre. Open circles represent the average of each of the 
three independent mice. (D) Quantification of the proportion of eGFP positive infected cells that co-expressed 
myogenin. For the statistical analysis, samples were compared to wild-type lamin A infected satellite cells; for each 
construct a total of at least 30 myofibres were analysed in three independent mice; * p<0.05, ** p<0.01 using a 




The proportion of myogenin positive (committed) satellite cells infected with control RV was 
69.0%. Interestingly, introducing wild-type lamin A significantly reduced the number of myogenin 
positive cells by 5.8%. The number of myogenin positive cells infected with lamin A-R25P and 
R249W is 68.7% and 68.3% respectively. This is similar to proportions found with control RV and 
slightly higher compared to wild-type lamin A infected cells. Introduction of lamin A-N456I 
resulted in the largest increase of myogenin positive cells (+10.1%, p=0.014) when compared to 
wild-type lamin A. In contrast, lamin A-R541P resulted in the largest although non-significant 
decrease (-10.2%, p=0.17) of myogenin positive cells when compared to wild-type lamin A (Fig. 
5.9D).  
5.3.6 Lamin A-N456I and R541P induce nuclear abnormalities in myotubes but do 
not result obvious effect on the differentiation capacity of primary lmna-null 
myoblasts  
Examination of satellite cells on isolated myofibres is an excellent model to study the early events 
of satellite cell activation, proliferation and commitment to differentiation. However, a drawback of 
the single fibre culture is the short time fibres can be kept alive. Three to four days after isolation, 
fibres hypercontract and can not be analysed. Further, satellite cells do not fuse on the fibre which 
makes it difficult to analyse later stages of differentiation.   
To overcome these issues, fibres are plated on matrigel, a substrate containing a mixture of 
extracellular matrix components such as laminin and collagen, which supports the growth of 
satellite cells which migrate off the myofibre  (Rosenblatt et al., 1995). These plated satellite cells 
have been removed from the satellite cell niche and are therefore referred to as satellite cell derived 
myoblasts or primary myoblasts. In serum rich medium supplemented with fibroblast growth factor 
(FGF), primary myoblasts are maintained in a proliferative state. Upon serum withdrawal, cells exit 
cell cycle, express myogenin and start to fuse to form multinucleated myotubes, very similar to 
C2C12 myoblasts used above.   
My results show that the effects of lamin A variants on myogenic commitment in wild-type satellite 
cells is very minimal and somewhat variable. One reason could be that mouse cells are less sensitive 
to mutations in the lmna gene. This has been shown in knock-in mouse models with dominant 
LMNA mutations such as N195K (Mounkes et al., 2005) and H222P (Arimura et al., 2005) which 
require homozygous expression of the mutant lamin to elicit a phenotype. 
To induce a stronger phenotype I have expressed mutant lamin variants in lmna-null satellite cell 
derived myoblasts which mimicks a homozygous state. Unfortunately, myofibres from lmna-null 
mice do not survive long enough in culture for infection studies so I used the plated satellite cell 
model. Satellite cells are difficult to obtain in large numbers, especially from lmna-null mice. I have 
therefore only chosen the two mutations that showed the strongest change in the single fibre 
culture, lamin A-N456I and R541P. Lmna-null primary myoblasts infected with control RV and 
wild-type lamin A served as a control. 
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Immunostaining confirmed the lack of lamin A/C expression in lmna-null myoblasts infected with 
the control RV while cells infected with wild-type lamin A are labelled by the lamin A/C antibody 
(Fig. 5.10A). Futher, all single cells express the satellite cell marker Pax7 confirming their identity as 
shown in figure 5.10B. Interestingly, the lamin A/C antibody used here (mouse monoclonal 131C3, 
Abcam) did not pick up the mutant forms of lamin which could be due to epitope masking. 
Degradation of the mutant protein is unlikely, as other cells infected with the RV vector express 
moderate levels of mutant protein shown by western blot (Fig. 4.1). Further, satellite cell derived 
myoblasts have robust eGFP expression which is driven by the IRES in the lamin A-IRES-eGFP 
construct, confirming the presence and active translation of the mRNA. 
When infected lmna-null primary myoblasts were differentiated for 48hrs and immunostained for 
myosin heavy chain, no obvious defects in differentiation were found. Cells infected with control 
RV, wild-type lamin A as well as the two mutant lamin A constructs (lamin A-N456I and R541P) 
formed large myotubes (Fig. 5.10C). 
Lmna-null fibroblasts are characterised by abnormal nuclear morphology and mislocalisation of 
lamin B (Fig. 6.6, and (Sullivan et al., 1999)). However, proliferating lmna-null satellite cell derived 
myoblasts did not show abnormalities in nuclear morphology. Furthermore, lamin B1 localisation 
was normal in lmna-null cells, which was unexpected (indicated by yellow arrowheads in Fig. 5.11A). 
Interestingly, nuclear herneations together with aberrant lamin B1 localisation were evident in 
nuclei of differentiated myotubes (indicated by white arrowheads in Fig. 5.11A). In contrast, nuclear 
abnormalities were not found in wild-type lamin A infected myoblasts or myonuclei in 
differentiated myotubes (Fig. 5.11B). 
Single, proliferating cells infected with lamin A-N456I and R541P also did not show any evidence 
of nuclear abnormalities (Fig. 5.11B and C). However, nuclei in myotubes demonstrate obvious 
nuclear abnormalities including herneations, and mislocalisation of lamin B1. Whether these 
mutations also induce similar nuclear alterations in differentiated wild-type satellite cells remains to 
be determined.  
Taken together, results obtained in lmna-null satellite cell-derived myoblasts suggests that mutant 
lamin A variants (N456I and R541P) do not affect the differentiation potential. Furthermore 
nuclear alterations are only induced after the formation of myotubes which might result in an 











Figure 5.10 Expression of mutant lamin A variants in lmna-null satellite cell derived myoblasts does not 
affect their differentiation potential. (A) Lmna-null cells (left panel as well as non-infected cells (yellow arrow) lack 
lamin A/C expression while cells infected with wild-type lamin A (white arrow) are labelled by the lamin A/C antibody. 
(B) Both infected and non-infected single cells (yellow arrowhead) but not myotubes (white arrowhead) express the 
satellite cell marker Pax7. (C) Lmna-null satellite cell derived myoblasts infected with mutant lamin A, 48 hours after 





Figure 5.11 Lamin B1 is mislocalised in nuclei of differentiated myotubes but not in proliferating myoblast of 
lmna-null control cells and cells expressing lamin A-N456I and R541P. Pictures show infected lmna-null satellite 
cell derived myoblasts infected with control RV (A), lamin A-wt (B), N456I (C) and R541P (D) immunostained for 
eGFP (marking infected cells expressing the transgene) and lamin B1 (abcam). Single cells with no obvious 
abnormalities in morphology or lamin B1 localisation are indicated by yellow arrowheads. Nuclei in myotubes show 
marked herneations and lamin B1 mislocalisation (indicated by white arrowheads) while myonuclei of lamin A-wt 




In this chapter I set out to test the effects of four mutant lamin A variants (lamin A-R25P, R249W, 
N456I and R541P) on proliferation and differentiation of myogenic cells. Patients with these 
mutations suffer from a skeletal muscle phenotype, being diagnosed with EDMD (table 4.1). 
Satellite cells are essential for adult muscle homeostasis and repair and defective satellite cell 
function could potentially contribute to the pathology of EDMD (Gnocchi et al., 2008; Morgan 
and Zammit, 2010). 
To find out if a dysfunctional muscle stem cell pool does indeed contribute to the skeletal muscle 
phenotype in EDMD and other skeletal muscle laminopathies, it is crucial to pinpoint what aspect 
of cell function is affected. To address this question, I have overexpressed mutant lamin variants in 
primary mouse satellite cells and C2C12 myoblasts. EDMD is a rare disease thus it is difficult to 
obtain patient myoblasts for functional studies. However the four chosen mutations (like almost all 
LMNA mutations) are autosomal dominant and expression of dominant lamin mutants in wild-
type myogenic cells is an accepted approach (Favreau et al., 2004; Hakelien et al., 2008; Ostlund et 
al., 2001). Usually transfection is used to express mutant lamin A protein in cell culture. However 
transfection efficiencies are generally low in myoblasts and clonal selection of stable cell lines can 
lead to a bias in the analysis (Favreau et al., 2004). I have instead chosen to use a retroviral 
expression system because it results in moderate protein expression level across a large proportion 
of cells (>98% in C2C12 cells). Furthermore, no epitope tag, which could potentially interfere with 
lamin function, was used. Mutant lamin A protein was expressed using a bicistronic vector and 
infected cells were identified by eGFP expression via an IRES sequence.  
As described in chapter 4, lamin A-R25P and R249W, located in the head and central rod domain 
of A-type lamins respectively, result in severe nuclear deformations as well as mislocalisation of 
lamin B. Interestingly, these cells also demonstrate a reduced colony growth when seeded at low 
density (Fig. 5.1A). There is evidence that lamin B provides a matrix for spindle assembly during M-
phase (Tsai et al., 2006). Abnormalities in the interaction of lamin A and B caused by mutant lamin 
A could therefore affect cell cycle progression. The cell cycle however was not affected in these 
cells infected with lamin A-R25P and R249W when analysed by multiple techniques including BrdU 
incorporation, flow cytometry to analyse cell cycle progression and Western blot to test for 
abnormal expression/phosphorylation of cell cycle regulators shown to interact with lamin A. The 
discrepancy seen between colony growth and cell cycle could still be due to delayed cell cycle entry 
upon seeding or prolonged cell cycle maintaining the proportion of G1, S and G2/M cells. EDMD 
patient fibroblasts with LMNA mutations display reduced cell spreading and delayed Erk1/2 
phosphorylation upon seeding (Emerson et al., 2009).  
In cells analysed in this study, Erk1/2 and phospho-Erk1/2 levels were not obviously different 
between the samples and when compared to wild-type lamin A. However, the cells analysed were a 
heterogeneous population of proliferating asynchronous C2C12 cells potentially masking an effect 
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on Erk phosphorylation. Synchronisation of cells, which can be achieved by either serum starvation 
(Emerson et al., 2009), or a combination of drugs that block mitosis (nocodazole) and/or S-phase 
progression (thymidine) (Dechat et al., 1998), and subsequent induction of the cells, may lead to a 
more conclusive result. 
Cells infected with lamin A-R25P and R249W also stained negative for senescence associated (SA) 
β-galactisodase, ruling this out as a contribution to cell-cycle exit. However, I did not test for 
molecular markers of apoptosis which might influence the number of cells/colony as has in fact 
been shown in C2C12 cells expressing the EDMD mutation p.R453W (Favreau et al., 2004). 
Although apoptotic nuclei were not observed in C2C12 expressing any of the mutant lamin A 
variants. Cells infected with lamin A-N456I and R541P did not display a phenotype in colony 
growth, S-Phase or other parts of the cell cycle. However, these mutants result in lamin A-foci 
within the nucleus in more than 20% of all cells (Fig. 4.4). Nucleoplasmic lamin A positive foci 
could potentially immobilise Lap2α affecting cell cycle in a pRb dependent manner (Markiewicz et 
al., 2002; Pekovic et al., 2007). I therefore tested if mutant lamin A affects localisation and 
expression levels of Lap2α. However, abnormal Lap2α localisation such as nuclear aggregates was 
not evident in cells infected with lamin A-N456I and R541P and altered expression levels were not 
detected by Western blot (data not shown). 
If defective satellite cells are involved in the pathology of EDMD, but do not affect myoblasts 
proliferation, myogenic differentiation must be affected. I therefore also studied the effects of all 
four lamin A mutations on myogenic commitment and differentiation in C2C12 cells and primary 
satellite cells. The results show that the missense mutation p.N456I increases myogenic 
commitment in C2C12 cells and to a greater extent in satellite cells. In later stages of myogenic 
progression, this trend towards enhanced differentiation was still evident but not statistically 
significant (p=0.085). Interestingly, increased myogenic differentiation was also found in presence 
of miR-100, which is specifically upregulated in LMNA-associated muscular dystrophy patients 
(Sylvius et al., 2011). 
In general, relatively little information is available on the effects of mutant lamin A on myogenic 
differentiation but other results published so far, lead to the general conclusion that LMNA 
mutations reduce the myogenic differentiation potential when expressed in cell lines (Favreau et al., 
2004; Markiewicz et al., 2005), or in human myoblasts (Kandert et al., 2009). However, the lack of 
data might be evidence in itself, in that the majority of LMNA mutations might not have an effect 
on myogenic differentiation. Myoblasts used for overexpression studies are generally derived from 
mouse, which could be less sensitive to mutations in the lmna gene. This has been shown in knock-
in mouse models with dominant LMNA mutations such as N195K (Mounkes et al., 2005) and 
H222P (Arimura et al., 2005) which require homozygous expression of the mutant lamin to elicit a 
phenotype. However, even when mutations associated with changes in myogenic commitment 
(p.N456I and p.R541P) are expressed in lmna-null cells, which mimics a homozygous state, no 
obvious phenotype is observed (Fig. 5.10). 
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A closer inspection of lamin B1 localisation however reveals a striking difference: proliferating, 
primary lmna-null myoblasts have no overt phenotype while differentiated, multinucleated 
myotubes show abnormal nuclear morphology and mislocalisation of lamin B1. Importantly, both 
mutations, which had no effect on lamin B localisation in proliferating C2C12 cells, showed similar 
abnormalities. In contrast, myonuclei in wild-type lamin A infected cells are normal. The absence of 
a nuclear phenotype in primary myoblasts could be related to the fact that they are more stem cell 
like as compared to C2C12 cells. Embryonic stem cells do not express A-type lamins 
(Constantinescu et al., 2006) and induced pluripotent cells from HGPS fibroblasts have been 
shown to lose nuclear abnormalities which is related to a loss in A-type lamins (Liu et al., 2011; 
Zhang et al., 2011). However, satellite cells in their niche are positive for lamin A/C (Gnocchi et al., 
2009; Morgan and Zammit, 2010) and primary myoblasts do express lamin A and C at equal levels 
(Frock et al., 2006). Why lmna-null primary myoblasts are less affected by mutant lamin A protein 
remains to be determined, however, primary myoblasts and C2C12 cells seem to be affected 
differently by LMNA mutations which is an important point to consider in future studies and data 
interpretation. 
One point to note is that all LMNA missense mutations associated with a reduced myogenic 
potential of myoblasts (p.R453W (Favreau et al., 2004), W520S (Markiewicz et al., 2005) and R545C 
(Kandert et al., 2009)), including p.R541P used in this study, are located in the Ig-fold domain, and 
likely to disrupt the structure based on my analysis in chapter 3, although different underlying 
mechanisms have been suggested such as Erk signalling (Favreau et al., 2008), epigenetic defects 
(Hakelien et al., 2008), Lap2α/pRb misregulation (Markiewicz et al., 2005) as well as proteasome 
inhibition (Kandert et al., 2009). In contrast, the second mutation used here (p.N456I, associated 
with increased myogenic commitment), is located on a loop, and results in a moderate (polar to 
non-polar) amino acid change. Together this provides evidence that these mutations affect the 
lamin A structure as well as myoblast function in different ways, which could be related to lamin 
interacting proteins.  
The missense mutation in the head domain (p.R25P) and central rod domain (p.R249W) resulted in 
severe nuclear abnormalities in proliferating C2C12 cells but did not affect myogenic commitment 
or differentiation. Interestingly, nuclear defects were also evident in myotubes (Fig. 5.8), supporting 
the ‘mechanical stress’ hypothesis which states that the disease is caused by an increased 
susceptibility of nuclei to physical stress (Worman, 2012). The central rod domain of lamin A 
interacts with nesprins (Mislow et al., 2002; Zhang et al., 2005) and mutations in the lamin A central 
rod domain disrupts its binding to SUN-domain proteins (Haque et al., 2010). Both, SUN-domain 
proteins and nesprins, are main components of the LINC complex, which support the structural 
integrity of the nucleus (Mellad et al., 2011).  Disruption of the LINC complex has been shown to 
induce defects in nuclear morphology (Khatau et al., 2009) and affect the localisation of skeletal 
muscle nuclei as well as strain transmission between the cell and nucleus (Zhang et al., 2010), while 
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mutations in giant nesprins 1 and 2 result in a pathology resembling that of EDMD (Zhang et al., 
2007). 
If mutations in the central rod domain result in a structural instability of the lamin polymer, affect 
protein protein interactions, or both, remains to be determined. Photobleaching experiments of 
fluorescently labeled lamins reveal that most LMNA mutations tested, result in increased protein 
mobility, with the most severe effects seen in mutations in the central rod-domain (Broers et al., 
2005; Gilchrist et al., 2004).  
The result presented here certainly raises the possibility of a contribution of a defective satellite cell 
pool in EDMD pathology. However mutant lamins are likely to act on multiple levels affecting 
structural integrity and chromatin organisation of myonuclei and satellite cells alike. Indeed, 
ultrastructural analysis of muscle from EDMD patients revealed that only approx. 20% of all 
myonuclei display irregular membrane contours (Park et al., 2009). However, more than 90% of all 
myonuclei as well as 50% of all satellite cells have markedly abnormal chromatin organisation 





Here I present data of four different lamin A mutations associated with skeletal muscle dystrophy 
that show no or only minor effects on C2C12 and satellite cell function. Cell infected with lamin A-
R25P and R249W demonstrated a reduced proliferation potential however showed no overt cell 
cycle defects when analysed by the methods used here. Myoblasts infected with lamin A-N456I 
showed increased differentiation potential in early phases of differentiation. 
Muscle satellite cells could still contribute to the pathology of EDMD, however, the result obtained 
in this and the previous chapter suggests that lamins affect muscle in various different ways which 
might not necessarily involve satellite cell function. 
So far, the effects of mutant lamin A variants on myogenesis has only been studied in a handful of 
mutations though. To identify the different mechanisms at work, it will be necessary to isolate 
myoblasts from a large number of EDMD patients and screen them in parallel for common 
phenotypes. Immortalisation of human myoblasts for patients is an encouraging way to produce 
large amounts of material for study (Mamchaoui et al., 2011). Since patient fibroblasts are easier to 
obtain, generation of iPS cells could be an alternative method to study the pathogenic mechanism 
of large number of different LMNA mutations (Liu et al., 2011; Zhang et al., 2011).   
This comparative study will allow to associate nuclear abnormalities commonly seen in cells 
expressing mutant lamin A with ability or inability to form myotubes. Once grouped into several 






Chapter 6  




The vast majority of eukaryotic genes produce primary transcripts (pre-mRNA) that contain introns 
and exons of various numbers and sizes (Lander et al., 2001). To form mature mRNA, the pre-
mRNA undergoes splicing which is a tightly regulated process and crucial for the translation of 
functional proteins. Splicing is carried out in a defined order by the splicing machinery, which 
recognises conserved 5’ and 3’ splice site sequences as well as the branch point adenine, resulting in 
the removal of introns (Cooper et al., 2009). 
Disease causing mutations often affect the splicing mechanism. Out of the 123656 mutations 
published in the human gene mutation database (as of March 2012) 11525 mutations (9.3%) affect 
splicing (Stenson et al., 2009). The outcome of the mutation depends on its location. If the 
consensus 5’ or 3’ splice site is mutated, an intron might be included in the final transcript. If a new 
splice site is created, part on an intron might get included or part of an exon excluded in the mature 
mRNA, leading to insertions, deletions or resulting in a frameshift. Antisense oligonucleotides 
(AONs) can be used to correct faulty splicing and restore expression of the wild-type protein, or to 
generate internally truncated version that can fully/partially restore function (Aartsma-Rus and van 
Ommen, 2007; Hammond and Wood, 2011). 
6.1.1 Potential use of exon skipping in laminopathies 
Laminopathies are a very heterogeneous group of diseases that affect a range of tissues depending 
on the LMNA mutation and the genetic background of the patient. It is therefore very difficult to 
develop general therapies for laminopathies. Currently, treatments that target very specific aspects 
of lamin A processing or signalling are under investigation. Examples of such treatments in mice 
include farnesytranferase inhibitors (FTIs) to treat HGPS (Yang et al., 2006) and ERK inhibitors to 
treat cardiomyopathy (Muchir et al., 2009). As a result these treatments will potentially only cover a 
minority of patients with very specific mutations. 
To target a larger number of patients a more general approach is needed. One such treatment 
would be the use of AONs to eliminate exons harbouring premature translation termination 
codons (PTCs) similar to the example described in figure 6.1B. A prerequisite for this therapy to 
work is that the exon eliminated is redundant and that the resulting protein product with the 
deletion is sufficiently partially functional and non-toxic. If individual LMNA exons are indeed 
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redundant, the removal of a single mutated exon by modulating LMNA splicing through AONs 
could be used as a novel treatment strategy for laminopathies. 
To go one step further exons harbouring missense mutations could also be considered as targets in 
this therapy. Given that the majority of pathogenic LMNA mutations are missense mutations, a 
larger number of patients would potentially benefit. The idea however does sound counter intuitive 
considering that the elimination of an entire exon is to generate a positive effect. However, if the 
pathogenic mutation results in a protein with a gain of function, replacing this protein with an 
inert/partially functional protein could ameliorate the phenotype. It is therefore well worth 
considering exon skipping as a therapeutic intervention for missense and nonsense mutations in 
LMNA. At present, the efficiency of AONs is low, but this should improve with advances in 
technology. Since laminopathies are usually dominant however, then exon skipping will also have 
the negative effect of reducing levels of wild-type protein, so it is important to consider the results 
of this side effect. 
6.1.2 Design and properties of common AON chemistries 
AONs are defined as oligonucleotides that are 8-50 nucleotides in length, that bind to RNA 
through Watson-Crick base pairing and upon binding to RNA, modulate its function (Bennett and 
Swayze, 2010). AONs can be grouped into two categories depending on the mechanism through 
which they act on the RNA target: (a) AONs that bind to the target sequence and modify its 
function without promoting degradation and (b) AONs that do promote degradation of the target 
RNA either through enzymes such as RNAse H or Argonaute 2, or through cleavage mechanisms 
designed into the oligonucleotide. AONs that modulate splicing are part of the former group and 
are designed to form stable dimers with pre-mRNA in the nucleus, and do not induce target 
degradation (Bennett and Swayze, 2010; Muntoni and Wood, 2011). 
The two major challenges in AON therapy are the design of stable oligonucleotides and their 
delivery to a specific target tissue. AONs that mediate splicing have to reach the nucleus without 
being degraded, and unlike siRNA, must not degrade the template they bind to. Several chemical 
modifications are used to achieve these properties. Many AONs carry a neutral charge to aid cell 
penetration and have either backbone modifications, sugar modifications or both (Bennett and 
Swayze, 2010). Commonly used AON chemistries include: (a) Morpholino oligonucleotides, where 
morpholino instead of ribose moieties are linked by an uncharged phosphorodiamidate linkage 
(Corey and Abrams, 2001) (b) Peptide nucleic acids (PNAs) which have a peptide bond in place of 
the sugar phosphate backbone but are still able to form Watson-Crick base pairs with 
complementary DNA and RNA (Egholm et al., 1993; Nielsen et al., 1991) (c) the 2’-O-
methoxyethyl (MOE) ribose modification which induces the 3'-endo (Northern) conformation and is 
thought to increase the affinity to RNA (Teplova et al., 1999) and (d) Locked Nucleic Acid (LNA) 
which have a bridge connecting the 2' oxygen and 4' carbon of the ribose which is “locked” in the 
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3'-endo conformation (Jepsen et al., 2004). All modifications listed above show increased resistance 
against DNA endo- or exonucleases and do not induce RNAse H activity (Bennett and Swayze, 
2010). 
In therapeutic applications, AONs are usually delivered systemically to achieve the best possible 
distribution in the organism. However, tissue uptake is often inefficient and as a result AONs are 
excreted rapidly (Muntoni and Wood, 2011). To overcome this problem and promote tissue uptake 
of AONs, they can be conjugated with arginine rich cell-penetrating peptides (CPPs) such as 
(RXR)4, which results in higher efficacy (Wu et al., 2008; Yin et al., 2008). In some cases AONs 
need to be delivered to specific target tissues such as muscle which can be achieved by using tissue 
specific targeting peptides. The B-peptide for example has been proven excellent to target AONs to 
the heart, while naked oligos fail to do so efficiently (Yin et al., 2009). 
6.1.3 The use of antisense oligonucleotides to modulate splicing  
AONs can be used to modulate splicing in three different ways: (a) correction of a cryptic splice site 
in a disease state (b) exon exclusion and (c) exon inclusion. All three are described briefly below and 
examples for clinical applications for each mechanism are given in the text and in table 6.1. 
 
Table 6.1 Current use of antisense oligonucleotides to modulate splicing (modified from Hammond and Wood 
(2011)) 
Mechanism Disorder Target Mode of action Reference 
Correction of 
active cryptic 















Blocking the recognition of cryptic splice 
sites 
 
Blocking the recognition of cryptic 5’ splice 
site 
 
Blocking the recognition of a cryptic splice 
site which results in the deletion of 50aa in 
exon 11, producing toxic progerin 
(Lacerra et al., 2000)
 
 
(Pros et al., 2009) 
 
 


























Skipping of exon 51 to correct reading 
frame and restore protein expression 
 
skipping of exon 32 removes a PTC and 
restores protein expression  
 
blocking the recognition of a pseudoexon 
(Cirak et al., 2011) 
 
 
(Aartsma-Rus et al., 
2010) 
 







Inclusion of exon 7 to provide same 
function as SMN1 
(Hua et al., 2008) 





6.1.3.1 Correction of active cryptic splice sites 
Cryptic splice sites are potential splice sites, are dormant or used only at low levels in RNA 
processing unless activated by mutation of nearby authentic or advantageous splice sites (Green, 
1986). The first example of how AONs can be used to modulate splicing is the correction of cryptic 
splice sites. In principle, a cryptic splice site recruits the splicing machinery and competes with a 
commonly used splice site. This results in the inclusion of part of an intron or in the exclusion of 
part of an exon, depending on where the new splice site is created (Hammond and Wood, 2011). 
When the created/deleted fragment is in frame with the rest of the transcript, a disease causing 
protein product with an insertion or deletion might be expressed. If the insertion/deletion is out of 
frame, the mRNA is either degraded by nonsense mediated decay (NMD) or results in the 
expression of a truncated protein resulting in disease (Rebbapragada and Lykke-Andersen, 2009). 
AONs are used to mask the cryptic splice site and prevent the binding of splicing factors. As a 
result normal splicing of the gene is restored, with the potential to reduce clinical symptoms of 
disease. The principle of using AONs to target a cryptic splice site is depicted in figure 6.1A.    
One of the first examples where AONs were used to correct a cryptic splice site was to restore 
normal splicing of the β-globin gene. Several mutations are described in intron 2 of the β-globin 
gene typically creating novel splice sites resulting in a loss of haemoglobin (Hb) A. Patients carrying 
such mutations suffer from β-thalassemia which is characterised by severe anaemia and sometimes 
death (Busslinger et al., 1981). AONs were shown to be able to restore normal Hb-A synthesis in 
erythrocytes from thallasemic patients using AON mediated masking of cryptic splice sites (Lacerra 
et al., 2000).  
Of relevance to laminopathies, this strategy was also used to explore the treatment of Hutchinson-
Gilford progeria syndrome (HGPS) with AONs. HGPS is caused by a silent substitution 
(c.1824C>T; p.G608G) which creates a cryptic 5’ donor splice site in LMNA exon 11 and results in 
the expression of a toxic protein product (progerin) that lacks 50 amino acids in the tail domain (see 
section 1.4 for details). Fibroblasts from HGPS patients show severly dysmorphic nuclei, and 
mislocalisation of lamin B and lamin associated proteins as well as reduced levels of HP1α 
(Eriksson et al., 2003; Paradisi et al., 2005; Scaffidi and Misteli, 2005). Using AONs to mask this 
novel splice site was shown to restore normal LMNA splicing and reverse phenotypes seen in 







Figure 6.1 The use of antisense oligonucleotides to modulate splicing. (A) The introduction of a cryptic splice 
can disrupt the open reading frame of the mRNA which leads to nonsense mediated decay and loss of protein 
expression. If the reading frame remains intact, a part of an intron might be included, or a part of an exon removed, 
resulting in the expression of a mutant protein. Antisense oligonucleotides (AONs) are used to mask cryptic splice 
sites and to restore the open reading frame of the mRNA and expression of wild-type protein. (B) A premature 
termination codon (PTC) located in an exon results in nonsense mediated decay of the mRNA. The addition of AONs 
masking splice sites or splice enhancers will result in the exclusion of that exon. Providing that the flanking exons 




6.1.3.2 Exclusion of an exon 
Antisense oligonucleotides are also used to exclude exons (exon skipping) (Aartsma-Rus and van 
Ommen, 2007). The principle of AON mediated exon skipping is described in figure 6.1B. In this 
example a gene with multiple exons has a point mutation in exon 5 which results in a PTC. The 
pre-mRNA gets spliced correctly the transcript however is degraded by nonsense mediated RNA 
degradation (NMD) and no functional protein is produced. The addition of AONs targeting either 
the splice donor or the splice acceptor site or exonic splice enhancer sites would lead to the 
exclusion of that exon and the PTC located in that exon. Providing that the flanking exons form an 
in-frame transcript, then the resulting transcript would be shorter but serves as a template for a 
protein with an internal deletion which is potentially beneficial to the organism.  
An example is the mouse model for Duchenne Muscular Dystrophy (mdx) which lacks dystrophin 
expression due to a PTC in exon 23. AON mediated skipping of exon 23 restores dystrophin 
expression and improves the muscle phenotype (Alter et al., 2006; Dunckley et al., 1998). As a 
result of this and similar work, AON mediated exon skipping is now being tested in clinical trials as 
a potential therapy for Duchenne muscular dystrophy, and is the most promising therapy so far 
(Cirak et al., 2011; Goemans et al., 2011). The vast majority of Duchene patients carry deletion 
mutations within the DMD gene, disrupting the reading frame to generate a PTC resulting in no 
dystrophin expression (www.umd.be/DMD). In human DMD patients, AONs are used to remove 
adjacent out-of-frame exons which allows for the expression of a shorter but partially functional 
dystrophin variant. 
6.1.3.3 Inclusion of an exon 
For some disease interventions AONs are used to include an exon that is typically spliced out. For 
example Spinal Muscular Atrophy (SMA) is caused by a homozygous loss of the survival of motor 
neurons 1 (SMN1) gene. The severity of the disease is modified by SMN protein encoded by the 
paralog SMN2 (Helmken et al., 2003). Although SMN2 is nearly identical to SMN1 there is a C to 
T transition in exon 7 of SMN2 which promotes the exclusion of exon 7 (Lorson et al., 1999). 
However, only full length SMN protein from the SMN2 gene is functional so the severity of the 
SMA disease phenotype is directly correlated with the exclusion of exon 7. An AON therapy that 
leads to the retention of exon 7 in SMN2 could therefore ameliorate the SMA phenotype which 
was confirmed in a mouse model (Hua et al., 2010). Hua Y. and colleagues have used AON 
mediated blocking of an hnRNP A1/A2 intronic splice silencer located in intron 6 to promote the 
retention of exon 7 in the SMN2 transcript. This resulted in the production of functional survival 
of motor neurons 2 protein which could rescue necrosis in the type III mouse model (Hua et al., 






In this chapter I will explore the possibility of using AONs to modulate splicing of the LMNA 
gene to remove mutated exons as a potential therapeutic strategy to treat laminopathies. 
Initially, I will identify LMNA exons that are potential candidates for exon skipping and then I will 
construct lamin A cDNAs to test if this works in practice. 
I hypothesise that the detrimental effects of missense mutations, insertions and deletions located in 
some exons of LMNA can ameliorated by removing the entire exon. Removing such exons would 
eliminate the pathogenic mutation resulting in a shortened but functional protein. If successful this 







6.3.1 Identification of LMNA exon targets for potential therapeutic skipping 
Out of 12 exons that form the A-type lamins, not all can be skipped without consequence for lamin 
function. To select potential target exons I analysed their reading frame and what part of the 
protein they encode (Fig. 6.2). In general, out of frame exons cannot be skipped as they would 
result in a disruption of the reading frame and loss of protein expression. A loss of A-type lamins 
would have severe consequences and has been reported to be lethal in man (Muchir et al., 2003; van 
Engelen et al., 2005). On this basis exons 2, 6 and 7 as well as the first and last exon were not 
considered as targets for exon skipping. 
 
 
Figure 6.2. Exon structure of the LMNA gene. The gene consists of 12 exons, and codes for both lamin A and C. 
Lamin A is alternatively spliced from exon 10 while lamin C stops in exon 10. All exons except exon 2 can be 
removed without affecting the open reading frame. Dotted lines indicate the regions of the peptide encoded by each 
exon. 
 
Exons that encode functional domains important for lamin maturation are further targets which 
should be excluded for exon skipping. One such exon is exon 11 which encodes the second 
proteolytic cleavage site necessary to form mature lamin A (Fig. 1.5). Removing exon 11 therefore 
results in a permanently farnesylated form of lamin A with a deletion similar to that of progerin. 
The deletion of exon 11 has been found in RD patients and is therefore to be avoided at all costs 
(Navarro et al., 2004). Similarly, the removal of exon 9 also results in a permanently farnesylated 
lamin A variant which causes a progeroid phenotype in mice. Lamin A lacking exon 9 most likely 
undergoes a conformational change which masks the second proteolytic cleavage site and inhibits 
the maturation of lamin A. In addition, transcripts lacking exon 9 are less stable which results in a 
reduced lamin A expression while lamin C is not expressed at all (Hernandez et al., 2010; Mounkes 
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et al., 2003). Given the evidence above, exons 9 and 11 were not considered as suitable candidates 
for exon skipping. 
The remaining exons 3, 4, 5, 8 and 10 can be subdivided into two groups: those that are likely to 
interfere with lamin A function (providing less suitable but possible targets for exon skipping) and 
those that are less likely to interfere with lamin function (providing good targets for exon skipping). 
Exons 4, 8 and 10 can be considered as potential targets however all three exons encode for 
important parts of the protein. Exon 4 forms a flexible linker region between coil 1 and 2 (L12) as 
well as coil 2A of the central rod domain. The removal of this region might reduce the flexibility of 
the central rod domain and interfere with filament formation. 
Exon 8 forms part of the Ig-fold domain and given the importance of this domain in protein 
interactions (see Fig. 1.8) it was considered to be an unlikely target for exon skipping. Further, the 
Ig-fold might play an important role in lamin filament assembly. Addition of the Ig-fold motif to 
Xenopus egg extracts before the introduction of chromatin is sufficient to completely inhibit lamin 
polymerisation (Shumaker et al., 2005). 
Exon 10 codes for part of lamin A Ig-fold as well as the tail of lamin C. Removal of exon 10 will 
therefore prevent the expression of lamin C. However, mice expressing only lamin A appear to be 
normal, suggesting lamin C may be redundant (Fong et al., 2006b). Lamin A protein lacking exon 
10 has been described as an alternative splice product of the LMNA gene, and was found in several 
carcinoma cell lines (Machiels et al., 1996). It remains to be determined however, if removal of part 
of the Ig-fold has any detrimental effects on the 3D structure of the Ig-fold and lamin function 
Carcinoma cells expressing lamin A-Δ10 show lamin A aggregates (Machiels et al., 1995; Machiels 
et al., 1996) although others have shown that GFP-tagged lamin A-Δ10 localises normally in CHO 
cells (Broers et al., 1999). Further, a specific role of lamin A-Δ10 in cancer cells can not be ruled out 
as other expression abnormalities of lamins have been associated with certain types of cancer 
(Venables et al., 2001; Willis et al., 2008). 
The two remaining exons (3 and 5) provide the best targets for initial testing for 2 reasons: Firstly 
they both encode for 6 complete heptad repeats in coils 1B and 2B respectively which resembles 
the central rod structure of cytoplasmic IF proteins (Appendix 1, (Herrmann and Aebi, 2004)). As a 
result their removal is not predicted to disrupt α-helical coiled coils. Secondly, deletion of exons 3 
or 5 does not affect any of the linker or hinge regions. Further, Schirmer et al. have shown that 5 
heptads on either end of the lamin B1 central rod domain are sufficient to promote filament 
formation in vitro (Schirmer et al., 2001). 
Patients with mutations in exons 3 or 5 would potentially benefit from an exon skipping therapy. 
Table 6.2 provides a list of mutations that would be targeted by skipping exons 3 and 5, and the 
number of patients recorded for each mutation. In total, 41 mutations (identified in 244 
symptomatic and asymptomatic individuals) have been reported in exons 3 and 5. These are 121 
reported cases (7.8%) in exon 3 and 123 reported cases (7.9%) in exon 5. Out of 193 symptomatic 
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cases (numbers reported in table 6.2), 95 (49.2%) have mutations in exon 3 and 98 (50.8%) have 
mutations in exon 5. 
 
Table 6.2 Summary of mutations reported in LMNA exons 3 and 5 (from www.umd.be/LMNA) 
LMNA Exon 3 LMNA Exon 5 
Mutation Reports Phenotype Mutation Reports Phenotype 
p.L183P 1 DCM-CD p.L271P 3 EDMD 
p.E186K 1 DCM-CD p.S277P 1 EDMD 
p.R189W 1 DCM-CD p.A278T 5 LGMD1B (4), DCM-CD (1) 
p.R189P 1 DCM-CD p.E291K 1 DCM-CD 
p.R190W 28 DCM-CD p.L292P 2 LGMD1B (1), L-CMD (1) 
p.R190Q 4 DCM-CD p.Q294P 2 EDMD 




p.R298C 51 AR-CMT2 (44), 
Cardiac disease (5), 
AR-CMT2/EDMD (2)
p.N195D 
1 EDMD p.D300N 3 WRN (2), 
Progeroid Syndrome 
(1) 
p.N195K* 14 DCM-CD p.D300G 1 Progeroid Syndrome 
p.R196S 1 EDMD p.L302P# 1 L-CMD 
p.E203K 15 DCM-CD p.S303P* 3 LGMD1B (2),  EDMD (1) 
p.E203G 6 DCM-CD p.K311R 1 LGMD1B 
p.E203V 1 DCM-CD p.Q312H 2 LGMD1B (1), DCM-CD (1) 
p.F206L 1 EDMD p.D272AfsX? 2  
p.I210S 1 DCM-CD p.A287LfsX193 1 LGMD1B 
p.R190dup* 1 EDMD p.A287RfsX44 1 DCM-CD 
p.L197_T199del 1 EDMD p.A287VfsX193 1 DCM-CD 
p.K208del 14 LGMD1B p.H289RfsX190 2 LGMD1B 
p.N209TfsX271 3 EDMD p.S303CfsX27 10 LGMD1B (8), 
DCM-CD (2) 
   c.IVS5+1G>T 1 DCM-CD 
 
6.3.2 Isolation of lmna-null and wild-type mouse embryonic fibroblasts 
In this proof of principle study, I used a retroviral expression vector (pMSVC-IRES-eGFP; see 
section 2.2.2) to express various lamin A constructs with deletions and missense mutations in 
lmna+/+ and lmna–/– primary mouse embryonic fibroblasts (pMEFs) (Fig. 6.3). Fibroblasts were 
chosen because they are easy to isolate and maintain in culture, well characterised and relatively flat 








Figure 6.3. Isolation of pMEFs and expression of lamin A variants by retroviral infection. (A) Primary MEFs 
isolated from lmna wild-type, heterozygous and null embryos stained for lamin A/C. Scale bar = 50μm (B) Western 
blot of lmna wild-type, heterozygous and null pMEFs for lamin A and C confirming the genotypes. (C) Constructs 
used in this study were in the same order as depicted in C: full length wild-type lamin A, lamin A with exon 3 deleted 
(lamin A-Δ3) and lamin A with exon 5 deleted (lamin A-Δ5) and separate four full length lamin A constructs with 
mutations in either exon 3 (R190dup or N195K) or exon 5 (S295P or S303P). (D) Western blot of wild-type pMEFs 
infected with retroviruses encoding each of the lamin A constructs to show their successful production. (E) Lmna-null 




The reason to use wild-type and lmna-null cells was twofold. Firstly, the lamin mutations used are 
dominant and should have a negative effect on wild-type cells. If the Δ3 and Δ5 lamin variants 
perform like wild-type protein, they should not affect the contour ratio of nuclei or lamin 
localisation.  
Secondly, lmna-null cells show severe nuclear defects which can be reversed by re-introducing wild-
type lamin A. If lamin A-Δ3 and lamin A-Δ5 act like wild-type lamin A they should also be localised 
correctly and revert the phenotypes observed in lmna-null cells. This is important as exon skipping 
also reduces the level of wild-type protein. Lamin variants with mutations in exons 3 and 5 on the 
other hand are expected to mislocalise and have no positive effect on lmna-null cells. 
Figure 6.3 shows pMEFs isolated from lamin wild-type, heterozygous and null embryos stained for 
lamin A/C as well as well as Western blot results confirming the genotype of the cells used. A 
heterogeneous population of primary cells before passage P4 from 3 different embryos for each 
genotype was used for all experiments. 
The lamin A constructs used in this study are depicted in figure 6.3 and listed below. 
1  Full length human wild-type lamin A (Lamin A-wt) 
2 Lamin A with an internal deletion of 42aa corresponding to exon 3: lamin A-Δ3 
3 Lamin A with an internal deletion of 42aa corresponding to exon 5: lamin A-Δ5 
4 Lamin A-R190dup (duplication mutation in exon 3) 
5 Lamin A-N195K (missense mutations in exon 3) 
5  Lamin A-S295P (missense mutation in exon 5) 
7  Lamin A-S303P (missense mutation in exon 5) 
The constructs were cloned into the pMSCV retroviral construct as described in section 2.2.2 (Fig. 
6.3C) where empty vector expressing eGFP served as a control RV. Western blot analysis of 
infected lmna-null pMEFs showed expression levels typically consistent with those found in wild-
type cells (Fig. 6.3D). These constructs contained lamin A only, so Lamin C is not expressed in 
infected lmna-null cells. 
6.3.3 Lamin A-Δ5, but not lamin A-Δ3 localises correctly to the nuclear envelope 
The first question in this study was whether the different lamin variants localise correctly to the 
nuclear lamina. Since there is no antibody available to discriminate mutant lamins from wild-type 
lamin A, the localisation of mutant lamin A was assessed in lmna-null pMEFs. Cells were infected 
with lamin A-wt, lamin A-Δ3 and lamin A-Δ5 and four days post infection, were stained for eGFP, 
Lamin A/C, LaminB1 and DAPI, and imaged with an LSM5 exciter confocal microscope. Figure 
6.4 shows single confocal sections of 0.8μm thickness, taken at the centre of infected cells. Wild-
type lamin A is shown to be localised at the nuclear lamina and throughout the nucleoplasm as 
expected. In contrast, the lamin A-Δ3 variant which lacks seven complete heptad repeats (42 amino 
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acids) in coil 1B, aggregated abnormally into nucleoplasmic foci. The lamin A-Δ3 expressing cells 
also show prominent lamin A capping, indicated by a yellow arrowhead in figure 6.4. To my 
surprise, lamin A-Δ5 which also lacks seven complete heptad repeats (42 amino acids), but in coil 
2B, had a similar localisation pattern to wild-type lamin A, being evenly localised to the nuclear 
lamina and nucleoplasm. Notably, lamin B1 mislocalisation found in lmna-null cells seems to be 
normalised by both wild-type lamin A and lamin A-Δ5. In marked contrast, lamin A-Δ3 however 
did not have a positive effect on lamin B1 localisation which is comparable to non-infected lmna-
null cells (indicated by white arrowheads in Fig. 6.4).  
   
 
 
Figure 6.4 Representative confocal images of lmna-null pMEFs infected with wild-type lamin A, lamin A-Δ3 
and lamin A-Δ5. Micrographs show a single confocal section through the centre of infected cells co-immunostained 
for eGFP (green), DAPI (blue), lamin A (red) and lamin B1 (grey). DAPI, lamin A and lamin B1 co-immunostaining 
are shown individually to the right of the merged picture. The yellow arrowhead indicates lamin A capping. White 
arrowhead indicates lamin B1 mislocalisation in non-infected (eGFP negative) cells. White arrows indicate a lamin A-





To examine if there was a temporal effect, i.e. if the abnormal distribution and localisation of lamin 
B1 resolved over time, lmna-null pMEFs infected with lamin A-wt, lamin A-Δ3 and lamin A-Δ5 
were also analysed 5 and 6 days post infection in two separate experiments. The results were very 
consistent and obvious, in that lamin A-Δ3 aggregates became even more prominent while lamin A-
Δ5 remained evenly distributed throughout the nucleus in the majority of cells (data not quantified). 
To quantify the number of nuclei that show normal lamin A localisation, lower magnification 
photographs of infected lmna-null pMEFs co-immunostained for eGFP, lamin A and DAPI were 
taken on a conventional fluorescence microscope 3-4 days post infection (Fig. 6.5A). Here I have 
included lamin A variants with missense mutations/duplications in exons 3 and 5. The results show 
that an average of 69.9% of all cells infected with wild-type lamin A demonstrated even lamin A 
distribution throughout the nuclei. In contrast, lamin A variants with a single amino acid 
change/insertion lack the potential to localise correctly in lmna-null pMEFs. Only 12.2% of cells 
infected with lamin A-R190dup, 20.2% of cells infected with lamin A-N195K, 12.9% of cells 
infected with lamin A-S295P and 12.7% of cells infected with lamin A-S303P demonstrate even 
distribution of lamin A comparable to that in the majority of wild-type lamin A infected cells. All 
other nuclei in these cells demonstrated abnormalities such as lamin A aggregation, capping and 
honeycomb structures (Fig. 6.5). Cells infected with lamin A-Δ3 also showed a large proportion of 
nuclei with lamin A abnormalities and only 8.5% with normal lamin A localisation, which is 
significantly less than wild-type infected cells. This stands in stark contrast to lamin A-Δ5 which 
was distributed normally in 66.5% of all infected pMEF nuclei. Importantly this was statistically 
similar to wild-type lamin A (p=0.17) and significantly different to the number of nuclei in cells 
expressing missense mutations in exon 5 with normal distribution of lamin A-S295P (p=0.0012) or 














   
 
 
Figure 6.5 Quantification of lmna-null pMEFs expressing mutant lamin A species with normal lamin A 
localisation. (A) Representative micrographs of nuclei from cells infected with retroviral constructs encoding 
different lamin A variants immunostained for lamin A. (B) Quantification of cells that show even distribution of lamin A 
throughout the nucleus and around the nuclear rim, as seen in wild-type cells and lmna-null pMEFs expressing native 
lamin A. Open circles represent values obtained from 3 independent lmna-null pMEF lines; A total of at least 230 





6.3.4 Lamin A-Δ5, but not Δ3, can rescue the nuclear abnormalities of lmna-null 
pMEFs 
Nuclei of lmna-null pMEFs show a range of abnormalities including severe deformations, lamin B 
capping and loss of emerin localisation from the nuclear rim (Sullivan et al., 1999). Re-introduction 
of wild-type lamin A into lmna-null cells can reverse these abnormalities as shown here and by 
others (Sullivan et al., 1999). The question was whether lamin variants containing mutations which 
allow for normal protein localisation can also rescue nuclear structural abnormalities, as expression 
of wild-type lamin A does. 
The first effect analysed was the reversal of lamin B1 capping and honeycomb structures by lamin 
A variants. In lmna-null pMEFs infected with the control RV 71.8% of all nuclei show 
abnormalities in lamin B1 localisation (Fig. 6.6A and B). In presence of wild-type lamin A, this 
proportion of cells was reduced to 22.0%, which was statistically significant. 
The introduction of lamin A variants with mutations in exons 3 and 5 did not have a positive effect 
on the abnormal lamin B1 localisation in lmna-null pMEFs, which remained in a large proportion of 
cells infected with lamin A-R190dup (78.1%), lamin A-N195K (75.8%), lamin A-S295P (80.0%) 
and lamin A-S303P (81.7%). Similarly, in the presence of the lamin A-Δ3 variant, lamin B1 
localisation did not improve abnormalities in the majority (76.2%) of cells. In comparison, cells 
infected with lamin A-Δ5 exhibited a reduction of the proportion of cells with mislocalised lamin 
B1 to 34.9% which was a significant improvement over control RV infected cells (p=0.0026). When 
this figure is statistically compared to the effect of lamin A variants with point mutations in exon 5 
on lamin B1 localisation, a significant improvement had been achieved over the cells infected with 
lamin A-S295P (p=0.00094) or lamin A-S303P (p=0.0026) (Fig. 6.6B). 
In addition to lamin B1 mislocalisation, lmna-null pMEFs also show a large variety of nuclear 
deformations. The roundness of a nucleus can be numerically represented by its contour ratio (CR). 
The contour ratio depends on the cross-sectional area and circumference and is 1 for a perfect 
circle. Normal ovoid nuclei have a contour ratio of approx. 0.9, and the figure decreases the more 
severe the deformations are. Cartoons of a range of nuclei with different degrees of deformations 
and their corresponding contour ratio is shown in figure 6.6C to give an indication of how the 
contour ratio equates to nuclear deformation. Lmna-null pMEFs infected with the control RV had 
an average contour ratio of 0.81 which corresponds to slight deformations. Reintroduction of wild-
type lamin A lead to a significant increase of the contour ratio to 0.92 corresponding to a normal 
ovoid shape, since wild-type pMEFs have an average contour ratio of 0.92 (Fig. 6.9D). Thus, 
introduction of wild-type lamin A in lmna-null cells can completely rescue the abnormal nuclear 






Figure 6.6 Rescue of nuclear abnormalities and lamin B1 localisation in lmna-null pMEFs by lamin A-Δ5. (A) 
Representative micrographs of nuclei from cells infected with retroviral constructs encoding different lamin A variants 
immunostained for lamin B1. Lamin B capping (white arrowhead) and honeycomb structures (yellow arrowhead) are 
indicated. (B) Quantification of cells that show even distribution of lamin B1 throughout the nucleus and around the 
nuclear rim. A total of at least 280 nuclei were analysed for each sample. (C) Range of nuclei found and their 
respective contour ratio. A perfect circle has a contour ratio of 1.0. If the deformations are more severe, the contour 
ratio is lower. (D) Average contour ratio of nuclei from a total of at least 85 infected cells. (E) Quantification of nuclear 
cross-sectional area of infected cells. Open circles represent values obtained from 3 independent lmna-null pMEF 
lines; * p<0.05; ** p<0.01, n.s. not significant compared to control-RV infected cells. 
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While wild-type lamin A can rescue nuclear deformations in lmna-null cells, two of the four 
pathogenic lamin A mutations tested (R190dup and S303P) resulted in a more severe phenotype: 
lamin A-R190dup and lamin A-S303P significantly reduced the contour ratio to 0.75 and 0.76 
respectively. Lamin A-N195K (CR 0.82) and lamin A-S295P (CR 0.78) do not have an effect on 
nuclear morphology when compared to control RV infected cells. Similarly,  lamin A-Δ3 (CR 0.75) 
did not have an effect on nuclear morphology. Importantly, lamin A-Δ5 (CR 0.89) significantly 
increased the contour ratio of lmna-null cells which is consistent with results above (Fig. 6.6C).  
As shown in figure 4.2, the introduction of lamin A-R25P and lamin A-R249W results in a decrease 
of the contour ratio together with an increase in the nuclear cross-sectional area in C2C12 cells. To 
find out if this is also the case in lmna-null pMEFs, the nuclear cross sectional area of cells infected 
with lamin mutants was calculated and compared to that of control RV infected cells. However as 
shown in figure 6.6E mutant lamin A variants do not have a significant effect on nuclear cross 
section area. Only the introduction of wild-type lamin A results in a notable but non-significant 
decrease (p=0.11). The reduction of the nuclear cross sectional area of lamin A-Δ3 infected 
compared to control RV infected cells while only small, was statistically significant. 
After establishing that the introduction of lamin A-Δ5 results in a significant improvement of the 
phenotype of lmna-null pMEFs, the question remained whether or not this improvement is 
statistically similar when compared to the effects of the introduction of wild-type lamin A. The 
proportion of nuclei with abnormal lamin B1 is slightly larger in lamin A-Δ5 infected cells (34.9%) 
compared to lamin A-wt infected cells (22.0%). However, when the proportion of nuclei with 
normal lamin B1 localisation in lamin A-wt and lamin A-Δ5 infected cells are directly compared to 
each other, there is no significant difference between them (p=0.054) (Fig. 6.6B). Similarily, the 
average contour ratio of lamin A-Δ5 infected pMEFs (0.89) was not significantly different to that of 
lamin A-Δ5 infected cells (p=0.21) (Fig. 6.6E). These results suggest that lamin A-Δ5 performs very 
similar to wild-type lamin A in terms of the positive effects on lmna-null pMEFs. 
The last parameter analysed was the effect wild-type and mutant lamin A variants have on emerin 
localisation in lmna-null pMEFs. As shown in figure 6.7A lmna-null cells do stain for emerin, but the 
majority of the protein is not localised to the nuclear membrane, but was instead mislocalised into 
the cytoplasm, probably the ER (Vaughan et al., 2001). A similar staining pattern was found when 
introducing lamin A-Δ3. In contrast, expression of wild-type lamin A and lamin A-Δ5 lead to a 
redistribution of emerin to the nuclear membrane, as observed in wild-type cells.  
The change in emerin localisation was visualised by measuring the fluorescence intensity of the 
emerin staining across the infected cell and plotting it together with DAPI (Fig. 6.7B and C). To be 
able to compare different cells with each other, 2.5μm sections through the mid-region of the cells 
were taken using a confocal microscope. 
In both cases (lamin A-wt and lamin A-Δ5) the fluorescence intensity of emerin across an infected 
cell was directly compared with that of a neighbouring non-infected cell. The DAPI intensity was 
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used to demarcate the nucleus. The result presented in figure 6.7B (lamin A-wt) and 6.7C (lamin A-
Δ5) clearly shows that non infected cells exhibit strong emerin immunostaining beyond the nucleus, 
which most likely represents emerin localised to the membranes of the endoplasmic reticulum. In 
cells infected with lamin A-wt and lamin A-Δ5 however, the vast majority of emerin staining was 
confined to the boundaries of the nucleus. This result supports the fact that lamin A-Δ5 acts in a 




Figure 6.7 Normalisation of emerin localisation in lmna-null pMEFs expressing lamin A-Δ5. (A) Representative 
micrographs of Infected lmna-null pMEFs co-immuno stained for emerin (red) eGFP (green) and DAPI (blue). The 
emerin is shown in b/w below the composite. Infected cells are indicated by a white arrowhead. (B) Confocal images 
and fluorescence intensity plots of emerin immunostaining across a lamin A-wt infected and non-infected cell for 
direct comparison. The fluorescence intensity plot shows emerin (red) as well as DAPI (blue) demarcate the 
boundaries of the nucleus. The white arrowhead indicates the infected (eGFP positive) cell. (C) The same analysis 
as in B was performed, however, the marked cell (eGFP positive) is infected with lamin A-Δ5. 
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6.3.5 Deletion of exon 5 does not have a deleterious effect on wild-type pMEFs   
Next to having positive effects on lmna-null pMEFs which I have shown in the results above, lamin 
A-Δ5 must not have a negative effect on wild-type cells to qualify as a suitable candidate for exon 
skipping therapy, since most human laminopathies arise from dominant LMNA mutations. To test 
this pMEFs from three different wild-type embryos were isolated and used to analyse three 
parameters in presence of lamin A variants: lamin A/C localisation, lamin B1 localisation and 
abnormalities in nuclear morphology. 
Wild-type pMEFs used here show slight abnormalities in lamin A/C localisation in an average of 
23.1% of all nuclei (Fig. 6.8). Overexpression of wild-type lamin A did not have a negative effect on 
lamin A/C localisation. Cells with abnormal lamin A/C localisation were mainly affected by 
honeycomb structures as indicated by white arrowheads in figure 6.8A. Nuclear aggregations of 
lamin A such as those seen in lmna-null pMEFs were not observed in wild-type pMEFs in the 
presence of any of the lamin A variants. 
 
 
Figure 6.8 Effects of lamin A variants on lamin A/C localisation in wild-type pMEFs. (A) Representative 
micrographs of infected wild-type pMEFs stained for lamin A/C. White arrowheads indicate honeycomb structures 
found in lamin A-Δ3 infected cells and in cells expressing lamin A variants with mutations in exons 3 and 5 (lamin A-
R190dup, N195K, S295P and S303P). (B) Quantification of nuclei with abnormalities in lamin A/C localisation. Bar 
chart shows average percentage of nuclei showing abnormal lamin A/C localisation (mainly honeycomb structures). 
Open circles represent means of 3 independent experiments; A total of at least 210 nuclei were analysed for each 




The proportion of nuclei affected varied between different constructs. Three mutations (R190dup, 
S295P and S303P) significantly increased the number of nuclei with abnormal lamin A/C 
localisation when compared to cells infected with lamin A-wt. The presence of lamin A-R190dup 
increased the proportion of nuclei with abnormal lamin A/C localisation to 40.8%. The expression 
of lamin A-N195K however did not have an effect on lamin A/C localisation. Lamin A-S295P and 
lamin A-S303P affected lamin A/C localisation in 46.5% and 50.3% respectively. In the presence of 
lamin A-Δ3, 66.7% of all nuclei showed mislocalisation of lamin A/C. Crucially, overexpression of 
lamin A-Δ5 had no effect on lamin A/C localisation when compared to wild-type lamin A infected 
cells (Fig. 6.8B). The proportion of affected nuclei in cells expressing lamin A species with point 
mutations in exon 5 was significantly larger when directly compared to pMEFs expressing lamin A-
Δ5, which is in line with my previous observations (Fig. 6.5). 
Next, I quantified the proportion of nuclei that display abnormal lamin B1 localisation in the 
presence of the different lamin A variants and calculated their contour ratio. In general two 
different types of abnormalities were seen: lamin B1 capping (indicated by a white arrowhead in 
Fig. 6.9A) and lamin B1 honeycomb structures (indicated by a yellow arrowhead in Fig. 6.9A). Cells 
that display such lamin B1 abnormalities in the presence of lamin A wild-type and mutants were 
quantified, shown in figure 6.9B. On average 5.6% of wild-type pMEFs infected with control RV 
and 6.5% of cells infected with lamin A-wt present mislocalisation of lamin B1. Their average 
contour ratio was 0.92 (control RV) and 0.93 (lamin A-wt). Interestingly, the proportion of nuclei 
with abnormal lamin B1 localisation is elevated by 9.8% in the presence of lamin A-N195K this 
however is not significantly different when compared to lamin A-wt infected cells (p=0.054). 
Similarly the contour ratio is slightly but not significantly reduced in presence of lamin A-N195K. 
Mutant lamin A variants lamin A-R190dup, S295P and S303P as well as lamin A-Δ3 significantly 
increased the proportion of nuclei with abnormal lamin B1 localisation (Fig. 6.9B). They also 
resulted in a significant reduction of the contour ratio when compared to lamin A-wt infected cells 
(Fig. 6.9D). 
Importantly, lamin A-Δ5 significantly affects neither lamin B1 localisation nor the contour ratio. 
Both the proportion of cells with abnormal lamin B1 localisation (8.0%) as well as the average 
contour ratio (0.91) are comparable to that of wild-type lamin A infected cells (Fig. 6.9D). However 
when directly compared to lamin A-S295P and S303P, the percentage of cells with mislocalised 
lamin B1 was significantly less and the contour ratio was significantly greater in lamin A-Δ5 infected 
cells (Fig. 6.9D. This provides yet more evidence that exon 5 is largely dispensable in the lamin A 
protein for the structural functions of lamin A. 
Lastly, none of the lamin A variants significantly affected the average nuclear cross sectional area 






Figure 6.9 Lamin A-Δ5 does not have deleterious effects on lamin B1 localisation and nuclear morphology in 
wild-type pMEFs. (A) Representative micrographs of nuclei from cells infected with retroviral constructs encoding 
different lamin A variants immunostained for lamin B1. The white arrowhead indicates lamin B1 capping, the yellow 
arrowhead indicates honeycomb structures. (B) Quantification of cells that show abnormalities in lamin B1 
localisation such as capping and honeycomb structures. A total of at least 260 nuclei were analysed per sample. (C) 
Range of nuclei found and their respective contour ratio. A perfect circle has a contour ratio of 1.0. If the 
deformations are more severe, the contour ratio is lower. (D) Average contour ratio of nuclei from a total of at least 
50 infected cells for each sample. (E) Quantification of nuclear cross-sectional area of infected cells. Open circles 
represent values obtained from 3 independent lmna-null pMEF lines; * p<0.05; ** p<0.01, n.s. not significant 
compared to lamin A-wt infected cells. 
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The data presented here is summarised in figure 6.10 and shows that reintroduction of wild-type 
lamin A and lamin A-Δ5 localise correctly and can normalise aberrant nuclear morphology and 
abnormal lamin B1 and emerin localisation in lmna-null pMEFs. All other lamin A variants 
mislocalise and do not improve lamin B1 localisation. In addition lamin A-R190dup and S303P 
significantly decrease the contour ratio of lmna-null pMEFs (Fig. 6.10A). Overexpression of wild-
type lamin A, lamin A-Δ5 as well as lamin A-N195K do not have a negative effect on wild-type 
pMEFs. In contrast, lamin A-Δ3, R190dup, S295P and S303P negatively affect nuclear morphology, 
lamin A/C localisation and lamin B1 localisation in wild-type pMEFs (Fig. 6.10B).  
 
 
Figure 6.10 Summary of effects of wild-type lamin A, lamin A variants with point/duplication mutations in 
exon 3 and 5, and lamin A lacking either exon 3 or 5 on lmna-null and wild-type pMEFs. (A) Effect of lamin A 
variants on nuclear morphology and lamin B1 distribution of lmna-null pMEFs. (B) Effect of lamin A variants on wild-




In this chapter I set out to explore the potential of exon skipping as a therapy for laminopathies by 
targeting and eliminating exons containing pathogenic mutations with AONs. An initial analysis of 
the 12 LMNA exons revealed exons 3 and 5 as potential candidates, since both exons encode 6 full 
heptad repeats and are not predicted to severely interfere with lamin A function. To put this theory 
to the test, lamin A constructs each lacking the 42 amino acids encoded by exons 3 or 5, as well as 
constructs with pathogenic mutations in exons 3 and 5 were created and expressed in lmna-null and 
wild-type pMEFs. To qualify as a potential target for exon skipping, the candidates had to meet 
three criteria: (1) they must be able to rescue abnormalities found in lmna-null pMEFs, (2) they must 
not have a negative effect on wild-type pMEFs and (3) they must improve nuclear morphology 
over lamin A proteins carrying pathogenic mutations in the corresponding exon. 
Lamin A-Δ5 turned out to exceed all expectations by fulfilling the three criteria. Even better, when 
it was compared to lamin A-wt, no significant difference was found. Unexpectedly Lamin A-Δ3 
failed in all criteria despite its structural similarity to lamin A-Δ5. 
The main difference between lamin A-Δ3 and lamin A-Δ5 is the location of the 6 heptad deletion. 
Notably, the central rod domain of cytoplasmic IF proteins, also lacks 6 heptad repeats in coil 1B 
(appendix 1). Moteiro and colleagues aimed to investigate the biological role these additional 6 
heptad repeats play in nuclear IF proteins. By swapping various domains between lamin A and the 
small neurofilament subunit (NF-L) they demonstrated that the lamin A head domain, 6 additional 
heptad repeats, an NLS and the CAAX motif are necessary to target NF-L to the nuclear 
membrane (Monteiro et al., 1994). They also showed that the insertion of 6 additional heptad 
repeats into NF-L affected its co-assembly with vimentin, which led them to speculate that the 42 
amino acid insertion in lamins prevent them from association with cytoplasmic IF proteins 
(Monteiro et al., 1994). In a follow up paper, Mical and Monteiro (1998) investigated the role of 
domains specific to nuclear IF proteins in nuclear localisation. They showed that removal of 6 
heptad repeats from lamin B does not affect lamin B localisation to the nucleus. However, the 
removal of 6 heptads together with the CAAX motif from lamin B (producing a protein which is 
similar to lamin A-Δ3) results in the accumulation of nuclear aggregates (Mical and Monteiro, 
1998). Interestingly, the deletion was also in coil 1B, which indicates that the additional 6 heptad 
repeats in coil 1B are not necessary for nuclear targeting of lamins but for their proper nuclear 
localisation. 
Why lamin A-Δ5 does not result in a similar phenotype remains speculative. Importantly, the amino 
acid composition and therefore the net charge of amino acids in exons 3 and 5 is not the same. 
Exon 5 harbours 7 positively charged and 10 negatively charged amino acids (net charge -3) while 
exon 5 harbours 6 positively charged but only 5 negatively charged amino acids (net charge +1). 
The reason for the discrepancy seen between lamin A-Δ3 and lamin A-Δ5 could therefore be that 
the loss of three negatives charges has a stronger effect on homodimerisation and/or 
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heterodimerisation or the interaction with lamin A binding partners. One potential candidate is the 
lamin interacting protein SUN1 which binds to lamin A (Haque et al., 2006). Deletion of the lamin 
A binding site in SUN1 has been shown to disrupt lamin A/C localisation in mouse fibroblasts 
(Haque et al., 2010). Other lamin A interaction partners specifically bind to either coil 1 or coil 2. 
These are c-Fos, which interacts with coil 1 (Ivorra et al., 2006), and pRb, Erk1/2 and MOK2 
which interact with coil 2 (Dreuillet et al., 2002; Gonzalez et al., 2008; Ozaki et al., 1994) (section 
1.3.5, Fig. 1.8). However, all of these are involved in cell signalling and therefore unlikely to 
interfere with lamin filament organisation or localisation. 
Another explanation for the observed phenotype could be that lamin A-Δ3 requires a longer time 
to localise properly. However my results show the opposite; the latest time point analysed was 6 
days post infection and instead of normalised lamin A-Δ3 localisation, I found more prominent 
nuclear aggregates in lmna-null pMEFs. Reduced proliferation as a cause for mislocalised lamin A-
Δ3 can be ruled out for two reasons. Firstly, cells continue to proliferate in presence of lamin A-Δ3 
as confirmed by GFP positive mitotic bodies observed 4 and 6 days post infection. Secondly, it has 
been shown that the reversal of nuclear abnormalities in HGPS fibroblasts (by introducing wild-
type lamin A) does not require the cells to go through a round of cell cycle (Scaffidi and Misteli, 
2005). This is likely explained by the dynamic property of the nuclear lamina which has been 
demonstrated by FRAP experiments (Gilchrist et al., 2004). 
Interestingly, lamin A-N195K is the only pathogenic mutation in this study that did not have a 
negative effect on wild-type pMEFs on the parameters studied. To date 14 patients have been 
reported with this mutation (www.umd.be/LMNA) all of which suffer from DCM-CD. The other 
three mutations used here, p.R190dup, p.S295P and p.S303P (reported in chapter 3) all result in a 
skeletal muscle phenotype.  
One of the reasons the p.N195K mutation was chosen for this study was that there is a knock in 
mouse model available which would have been very useful to test the effects of skipping exon 3 in 
vivo (Mounkes et al., 2005). Homozygous mutants develop cardiomyopathy and die at the age of 3 
months. Homozygous mutant pMEFs show severe nuclear deformationas as well as abnormal 
lamin A, lamin B, emerin and Nup 154 localisation. Heterozygous mice have a normal life 
expectancy and show no overt phenotype (Mounkes et al., 2005). This is similar to my results 
obtained by overexpression of lamin A-N195K in lmna-null and wild-type pMEFs. As mentioned in 
chapter 3, lamin mutations that result in cardiomyopathy are thought to be loss-of-function while 
other missense mutations might result in a toxic gain-of-function (Davies et al., 2011). My results 
support this theory, although functional assays (migration, proliferation, differentiation, etc.) are still 
outstanding, but I would predict that a negative effect of lamin A-N195K on wild-type cells, if any, 
would be negligible. If cardiomyopathy is indeed caused by loss of function protein, it would be 
meaningless to delete exon 3 which, in the best case scenario, also results in a loss of function. 
Unfortunately, the majority of mutations in exon 3 result in cardiomyopathy (table 3.2) wich makes 
exon 3 a poor target for exon skipping therapy. 
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Although LMNA exon 3 does not seem to be a good candidate for exon skipping therapy, exon 5 
remains a valid candidate. Several different types of mutations are located in exon 5 and therefore 
valid targets for exon skipping therapy. These include 6 nonsense mutations, 13 autosomal 
dominant missense mutations, 1 autosomal recessive missense mutation and 1 frameshift mutation 
(table 6.1). AON mediated exon skipping is currently in use to restore the expression of a shorter, 
partially functional dystrophin protein by targeting nonsense mutations in Duchenne MD patients 
(Cirak et al., 2011; Goemans et al., 2011). On a first glance it might seem sensible to apply the same 
logic to the lamin protein. However, as mentioned above and in chapter 3, non-functional or 
partially functional lamin A protein is thought to result in cardiomyopathy (Davies et al., 2011). So 
in order to target nonsense mutations which tend to cause cardiomyopathy, the lamin A-Δ5 must 
have similar functional properties to wild-type lamin A in order to restore the phenotype. 
For laminopathies it might therefore be easier to target lamin variants with mutations resulting in a 
toxic gain-of-function as has been shown for progerin (Scaffidi and Misteli, 2005). Replacing such 
toxic proteins with a partially functional product might not necessarily eliminate the phenotype 
completely, but it could alleviate it. One example of a mutation in exon 5 is p.L302P which has 
been reported to cause congenital muscular dystrophy (CMD) in one patient (Quijano-Roy et al., 
2008). If this mutation results in a toxic gain of function (which remains to be determined), 
removing part of it would shift the phenotype from CMD to a milder, more manageable phenotype 
such as cardiomyopathy. Although the patient might still suffer from cardiac disease, this would 
mean a dramatic increase the quality of life for this patient.  
AON therapies have a range of limitations, however, the two major hurdles to overcome before 
AON mediated exon skipping can be considered for laminopathies are improving skipping 
efficiency, and tissue targeting (Muntoni and Wood, 2011). 
The vast majority of missense mutations in LMNA are autsosomal dominant 
(www.umd.be/LMNA). In order to eliminate a phenotype virtually all lamin A protein needs to be 
skipped. Although to my knowledge the amount of mutant lamin protein necessary to cause a 
phenotype remains to be determined and likely depends on the type of mutation. With current 
technology, exon skipping is nowhere near 100% efficient (Yin et al., 2009) and as a result, cells 
would co-express six different A-type lamin variants: wild-type lamin A and C, mutated lamin A 
and C and skipped lamin A and C, which at the end might be more detrimental to the cell than 
higher levels of mutant and wild-type lamins A and C. It is important to note that in this study I 
only used lamin A-Δ5. Whether lamin C-Δ5 performs in a similar way or is any different to lamin 
A-Δ5 or wild-type lamin C remains to be determined.  
One of the mutations in exon 5 (p.R298C), results in AR-CMT2 (De Sandre-Giovannoli et al., 
2002). In this case partial skipping might be enough to ameliorate the phenotype provided that 
lamin A-Δ5 performs like wild-type lamin A. AR-CMT2 is a peripheral neuropathy characterised by 
improper myelination and demyelination assumed to originate from defective Schwann cells, which 
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leads to axonal loss (Bernard et al., 2006). Hence, Schwann cells in peripheral nerve fibres must be 
targeted in order to treat the phenotype. 
This brings me to the second limitation of AON therapies, tissue specific targeting of AONs. 
AONs to target the dmd gene were initially delivered by intra-muscular injections in mdx-mice to 
achieve high concentrations and efficient skipping (Mann et al., 2001). It was later found that 
systemic delivery of AONs also induces exon skipping in muscle of mdx-mice (Alter et al., 2006). 
However, skeletal muscle in mdx-mice and DMD patients undergoes constant regeneration and is 
inflamed which is thought to make it leaky which promotes AON uptake (Aartsma-Rus and van 
Ommen, 2007). Skeletal muscle in EDMD patients on the other hand is characterised by mild 
dystrophic features and does not show overt signs of regeneration (Mittelbronn et al., 2006; Sewry 
et al., 2001), and so, may not take up AON as easily. Furthermore the primary cause of death in 
EDMD is cardiac failure and to target heart tissue with AONs is still an issue using current 
technology.  
For laminopathies in general, the tissue that is needed to be targeted depends on the mutation and 
what phenotype it causes. The disease phenotype of AR-CMT is restricted to peripheral nerve 
fibres (De Sandre-Giovannoli et al., 2002). Targeting Schwann cells associated with peripheral 
neurons with AONs, might therefore be sufficient. However, currently there is no technology 
available to do so (M.J. Wood, personal communication). So far advances have been made in other 
directions. For example it was shown that oligos conjugated with arginine rich targeting peptides 
such as the B-peptide are very efficient in penetrating cardiomyocytes (Yin et al., 2009). Hence 
there may be yet unidentified peptides to specifically target the peripheral nervous system. Other 
AON delivery methods such as targeted exosomes are being developed to help cross the blood-
brain barrier and deliver AONs to the central nervous system, providing novel ways to deliver 






In conclusion LMNA exon 5 presents a strong candidate for exon skipping therapy. However 
before therapies like that can be considered, the properties of lamin A-Δ5 have to be studied in 
great detail. Some aspects such as the effects of lamin A-Δ5 on cell cycle and migration are 
currently under investigation and additional experiments addressing the effects of lamin-Δ5 on 
myogenic differentiation are already planned. It will also be necessary to examine the effects of 
lamin C-Δ5 on nuclear morphology and cell function. Once these assays have been completed 
successfully, effective target sites for AONs to skip exon 5 have to be identified. AONs can then be 
used to skip exon 5 from A-type lamins in wild-type cells, and patient fibroblasts before moving on 
to testing the idea in mouse models. In summary many challenges lie ahead and with a bit of luck 
and hard work it will not be too long before AON targeting and delivery technology is advanced 
enough for it to be considered a serious therapy for certain laminopathies caused by mutations 





Chapter 7  
General Discussion and Conclusion 
 
Laminopathies are a heterogeneous group of diseases associated with defects in A-type lamins. A-
type lamins are encoded by the LMNA gene and together with B-type lamins, form the nuclear 
lamina, a proteinaceous network underlying the inner nuclear membrane (Worman et al., 2009). To 
date more than 300 different mutations have been described in the LMNA gene, which are 
associated with more than 16 different phenotypes (www.umd.be/LMNA). The majority of 
mutations affect striated muscle and result in Emery-Dreifuss muscular dystrophy or 
cardiomyopathy while others affect other systems and cause lipodystrophy, neuropathy or 
premature ageing syndromes.  
According to the current understanding, mutations can be classified according to the protein 
modification/functional consequence they result in, which are (1) mutations resulting in protein 
degradation (2) mutations affecting lamin A filament formation (3) mutations affecting the 
function/integrity of lamin A interacting proteins (4) mutations resulting in the accumulation of 
farnesylated lamin A (Worman and Bonne, 2007). Furthermore, three non-mutually exclusive 
hypotheses for pathogenic mechanisms underlying the disease phenotypes have been proposed: the 
‘mechanical stress’ hypothesis and the ‘gene expression’ hypothesis and the ‘cell 
proliferation/differentiation’ hypothesis (Broers et al., 2006; Worman, 2012). 
Some of these changes are very consistent with the resulting phenotype. Nonsense mutations for 
example, mainly result in cardiomyopathy (Benedetti et al., 2007; Bonne et al., 2000) which was 
statistically confirmed in this study. However, the underlying pathogenic mechanism is unclear 
although different mechanisms including haploinsufficiency (Davies et al., 2011; Wolf et al., 2008), 
as well as interference of truncated lamin protein with structure or function (Geiger et al., 2008; 
Renou et al., 2008) have been proposed. Furthermore, missense mutations also result in 
cardiomyopathy in man (www.umd.be/LMNA) and mouse (Arimura et al., 2005; Mounkes et al., 
2005) for which other mechanism might be involved such as mis-regulation of Erk1/2 signalling 
(Muchir et al., 2007a; Muchir et al., 2009; Wu et al., 2011).  
Premature ageing syndromes are primarily caused by the accumulation of farnesylated lamin A, 
either through mutations in LMNA (De Sandre-Giovannoli et al., 2003; Eriksson et al., 2003) or in 
the lamin A processing enzyme ZMPSTE24 (Navarro et al., 2004). In contrast, skeletal muscle 
disorders (and to a lesser extent lipodystrophy disorders and peripheral neuropathy), are caused by 
mutations distributed throughout the protein with no evident genotype-phenotype correlation, 
although hot-spots have been described for each disorder (reviewed in Scharner et al. (2010)) 
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Correlations between lamin structure and disease 
Nuclear lamins are type V intermediate filament proteins and characterised by a tripartite domain 
organisation formed by the central rod domain flanked by a short N-terminal head domain and a 
larger C-terminal tail domain (Fuchs and Weber, 1994). The central rod domain is characterised by 
seven amino acid repeat sequences or heptad repeats (a-b-c-d-e-f-g)n are characteristic for α-helices 
engaging in coiled coil formation (Herrmann and Aebi, 2004; Mason and Arndt, 2004; Parry et al., 
2008). Mutations of hydrophobic residues (a and d) have been shown to disrupt the dimers and 
promote tetramer formation in the GCN4 leucine zipper (Harbury et al., 1993), however, similar 
data for lamins not available. Given that a successful lamin dimerisation via an α-helical coiled-coil 
interaction is central to higher filament formation, I tested if key residues in the stabilisation of the 
α-helical coiled-coil are affected at an increased frequency in laminopathies. 
Interestingly, heptad positions a and d did not show a higher incidence in pathogenic mutations 
when compared to other residues (see section 3.3.6). However, lamin dimers form higher filament 
structures and other residues might be equally likely to destabilise the filament network. Evidence 
for this hypothesis is provided by photobleaching experiments of fluorescently labelled lamins 
which reveals that most LMNA mutations tested, result in increased protein mobility, with the 
most severe effects seen in mutations in the central rod-domain (Broers et al., 2005; Gilchrist et al., 
2004). Importantly, destabilisation of the nuclear lamina can also be caused by the Ig-fold, which 
has been shown in Xenopus, were the addition of Ig-fold domains prevented the formation of the 
lamina (Shumaker et al., 2005). The solving of the structure of the Ig-like fold (Krimm et al., 2002) 
has allowed detailed 3D mapping of the localisation of mutations, revealing associations not clear 
when analysing the linear sequence. For example mutations associated with a skeletal muscle 
phenotype are often located on buried residues and likely to destabilise the Ig-fold (first proposed 
by (Krimm et al., 2002) and supported by my results). 
Disruption of lamin A protein interactions (but not necessarily the lamin A structure) has also been 
suggested to be the underlying mechanism for some laminopathies. For example, a large number of 
FPLD2 patients carry the missense mutation p.R482W which results in the elimination of a positive 
charge on the surface of the Ig-fold (Krimm et al., 2002). Interestingly, there are other mutations on 
the Ig-fold (p.R439C, p.G485D and K486N) which also cause lipodystrophy. By mapping these 
mutations on the 3D structure of the Ig-fold, I found that they cluster in the same region and cause 
a similar change in surface charge distribution which strongly suggests that a specific protein 
interaction is disrupted, providing a unifying theory as to why they all cause the same phenotype 
(see section 3.3.7). Sterol regulatory element binding protein 1 (SREBP1), a transcription factor 
involved in adipocyte differentiation, has been shown to bind to the Ig-fold domain, and this 
interaction was disrupted in presence of p.R482W, p.G485D and p.K486N, suggesting an 
involvement of SREBP1 in FPLD pathology (Lloyd et al., 2002). 
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Interestingly, I have uncovered a second cluster of mutations in the Ig-fold that presents a striking 
correlation with premature ageing phenotypes. All patients are homozygous or compound 
heterozygous for missense mutations that primarily result in a loss of positive charge in that cluster 
(Agarwal et al., 2008; Cao and Hegele, 2003; Kosho et al., 2007; Novelli et al., 2002; Plasilova et al., 
2004; Simha et al., 2003; Verstraeten et al., 2006; Youn et al., 2010). A mechanism, similar to that 
proposed for skeletal muscle disorders involving the destabilisation of the structure by these 
mutations is unlikely, because heterozygous relatives (of homozygous patients) are unaffected. 
Furthermore, accumulation of farnesylated lamin A, a typical feature in HGPS, was not evident 
(Agarwal et al., 2008; Verstraeten et al., 2006). It is therefore likely that specific protein interactions 
are affected by the mutations in this cluster. The Ig-fold interacts with a large array of binding 
partners involved in cell signalling (SREBP1, MAN1) and cell cycle control (Lap2α, cyclin D3, 
PCNA) (see section 1.3.5) although which of these might be affected, remains speculation. 
Some evidence suggests that the underlying mechanism is similar to that of FPLD patients. Firstly, 
one mutation in this cluster (p.T528M) which is non-pathogenic when inherited alone, has been 
shown to modify the lipodystrophy phenotype from FPLD2 to FPLD1 when inherited together 
with p.S583L (Savage et al., 2004). Secondly, all patients had prominent lipodystrophy. Thus, the 
explanation may simply be that the mutation is present in a homozygous state, and that the 
premature ageing phenotype seen in these patients is a severe/modified form of lipodystrophy. 
Homozygous FPLD or EDMD mutations located in the Ig-fold, would provide further insight into 
this question, however, such mutations have not been described yet. 
Taken together my observations suggest that the modification of specific protein interactions, 
possibly via the alterations in the charge domains in specific regions of the Ig-fold, is very likely to 
contribute to the pathology of different phenotypes. 
It is important to note that the genetic background can have a big impact on the phenotypic 
outcome of a mutation which is shown by a large inter- and intra-familial variability seen in 
laminopathies (Bonne et al., 2000; Granger et al., 2011; Mercuri et al., 2005). 6.2% of all patients 
reported in the UMD database have overlapping phenotypes or other phenotypes and many 
mutations have been shown to result in different phenotypes in different patients 
(www.umd.be/LMNA). In some laminopathy patients with mutations in LMNA modifying 
mutations in desmin or emerin were found to increase the severity of the phenotype (Muntoni et 
al., 2006). Recently, linkage analysis identified a modifier locus on chromosome 2 (harbouring the 
genes for desmin and myosin light chain) which is strongly associated with the age of onset of 
LMNA related myopathy (Granger et al., 2011). Mutations in nesprin and SUN-domain proteins 
have also been implicated in modulating the disease severity of EDMD patients (Taranum et al., 
2012). In one case, a modifying mutation has been shown to reduce the severity of the phenotype. 
The patient had a homozygous null mutation in ZMPSTE24 together with a heterozygous 
nonsense mutation in LMNA, which lead to the reduction of the amount of farnesylated lamin A, 
resulting in HGPS rather than RD, which is postnatally lethal (Denecke et al., 2006). 
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In other cases, patients inherit two non-pathogenic LMNA SNPs (one from each parent) which 
together result in disease (Verstraeten et al., 2006). Significantly, about 60% of patients diagnosed 
with EDMD have no mutations in EMD, LMNA or FHL1 which suggests that there are additional 
genes involved in EDMD pathology (Gueneau et al., 2009; Meinke et al., 2011). Thus, EDMD 
likely has a broad spectrum of genetic causes, which will be revealed once whole genome 
sequencing becomes cheaper and more widely available. It will be interesting to learn if new targets 
also affect the nuclear lamina or act via different mechanisms. 
Mutant lamin A variants affect nuclear morphology in myogenic cells 
To investigate the pathogenic mechanism in detail, mutant lamin variants have to be studied in vitro 
and in vivo. Currently there are several mouse models available for LMNA associated muscular 
dystrophies including lmna-null mice, which are characterised by postnatal growth retardation, 
muscular dystrophy and progressive DCM also present features of other laminopathies (Nikolova 
et al., 2004; Sullivan et al., 1999). Other models available which resemble the human phenotype are 
knock-in mice which carry dominant lmna mutations p.N195K which causes cardiomyopathy 
(Mounkes et al., 2005) and p.H222P which results in skeletal muscle disease and cardiomyopathy 
(Arimura et al., 2005). Importantly, all the knock-in mouse models only show a phenotype when 
homozygous for the mutant alleles, in contrast with the heterozygous state in patients 
(www.umd.be/LMNA). 
To explore pathogenic mechanisms induced by different LMNA mutations requires the analysis of 
many more mutations in parallel. However, to produce knock-in mouse models is a lengthy and 
expensive process, and because laminopathies are rare diseases, patient samples are generally 
difficult to obtain. The majority of pathogenic LMNA mutations are dominant, so in order to study 
their effects on cellular function overexpression studies have become widely accepted in wild-type 
cells with native lamin A/C (Favreau et al., 2004; Hakelien et al., 2008; Ostlund et al., 2001). I have 
chosen a retroviral expression system which, in comparison to transfection, yields moderate 
transgene expression with very high efficiencies even in primary cells. 
Given the important function of satellite cells in muscle homeostasis and repair, they are a good 
candidate to explain the late onset and slow progression of the EDMD pathology (Morgan and 
Zammit, 2010). However, it is still unknown if dysfunctional satellite cells or myoblasts contribute 
to the pathology of EDMD (Gnocchi et al., 2008) although there is some evidence that mutant 
lamin protein interferes with myoblast function when expressed in mouse myoblasts (Favreau et al., 
2004; Markiewicz et al., 2005), or in human myoblasts (Kandert et al., 2009). Mutant lamin A 
protein can functionally affect myoblasts at multiple stages during myogenic progression including, 
proliferation, cell cycle exit and differentiation.  
I tested the effects of four EDMD mutations on nuclear morphology in myoblasts and found that 
two mutations (p.R25P and p.R249W) result in abnormal nuclear morphology and mislocalisation 
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of lamin B, which is similar to phenotypes induced by many other mutations exogenously expressed 
in various cell types (Ostlund et al., 2001; Raharjo et al., 2001), or found in human patient cells 
(Muchir et al., 2004). However, if and more importantly how these defects are associated with 
myoblast function is not well understood. 
Interestingly, none of the four mutations affected proliferation or cell cycle in C2C12 cells. 
Additionally, no drastic defect in myogenic differentiation was observed, even when they were 
expressed in lmna-null primary myoblasts, to simulate a homozygous state. The only significant 
change noted was a slight increase in myogenic commitment of wild type satellite cells and C2C12 
cells in presence of lamin A-N456I.  
Importantly, all four mutations shared one common feature which was that they all induced nuclear 
alterations in fused myotubes from C2C12 myoblasts (p.R25P and p.R249W) or satellite cell 
derived myoblasts (p.N456I and p.R541P). Since some differences were observed in C2C12 cells 
they are likely to act via different mechanisms but which results in a similar phenotype in myotubes.    
Lamin A interacts with SUN-domain proteins (Haque et al., 2006; Haque et al., 2010) and nesprins 
(Mislow et al., 2002; Zhang et al., 2005), main components of the LINC complex, which support 
the structural integrity of the nucleus (Mellad et al., 2011).  Disruption of the LINC complex has 
been shown to induce defects in nuclear morphology (Khatau et al., 2009) and affect the 
localisation of skeletal muscle nuclei as well as strain transmission between the cell and nucleus 
(Zhang et al., 2010), while mutations in giant nesprins 1 and 2 result in a pathology resembling that 
of EDMD (Zhang et al., 2007). In addition, accumulation of Sun1 has recently been implicated in 
the pathology of lmna-null mice which also suffer from muscle dystrophy (Gnocchi et al., 2011; 
Sullivan et al., 1999). Furthermore, nuclei of cells with LMNA mutations have been shown to be 
less resistant to mechanical stress (J. Lammerding, personal communication) and ultrastructural 
analysis of myonuclei from EDMD patients reveals damage to the nuclear membrane and and 
leakage of chromatin into the cytoplasm (Fidzianska and Hausmanowa-Petrusewicz, 2003; 
Fidzianska et al., 1998; Park et al., 2009). 
Taken together, this observations reinforce the hypothesis that mutations in LMNA or lamin 
interacting proteins result in a dysfunctional A-type lamin filament network, which might not be as 
flexible as a nuclear lamina composed of only wild-type forms and/or less able to integrate into the 
nuclear lamina, leading to increase susceptibility of nuclei to mechanical stress and the EDMD 
pathology. A contribution of dysfunctional satellite cells to the disease pathology (Gnocchi et al., 
2008) seems unlikely for the four mutations tested in this study. However, they remain a potential 
contributing factor to EDMD pathology, at least for a subset of mutations (Favreau et al., 2004; 





AON-mediated exon skipping of LMNA exon 5 as a potential therapy for particular 
laminopathies 
With extensive research on the role of lamins and lamin interacting proteins in health and disease, 
therapies for laminopathies start to emerge. Treatments could either target the consequence of 
lamin A mutations indirectly, or defects in lamin A protein directly. Indirect treatment for example 
target the Erk1/2 pathway which has been shown to be active in emd-null and lmnaH222P/H222P knock-
in mice which both suffer from cardiac phenotypes resembling cardiomyopathy (Muchir et al., 
2007a; Muchir et al., 2007b). Administration of Erk1/2 inhibitors, prior to the onset of heart 
disease has been shown to prevent left ventricular dilatation and deterioration of cardiac 
contractility (Muchir et al., 2009; Wu et al., 2011). While, modulating the Erk1/2 pathway has been 
shown to work in mice, human trials have not. Another example is an adipo-cytokine replacement 
therapy (such as leptin) which has been shown to improve, common metabolic phenotypes found 
in FPLD2 patients such as hyperglycemia, triglyceridaemia and hepatic steatosis (Park et al., 2007). 
An example for a treatment which targets defective lamin A protein directly are farnesyltransferase 
inhibitors (FTIs) (Fong et al., 2006a; Toth et al., 2005; Yang et al., 2005; Yang et al., 2006). The 
expression of farnesylated lamin A (either caused by a cryptic splice site resulting in internal 
deletions in lamin A or mutations in the lamin A processing enzyme Zmpste24) is associated with 
nuclear blebs, defective DNA repair and premature senescence on a cellular level which translated 
into premature ageing phenotypes (Goldman et al., 2004; Liu et al., 2005; Moulson et al., 2007; 
Scaffidi and Misteli, 2005). Reducing the amount of farnesylated lamin A by applying FTIs has been 
shown to ameliorate nuclear phenotypes in mouse and human fibroblasts (Toth et al., 2005; Yang 
et al., 2005) as well as disease phenotypes including mean survival in animals (Fong et al., 2006a; 
Yang et al., 2006). Clinical trials for the use of FTIs in progeria are currently in progress under the 
supervision of Mark Kieran, at the Children's Hospital Boston, USA. Similarly, the restoration of 
full length lamin A expression (and restoration of normal lamina processing) by masking the cryptic 
splice site with antisense oligonucleotides (AONs), can revert abnormal nuclear phenotypes in 
HGPS cells, and has great potential for therapy (Scaffidi and Misteli, 2005). 
Antisense oligonucleotides are also used to restore the reading frame by removing out of frame 
exons, or exons with premature termination codons (PTCs) (Aartsma-Rus and van Ommen, 2007; 
Hammond and Wood, 2011). An example where this is clinically relevant is in Duchenne muscular 
dystrophy, which is caused by loss of dystrophin expression due to nonsense mutations (Hoffman 
et al., 1987; Muntoni et al., 2003). By removing the mutated exon, expression of a shorter but 
partially functional dystrophin is restored (Dunckley et al., 1998) which has been shown to 
ameliorate the phenotype in the mdx-mouse (Alter et al., 2006; Mann et al., 2001). This led to the 
development of therapies for DMD which are now in clinical trial (Cirak et al., 2011; Goemans et 
al., 2011). The same rational can be applied to mutations in LMNA. If the deletion of a specific 
exon results in a protein product that is functionally superior to the mutated protein, it is a valid 
target for exon skipping therapy.  
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I have analysed the exon structure of LMNA and found that exons 3 and 5 both encode for 42 
amino acids (6 complete heptad repeats) of the central rod domain of lamin A (appendix 1). The 
rod domains of cytoplasmic intermediate filament proteins also lack 6 heptad repeats (Weber et al., 
1989) which led to the hypothesis that LMNA exons 3 and 5 are potentially redundant. In a series 
of proof-of-principle experiments I confirmed that deletion of exon 5, but not exon 3, results in a 
partially functional protein which can rescue nuclear abnormalities in lmna-null primary mouse 
embryonic fibroblasts, such as lamin B1 and emerin localisation as well as nuclear morphology. 
The reason why exon 5 is apparently redundant, but not exon 3, is unexpected given the similar 
structural change their removal results in, and remains to be determined. One explanation might be 
that they differentially affect lamin binding proteins. Functional studies such as their effects on cell 
proliferation and differentiation are still outstanding. Since exon skipping therapy would also result 
in lamin C-Δ5, it needs to be included in these studies, preferably in combination with lamin A-Δ5. 
The next step in the process is to design antisense oligonucleotides, test their skipping efficiency 
and try to rescue nuclear abnormalities in human cells from laminopathy patients. I have already 
obtained human dermal fibroblasts (kind gift from G. Bonne) which were isolated from an L-CMD 
patient with the missense mutation p.L302P (Quijano-Roy et al., 2008). Preliminary results show 
that lamin A/C and lamin B1 is mislocalised in more than 30% of all cells, which provides a good 
starting point to test the effectiveness of AONs. Unfortunately, there are currently no mouse 
models available with mutations in exon 5, to test the therapy in vivo. However, if experiments in 
human cells yield positive results it is definitely worth considering producing one. 
To date 21 different mutations have been described in LMNA exon 5 which together, affect 7.9% 
of all reported patients (www.umd.be/LMNA). These mutations include missense mutations, 
nonsense mutations and one splice site mutation (see table 6.2). If lamin A-Δ5 is indeed 
functionally similar to the wild type protein, all of these mutations would be treatable. 
However, current limitations of AON technology include inefficient skipping (Muntoni and Wood, 
2011). This could be an issue since the majority of mutations in exon 5 are dominant mutations, 
which might need to be removed completely to treat the phenotype. In addition, incomplete 
skipping of exon 5 would result in the co-expression of six different A-type lamin variants: wild-
type lamin A and C, mutated lamin A and C and skipped lamin A and C, which at the end might be 
more detrimental to the cell than higher levels of mutant and wild-type lamins A and C. 
One of the mutations in exon 5 (p.R298C), results in AR-CMT2 which is characterised by 
myelination defects in peripheral neurons (De Sandre-Giovannoli et al., 2002). In this case partial 
skipping might be enough to ameliorate the phenotype, provided that lamin A-Δ5 performs like 
wild-type lamin A. However, tissue specific targeting of AONs is another limitation yet to 
overcome. Although progress has been made towards the identification of arginine-rich cell 
penetrating peptides which promote AON uptake in cardiomyocytes (Yin et al., 2009), technology 
to target the peripheral nervous system is not yet available (M.J. Wood, personal communication). 
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In future exon exchange technologies such as spliceosome-mediated RNA trans-splicing, may 
replace exon skipping (Puttaraju et al., 1999) but until such technologies become available and are 
efficient enough, AON mediated exon skipping remains the best possible alternative to target 
specific laminopathies.  
Thesis conclusion 
In conclusion, my work advances the current understanding of genotype-phenotype correlations in 
laminopathies as well as the involvement of satellite cells in the pathology of EDMD. Further, it 
provides proof-of-principle for exon skipping to target missense mutations in the LMNA gene, 
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The central rod domain of eight different human intermediate filament proteins is shown. The 
sequences were obtained from the UniProt protein sequence database (www.uniprot.org) and 
aligned using the free online tool Clustal2W (available at: www.ebi.ac.uk/Tools/msa/clustalw2). 
Coils 1a, 1b, 2a and 2b as well as linker regions L1, L12 and L2 are indicated above the sequence. 
The heptad repeat position for each residue (a-g) is indicated as well. The sequence encoded by 
LMNA exons 3 or 5 is highlighted in red; NF-L, Neurofilament light; (.) semi-conserved; (:) 









The lamin A protein sequence from three different species is shown. The sequences were obtained 
from the UniProt protein sequence database (www.uniprot.org) and aligned using the free online 
tool Clustal2W (available at: www.ebi.ac.uk/Tools/msa/clustalw2). The location of coils 1a, 1b, 2a 
and 2b as well as linker regions L1, L12 and L2 and the Ig-fold are indicated above the sequence; (.) 




Appendix 3: Classification and structures of the 20 standard amino acids 
 
The ionisation state of the amino acids and their R-groups shown in this illustration represents the 
dominant form at pH7. The R-groups are highlighted by coloured boxes indicating nonpolar (grey), 
polar (green), positively charged (blue) and negatively charged (red) side chains. The structures were 
drawn using ACD Chemsketch. 
